

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended **September 30, 2018**

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Commission File Number **001-36794**

**The Chemours Company**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or other Jurisdiction of  
Incorporation or Organization)

**46-4845564**

(I.R.S. Employer  
Identification No.)

**1007 Market Street, Wilmington, Delaware 19899**

(Address of Principal Executive Offices)

**(302) 773-1000**

(Registrant's Telephone Number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Non-Accelerated Filer

Accelerated Filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The registrant had 171,084,799 shares of common stock, \$0.01 par value, outstanding at October 29, 2018.

---

---

## The Chemours Company

### TABLE OF CONTENTS

|   | <u>Page</u> |
|---|-------------|
| <b><u>Part I</u></b>  |             |
| <b>Financial Information</b>  |             |
| Item 1. Interim Consolidated Financial Statements   |             |
| Interim Consolidated Statements of Operations (Unaudited)                                     | 2           |
| Interim Consolidated Statements of Comprehensive Income (Unaudited)                           | 3           |
| Interim Consolidated Balance Sheets   | 4           |
| Interim Consolidated Statements of Stockholders' Equity (Unaudited)                           | 5           |
| Interim Consolidated Statements of Cash Flows (Unaudited)                                     | 6           |
| Notes to the Interim Consolidated Financial Statements (Unaudited)                            | 7           |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | 46          |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk                            | 70          |
| Item 4. Controls and Procedures   | 70          |
| <b><u>Part II</u></b>   |             |
| <b>Other Information</b>  |             |
| Item 1. Legal Proceedings   | 72          |
| Item 1A. Risk Factors   | 73          |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds                           | 73          |
| Item 3. Defaults Upon Senior Securities   | 74          |
| Item 4. Mine Safety Disclosures   | 74          |
| Item 5. Other Information   | 74          |
| Item 6. Exhibits  | 74          |
| <b><u>Signature</u></b>   | 75          |

PART I. FINANCIAL INFORMATION

Item 1. INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The Chemours Company  
Interim Consolidated Statements of Operations (Unaudited)  
(Dollars in millions, except per share amounts)

|  | Three Months Ended September 30, |               | Nine Months Ended September 30, |               |
|--|----------------------------------|---------------|---------------------------------|---------------|
|  | 2018                             | 2017          | 2018                            | 2017          |
| Net sales  | \$ 1,628                         | \$ 1,584      | \$ 5,174                        | \$ 4,608      |
| Cost of goods sold   | 1,151                            | 1,119         | 3,603                           | 3,347         |
| Gross profit   | 477                              | 465           | 1,571                           | 1,261         |
| Selling, general, and administrative expense               | 163                              | 153           | 466                             | 461           |
| Research and development expense                           | 20                               | 20            | 61                              | 62            |
| Restructuring, asset-related, and other charges            | 12                               | 8             | 32                              | 31            |
| Total other operating expenses                             | 195                              | 181           | 559                             | 554           |
| Equity in earnings of affiliates                           | 10                               | 9             | 32                              | 26            |
| Interest expense, net                                      | (47)                             | (55)          | (148)                           | (160)         |
| Loss on extinguishment of debt                             | —                                | —             | (38)                            | (1)           |
| Other income, net  | 24                               | 12            | 115                             | 77            |
| <b>Income before income taxes</b>                          | <b>269</b>                       | <b>250</b>    | <b>973</b>                      | <b>649</b>    |
| (Benefit from) provision for income taxes                  | (6)                              | 43            | 119                             | 130           |
| <b>Net income</b>  | <b>275</b>                       | <b>207</b>    | <b>854</b>                      | <b>519</b>    |
| Less: Net income attributable to non-controlling interests | —                                | —             | 1                               | 1             |
| <b>Net income attributable to Chemours</b>                 | <b>\$ 275</b>                    | <b>\$ 207</b> | <b>\$ 853</b>                   | <b>\$ 518</b> |
| <b>Per share data</b>                                      |                                  |               |                                 |               |
| Basic earnings per share of common stock                   | \$ 1.56                          | \$ 1.12       | \$ 4.77                         | \$ 2.81       |
| Diluted earnings per share of common stock                 | 1.51                             | 1.08          | 4.62                            | 2.72          |

See accompanying notes to the interim consolidated financial statements.

**The Chemours Company**  
**Interim Consolidated Statements of Comprehensive Income (Unaudited)**  
*(Dollars in millions)*

|  | Three Months Ended September 30, |             |               |               |                |               |
|--|----------------------------------|-------------|---------------|---------------|----------------|---------------|
|  | 2018                             |             |               | 2017          |                |               |
|  | Pre-tax                          | Tax         | After-tax     | Pre-tax       | Tax            | After-tax     |
| <b>Net income</b>  | \$ 269                           | \$ 6        | \$ 275        | \$ 250        | \$ (43)        | \$ 207        |
| Other comprehensive income (loss):                                   |                                  |             |               |               |                |               |
| Hedging activities:  |                                  |             |               |               |                |               |
| Unrealized loss on net investment hedge                              | (11)                             | 3           | (8)           | (26)          | 10             | (16)          |
| Unrealized loss on cash flow hedge                                   | (1)                              | —           | (1)           | —             | —              | —             |
| Reclassifications to net income - cash flow hedge                    | (1)                              | —           | (1)           | —             | —              | —             |
| Hedging activities, net  | (13)                             | 3           | (10)          | (26)          | 10             | (16)          |
| Cumulative translation adjustment                                    | 36                               | —           | 36            | 35            | —              | 35            |
| Defined benefit plans:   |                                  |             |               |               |                |               |
| Additions to accumulated other comprehensive loss:                   |                                  |             |               |               |                |               |
| Net gain   | —                                | —           | —             | 5             | —              | 5             |
| Effect of foreign exchange rates                                     | (2)                              | —           | (2)           | (9)           | 2              | (7)           |
| Reclassifications to net income:                                     |                                  |             |               |               |                |               |
| Amortization of prior service gain                                   | —                                | —           | —             | (1)           | —              | (1)           |
| Amortization of actuarial loss                                       | 4                                | (1)         | 3             | 5             | (1)            | 4             |
| Settlement loss  | 2                                | —           | 2             | 1             | —              | 1             |
| Defined benefit plans, net   | 4                                | (1)         | 3             | 1             | 1              | 2             |
| <b>Other comprehensive income</b>                                    | 27                               | 2           | 29            | 10            | 11             | 21            |
| <b>Comprehensive income</b>  | 296                              | 8           | 304           | 260           | (32)           | 228           |
| Less: Comprehensive income attributable to non-controlling interests | —                                | —           | —             | —             | —              | —             |
| <b>Comprehensive income attributable to Chemours</b>                 | <u>\$ 296</u>                    | <u>\$ 8</u> | <u>\$ 304</u> | <u>\$ 260</u> | <u>\$ (32)</u> | <u>\$ 228</u> |

|  | Nine Months Ended September 30, |                 |               |               |                 |               |
|--|---------------------------------|-----------------|---------------|---------------|-----------------|---------------|
|  | 2018                            |                 |               | 2017          |                 |               |
|  | Pre-tax                         | Tax             | After-tax     | Pre-tax       | Tax             | After-tax     |
| <b>Net income</b>  | \$ 973                          | \$ (119)        | \$ 854        | \$ 649        | \$ (130)        | \$ 519        |
| Other comprehensive income (loss):                                   |                                 |                 |               |               |                 |               |
| Hedging activities:  |                                 |                 |               |               |                 |               |
| Unrealized gain (loss) on net investment hedge                       | 2                               | (1)             | 1             | (76)          | 20              | (56)          |
| Unrealized gain on cash flow hedge                                   | 6                               | —               | 6             | —             | —               | —             |
| Reclassifications to net income - cash flow hedge                    | (1)                             | —               | (1)           | —             | —               | —             |
| Hedging activities, net  | 7                               | (1)             | 6             | (76)          | 20              | (56)          |
| Cumulative translation adjustment                                    | (17)                            | —               | (17)          | 224           | —               | 224           |
| Defined benefit plans:   |                                 |                 |               |               |                 |               |
| Additions to accumulated other comprehensive loss:                   |                                 |                 |               |               |                 |               |
| Net gain   | —                               | —               | —             | 5             | —               | 5             |
| Effect of foreign exchange rates                                     | 3                               | —               | 3             | (36)          | 8               | (28)          |
| Reclassifications to net income:                                     |                                 |                 |               |               |                 |               |
| Amortization of prior service gain                                   | (1)                             | —               | (1)           | (1)           | —               | (1)           |
| Amortization of actuarial loss                                       | 11                              | (2)             | 9             | 15            | (3)             | 12            |
| Settlement loss  | 2                               | —               | 2             | 1             | —               | 1             |
| Defined benefit plans, net   | 15                              | (2)             | 13            | (16)          | 5               | (11)          |
| <b>Other comprehensive income</b>                                    | 5                               | (3)             | 2             | 132           | 25              | 157           |
| <b>Comprehensive income</b>  | 978                             | (122)           | 856           | 781           | (105)           | 676           |
| Less: Comprehensive income attributable to non-controlling interests | 1                               | —               | 1             | 1             | —               | 1             |
| <b>Comprehensive income attributable to Chemours</b>                 | <u>\$ 977</u>                   | <u>\$ (122)</u> | <u>\$ 855</u> | <u>\$ 780</u> | <u>\$ (105)</u> | <u>\$ 675</u> |

**See accompanying notes to the interim consolidated financial statements.**

**The Chemours Company**  
**Interim Consolidated Balance Sheets**  
*(Dollars in millions, except per share amounts)*

|   | (Unaudited)        |                   |
|---|--------------------|-------------------|
|   | September 30, 2018 | December 31, 2017 |
| <b>Assets</b>   |                    |                   |
| Current assets:   |                    |                   |
| Cash and cash equivalents   | \$ 1,275           | \$ 1,556          |
| Accounts and notes receivable, net  | 998                | 919               |
| Inventories   | 1,086              | 935               |
| Prepaid expenses and other  | 89                 | 83                |
| <b>Total current assets</b>   | <b>3,448</b>       | <b>3,493</b>      |
| Property, plant, and equipment  | 8,885              | 8,511             |
| Less: Accumulated depreciation  | (5,678)            | (5,503)           |
| Property, plant, and equipment, net   | 3,207              | 3,008             |
| Goodwill and other intangible assets, net   | 187                | 166               |
| Investments in affiliates   | 179                | 173               |
| Other assets  | 491                | 453               |
| <b>Total assets</b>   | <b>\$ 7,512</b>    | <b>\$ 7,293</b>   |
| <b>Liabilities</b>  |                    |                   |
| Current liabilities:  |                    |                   |
| Accounts payable  | \$ 1,123           | \$ 1,075          |
| Current maturities of long-term debt  | 14                 | 15                |
| Other accrued liabilities   | 561                | 558               |
| <b>Total current liabilities</b>  | <b>1,698</b>       | <b>1,648</b>      |
| Long-term debt, net   | 3,985              | 4,097             |
| Deferred income taxes   | 220                | 208               |
| Other liabilities   | 463                | 475               |
| <b>Total liabilities</b>  | <b>6,366</b>       | <b>6,428</b>      |
| Commitments and contingent liabilities  |                    |                   |
| <b>Equity</b>   |                    |                   |
| Common stock (par value \$0.01 per share; 810,000,000 shares authorized; 187,149,447 shares issued and 173,849,387 shares outstanding at September 30, 2018; 185,343,034 shares issued and 182,956,628 shares outstanding at December 31, 2017) | 2                  | 2                 |
| Treasury stock at cost (13,300,060 shares at September 30, 2018; 2,386,406 shares at December 31, 2017)   | (636)              | (116)             |
| Additional paid-in capital  | 856                | 837               |
| Retained earnings   | 1,358              | 579               |
| Accumulated other comprehensive loss  | (440)              | (442)             |
| <b>Total Chemours stockholders' equity</b>  | <b>1,140</b>       | <b>860</b>        |
| Non-controlling interests   | 6                  | 5                 |
| <b>Total equity</b>   | <b>1,146</b>       | <b>865</b>        |
| <b>Total liabilities and equity</b>   | <b>\$ 7,512</b>    | <b>\$ 7,293</b>   |

*See accompanying notes to the interim consolidated financial statements.*

**The Chemours Company**  
**Interim Consolidated Statements of Stockholders' Equity (Unaudited)**  
*(Dollars in millions, except per share amounts)*

|   | Three Months Ended September 30, |             |                        |                   |                 |               |                                  |                      |  |                                  |              |
|---|----------------------------------|-------------|------------------------|-------------------|-----------------|---------------|----------------------------------|----------------------|--|----------------------------------|--------------|
|   | Common Stock                     |             |                        | Treasury Stock    |                 |               | Additional<br>Paid-in<br>Capital | Retained<br>Earnings | Accumulated<br>Other<br>Comprehensive<br>(Loss) Income | Non-<br>controlling<br>Interests | Total Equity |
|   | Shares                           | Amount      | Dividends per<br>Share | Shares            | Amount          | Amount        |                                  |                      |  |                                  |              |
| <b>Balance at July 1, 2017</b>                                | 184,691,137                      | \$ 2        | \$ —                   | —                 | \$ —            | \$ 820        | \$ 186                           | \$ (441)             | \$ 5   | \$ 572                           |              |
| Common stock issued - compensation plans                      | 42,344                           | —           | —                      | —                 | —               | —             | —                                | —                    | —  | —                                |              |
| Exercise of stock options, net                                | 358,577                          | —           | —                      | —                 | —               | 4             | —                                | —                    | —  | 4                                |              |
| Stock-based compensation expense                              | —                                | —           | —                      | —                 | —               | 6             | —                                | —                    | —  | 6                                |              |
| Cancellation of unissued stock awards withheld to cover taxes | —                                | —           | —                      | —                 | —               | —             | —                                | —                    | —  | —                                |              |
| Net income  | —                                | —           | —                      | —                 | —               | —             | 207                              | —                    | —  | 207                              |              |
| Dividends   | —                                | —           | 0.03                   | —                 | —               | —             | (5)                              | —                    | —  | (5)                              |              |
| Other comprehensive income                                    | —                                | —           | —                      | —                 | —               | —             | —                                | 21                   | —  | 21                               |              |
| <b>Balance at September 30, 2017</b>                          | <u>185,092,058</u>               | <u>\$ 2</u> | <u>\$ 0.03</u>         | <u>—</u>          | <u>\$ —</u>     | <u>\$ 830</u> | <u>\$ 388</u>                    | <u>\$ (420)</u>      | <u>\$ 5</u>  | <u>\$ 805</u>                    |              |
| <b>Balance at July 1, 2018</b>                                | 186,594,368                      | \$ 2        | \$ —                   | 10,073,236        | \$ (500)        | \$ 859        | \$ 1,127                         | \$ (469)             | \$ 6   | \$ 1,025                         |              |
| Common stock issued - compensation plans                      | 431,744                          | —           | —                      | —                 | —               | —             | —                                | —                    | —  | —                                |              |
| Exercise of stock options, net                                | 123,335                          | —           | —                      | —                 | —               | 2             | —                                | —                    | —  | 2                                |              |
| Purchases of treasury stock, at cost                          | —                                | —           | —                      | 3,226,824         | (136)           | —             | —                                | —                    | —  | (136)                            |              |
| Stock-based compensation expense                              | —                                | —           | —                      | —                 | —               | 5             | —                                | —                    | —  | 5                                |              |
| Cancellation of unissued stock awards withheld to cover taxes | —                                | —           | —                      | —                 | —               | (10)          | —                                | —                    | —  | (10)                             |              |
| Net income  | —                                | —           | —                      | —                 | —               | —             | 275                              | —                    | —  | 275                              |              |
| Dividends   | —                                | —           | 0.25                   | —                 | —               | —             | (44)                             | —                    | —  | (44)                             |              |
| Other comprehensive income                                    | —                                | —           | —                      | —                 | —               | —             | —                                | 29                   | —  | 29                               |              |
| <b>Balance at September 30, 2018</b>                          | <u>187,149,447</u>               | <u>\$ 2</u> | <u>\$ 0.25</u>         | <u>13,300,060</u> | <u>\$ (636)</u> | <u>\$ 856</u> | <u>\$ 1,358</u>                  | <u>\$ (440)</u>      | <u>\$ 6</u>  | <u>\$ 1,146</u>                  |              |

|   | Nine Months Ended September 30, |             |                        |                   |                 |               |                                  |  |  |                                  |              |
|---|---------------------------------|-------------|------------------------|-------------------|-----------------|---------------|----------------------------------|--|--|----------------------------------|--------------|
|   | Common Stock                    |             |                        | Treasury Stock    |                 |               | Additional<br>Paid-in<br>Capital | (Accumulated<br>Deficit)<br>Retained<br>Earnings | Accumulated<br>Other<br>Comprehensive<br>(Loss) Income | Non-<br>controlling<br>Interests | Total Equity |
|   | Shares                          | Amount      | Dividends per<br>Share | Shares            | Amount          | Amount        |                                  |  |  |                                  |              |
| <b>Balance at January 1, 2017</b>                             | 182,600,533                     | \$ 2        | \$ —                   | —                 | \$ —            | \$ 789        | \$ (114)                         | \$ (577)   | \$ 4   | \$ 104                           |              |
| Common stock issued - compensation plans                      | 504,098                         | —           | —                      | —                 | —               | —             | —                                | —  | —  | —                                |              |
| Exercise of stock options, net                                | 1,987,427                       | —           | —                      | —                 | —               | 30            | —                                | —  | —  | 30                               |              |
| Stock-based compensation expense                              | —                               | —           | —                      | —                 | —               | 21            | —                                | —  | —  | 21                               |              |
| Cancellation of unissued stock awards withheld to cover taxes | —                               | —           | —                      | —                 | —               | (10)          | —                                | —  | —  | (10)                             |              |
| Net income  | —                               | —           | —                      | —                 | —               | —             | 518                              | —  | 1  | 519                              |              |
| Dividends   | —                               | —           | 0.09                   | —                 | —               | —             | (16)                             | —  | —  | (16)                             |              |
| Other comprehensive income                                    | —                               | —           | —                      | —                 | —               | —             | —                                | 157  | —  | 157                              |              |
| <b>Balance at September 30, 2017</b>                          | <u>185,092,058</u>              | <u>\$ 2</u> | <u>\$ 0.09</u>         | <u>—</u>          | <u>\$ —</u>     | <u>\$ 830</u> | <u>\$ 388</u>                    | <u>\$ (420)</u>                                  | <u>\$ 5</u>  | <u>\$ 805</u>                    |              |
| <b>Balance at January 1, 2018</b>                             | 185,343,034                     | \$ 2        | \$ —                   | 2,386,406         | \$ (116)        | \$ 837        | \$ 579                           | \$ (442)   | \$ 5   | \$ 865                           |              |
| Common stock issued - compensation plans                      | 787,451                         | —           | —                      | —                 | —               | —             | —                                | —  | —  | —                                |              |
| Exercise of stock options, net                                | 1,018,962                       | —           | —                      | —                 | —               | 15            | —                                | —  | —  | 15                               |              |
| Purchases of treasury stock, at cost                          | —                               | —           | —                      | 10,926,065        | (520)           | —             | —                                | —  | —  | (520)                            |              |
| Shares issued under employee stock purchase plan              | —                               | —           | —                      | (12,411)          | —               | —             | —                                | —  | —  | —                                |              |
| Stock-based compensation expense                              | —                               | —           | —                      | —                 | —               | 20            | —                                | —  | —  | 20                               |              |
| Cancellation of unissued stock awards withheld to cover taxes | —                               | —           | —                      | —                 | —               | (16)          | —                                | —  | —  | (16)                             |              |
| Net income  | —                               | —           | —                      | —                 | —               | —             | 853                              | —  | 1  | 854                              |              |
| Dividends   | —                               | —           | 0.42                   | —                 | —               | —             | (74)                             | —  | —  | (74)                             |              |
| Other comprehensive income                                    | —                               | —           | —                      | —                 | —               | —             | —                                | 2  | —  | 2                                |              |
| <b>Balance at September 30, 2018</b>                          | <u>187,149,447</u>              | <u>\$ 2</u> | <u>\$ 0.42</u>         | <u>13,300,060</u> | <u>\$ (636)</u> | <u>\$ 856</u> | <u>\$ 1,358</u>                  | <u>\$ (440)</u>                                  | <u>\$ 6</u>  | <u>\$ 1,146</u>                  |              |

**See accompanying notes to the interim consolidated financial statements.**

**The Chemours Company**  
**Interim Consolidated Statements of Cash Flows (Unaudited)**  
*(Dollars in millions)*

|   | Nine Months Ended September 30, |                 |
|---|---------------------------------|-----------------|
|   | 2018                            | 2017            |
| <b>Cash flows from operating activities</b>                                   |                                 |                 |
| Net income  | \$ 854                          | \$ 519          |
| Adjustments to reconcile net income to cash provided by operating activities: |                                 |                 |
| Depreciation and amortization   | 213                             | 204             |
| Asset-related charges   | —                               | 3               |
| Gain on sales of assets and businesses  | (45)                            | (14)            |
| Equity in earnings of affiliates, net   | (4)                             | (26)            |
| Loss on extinguishment of debt  | 38                              | 1               |
| Amortization of debt issuance costs and issue discounts                       | 9                               | 10              |
| Deferred tax provision  | 3                               | 53              |
| Other operating charges and credits, net                                      | 9                               | 26              |
| Decrease (increase) in operating assets:                                      |                                 |                 |
| Accounts and notes receivable, net  | (87)                            | (110)           |
| Inventories and other operating assets  | (186)                           | (91)            |
| (Decrease) increase in operating liabilities:                                 |                                 |                 |
| Accounts payable and other operating liabilities                              | 77                              | (238)           |
| Cash provided by operating activities   | 881                             | 337             |
| <b>Cash flows from investing activities</b>                                   |                                 |                 |
| Purchases of property, plant, and equipment                                   | (344)                           | (246)           |
| Acquisition of business, net  | (37)                            | —               |
| Proceeds from sales of assets and businesses, net                             | 46                              | 39              |
| Foreign exchange contract settlements, net                                    | 8                               | 5               |
| Cash used for investing activities  | (327)                           | (202)           |
| <b>Cash flows from financing activities</b>                                   |                                 |                 |
| Proceeds from issuance of debt, net   | 520                             | 494             |
| Debt repayments   | (675)                           | (24)            |
| Payments related to extinguishment of debt                                    | (29)                            | (1)             |
| Payments of debt issuance costs   | (12)                            | (6)             |
| Purchases of treasury stock, at cost  | (520)                           | —               |
| Proceeds from exercised stock options, net                                    | 15                              | 30              |
| Payments related to tax withholdings on vested restricted stock units         | (16)                            | (10)            |
| Payments of dividends   | (106)                           | (16)            |
| Cash (used for) provided by financing activities                              | (823)                           | 467             |
| Effect of exchange rate changes on cash and cash equivalents                  | (12)                            | 31              |
| <b>(Decrease) increase in cash and cash equivalents</b>                       | <b>(281)</b>                    | <b>633</b>      |
| <b>Cash and cash equivalents at January 1,</b>                                | <b>1,556</b>                    | <b>902</b>      |
| <b>Cash and cash equivalents at September 30,</b>                             | <b>\$ 1,275</b>                 | <b>\$ 1,535</b> |
| <b>Supplemental cash flows information</b>                                    |                                 |                 |
| Non-cash investing and financing activities:                                  |                                 |                 |
| Changes in property, plant, and equipment included in accounts payable        | \$ 12                           | \$ (16)         |
| Obligations incurred under build-to-suit lease arrangement                    | 41                              | —               |
| Purchases of treasury stock not settled by period-end                         | 10                              | —               |

*See accompanying notes to the interim consolidated financial statements.*

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Note 1. Background, Description of the Business, and Basis of Presentation**

The Chemours Company (Chemours, or the Company) is a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. The Company delivers customized solutions with a wide range of industrial and specialty chemical products for markets, including plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining. The Company's principal products include refrigerants, industrial fluoropolymer resins, sodium cyanide, performance chemicals and intermediates, and titanium dioxide (TiO<sub>2</sub>) pigment. Chemours' business consists of three reportable segments: Fluoroproducts, Chemical Solutions, and Titanium Technologies. The Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrials, and consumer applications. The Titanium Technologies segment is a leading, global provider of TiO<sub>2</sub> pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications.

The accompanying interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles (GAAP) in the United States of America (U.S.) for interim financial information. In the opinion of management, all adjustments (consisting of normal, recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. The Company's results for interim periods should not be considered indicative of its results for a full year, and the year-end consolidated balance sheet does not include all of the disclosures required by GAAP. As such, these interim consolidated financial statements should be read in conjunction with the *Consolidated Financial Statements* and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.

Certain prior period amounts have been reclassified to conform to the current period presentation, the effect of which was not material to the Company's interim consolidated financial statements.

Unless the context otherwise requires, references herein to "The Chemours Company," "Chemours," "the Company," "our Company," "we," "us," and "our" refer to The Chemours Company and its consolidated subsidiaries. References herein to "DuPont" refer to E. I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries (other than Chemours and its consolidated subsidiaries), unless the context otherwise requires.

**Note 2. Recent Accounting Pronouncements**

***Accounting Guidance Issued and Not Yet Adopted***

*Leases*

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, *Leases (Topic 842)* (ASU No. 2016-02), which supersedes the leases requirements in Topic 840. The core principle of ASU No. 2016-02 is that a lessee should recognize on the balance sheet the lease assets and lease liabilities that arise from all lease arrangements with terms greater than 12 months. Recognition of these lease assets and lease liabilities represents a change from previous GAAP, which did not require lease assets and lease liabilities to be recognized for operating leases. Qualitative disclosures along with specific quantitative disclosures will be required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity's leasing activities.

The provisions of ASU No. 2016-02 are effective for the Company's fiscal year beginning January 1, 2019, including interim periods within that fiscal year. The guidance includes a number of optional practical expedients that the Company may elect to apply.

In July 2018, the FASB issued ASU No. 2018-11, *Leases - Targeted Improvements*, as an update to the previously issued guidance. This update added a transition option which allows for recognition of a cumulative effect adjustment to the opening balance of retained earnings in the period of adoption without recasting the financial statements in periods prior to adoption. The Company plans to elect this transition option.

At adoption, the Company expects to recognize a material increase in total assets and total liabilities resulting from the recognition of right-of-use assets and the related lease liabilities initially measured at the present value of its future operating lease payments. The impact of adopting ASU No. 2016-02 will depend on the Company's lease portfolio as of the adoption date. The Company continues to evaluate the impacts of adopting this guidance on its financial position, results of operations, and cash flows, and is updating its systems, processes, and internal controls to meet the new reporting and disclosure requirements in ASU No. 2016-02.



**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

*Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income*

In February 2018, the FASB issued ASU No. 2018-02, *Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income* (ASU No. 2018-02), which allows for a reclassification from accumulated other comprehensive income or loss to retained earnings for any stranded tax effects resulting from U.S. tax reform. The amendments in this update also require certain disclosures about stranded tax effects. ASU No. 2018-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company does not expect that the adoption of this guidance will have a significant impact on its financial position.

*Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract*

In August 2018, the FASB issued ASU No. 2018-15, *Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract* (ASU No. 2018-15), which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. Pursuant to the amendments, the Company, when acting as a customer to a cloud computing arrangement that is a service contract, is required to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU No. 2018-15 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted in any interim period. Upon adoption, the Company will have the option to elect whether it applies the amendments under ASU No. 2018-15 retrospectively, or prospectively to all implementation costs incurred after the date of adoption. The Company is currently evaluating the impacts of adopting this guidance on its financial position, results of operations, and cash flows.

**Recently Adopted Accounting Guidance**

*Revenue from Contracts with Customers*

In May 2014, the FASB issued ASU No. 2014-09, *Revenue from Contracts with Customers (Topic 606)* (ASU No. 2014-09). The objective of this standard is to remove inconsistent practices with regard to revenue recognition between GAAP and International Financial Reporting Standards. The standard intends to improve the comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. Subsequent to the issuance of ASU No. 2014-09, the FASB issued multiple clarifying updates in connection with the standard (collectively, Topic 606).

Effective January 1, 2018, Chemours adopted the new revenue recognition guidance contained in Topic 606 using the modified retrospective transition method. The Company elected to utilize a practical expedient allowed under the modified retrospective transition method to apply the new standard only to contracts that are not completed on the date of initial adoption. In applying this guidance, the Company evaluated its population of open contracts with customers on January 1, 2018 and determined that the impact of adopting Topic 606 was not material to its consolidated financial statements as a whole. No cumulative adjustment to the Company's opening retained earnings balance was required. As a result of applying this new guidance, there are changes to the classification of certain amounts in the consolidated statements of operations. Certain royalty income amounts for trademark licensing arrangements that were previously reflected as a component of other income, net in the consolidated statements of operations are now reflected as a component of net sales, which amounted to \$1 and \$4 for the three and nine months ended September 30, 2018, respectively. Additionally, certain expenses related to the Company's provision of technical services to customers that were previously reflected as a component of selling, general, and administrative expense in the consolidated statements of operations will now be reflected as a component of the cost of goods sold, which amounted to less than \$1 and \$2 for the three and nine months ended September 30, 2018, respectively. Under the modified retrospective transition method, the Company's comparative financial information as of and for the three and nine months ended September 30, 2017 and as of December 31, 2017 has not been restated, and as such, continues to be reported using the accounting standards in effect during those time periods.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

The following table sets forth the impacts of the adoption of Topic 606 on the Company's consolidated statements of operations for the three months ended September 30, 2018.

|  | Three Months Ended September 30, 2018 |                          |               |
|--|---------------------------------------|--------------------------|---------------|
|  | Without<br>Topic 606                  | Topic 606<br>Adjustments | As Reported   |
| Net sales  | \$ 1,627                              | \$ 1                     | \$ 1,628      |
| Cost of goods sold   | 1,151                                 | —                        | 1,151         |
| Gross profit   | 476                                   | 1                        | 477           |
| Selling, general, and administrative expense               | 163                                   | —                        | 163           |
| Research and development expense                           | 20                                    | —                        | 20            |
| Restructuring, asset-related, and other charges            | 12                                    | —                        | 12            |
| Total other operating expenses                             | 195                                   | —                        | 195           |
| Equity in earnings of affiliates                           | 10                                    | —                        | 10            |
| Interest expense, net                                      | (47)                                  | —                        | (47)          |
| Loss on extinguishment of debt                             | —                                     | —                        | —             |
| Other income, net  | 25                                    | (1)                      | 24            |
| <b>Income before income taxes</b>                          | <b>269</b>                            | <b>—</b>                 | <b>269</b>    |
| Benefit from income taxes                                  | (6)                                   | —                        | (6)           |
| <b>Net income</b>  | <b>275</b>                            | <b>—</b>                 | <b>275</b>    |
| Less: Net income attributable to non-controlling interests | —                                     | —                        | —             |
| <b>Net income attributable to Chemours</b>                 | <b>\$ 275</b>                         | <b>\$ —</b>              | <b>\$ 275</b> |

The following table sets forth the impacts of the adoption of Topic 606 on the Company's consolidated statements of operations for the nine months ended September 30, 2018.

|  | Nine Months Ended September 30, 2018 |                          |               |
|--|--------------------------------------|--------------------------|---------------|
|  | Without<br>Topic 606                 | Topic 606<br>Adjustments | As Reported   |
| Net sales  | \$ 5,170                             | \$ 4                     | \$ 5,174      |
| Cost of goods sold   | 3,601                                | 2                        | 3,603         |
| Gross profit   | 1,569                                | 2                        | 1,571         |
| Selling, general, and administrative expense               | 468                                  | (2)                      | 466           |
| Research and development expense                           | 61                                   | —                        | 61            |
| Restructuring, asset-related, and other charges            | 32                                   | —                        | 32            |
| Total other operating expenses                             | 561                                  | (2)                      | 559           |
| Equity in earnings of affiliates                           | 32                                   | —                        | 32            |
| Interest expense, net                                      | (148)                                | —                        | (148)         |
| Loss on extinguishment of debt                             | (38)                                 | —                        | (38)          |
| Other income, net  | 119                                  | (4)                      | 115           |
| <b>Income before income taxes</b>                          | <b>973</b>                           | <b>—</b>                 | <b>973</b>    |
| Provision for income taxes                                 | 119                                  | —                        | 119           |
| <b>Net income</b>  | <b>854</b>                           | <b>—</b>                 | <b>854</b>    |
| Less: Net income attributable to non-controlling interests | 1                                    | —                        | 1             |
| <b>Net income attributable to Chemours</b>                 | <b>\$ 853</b>                        | <b>\$ —</b>              | <b>\$ 853</b> |

The adoption of Topic 606 did not impact the Company's consolidated balance sheets or consolidated statements of cash flows as of and for the nine months ended September 30, 2018 and is not expected to have a material impact on the Company's financial position, results of operations, or cash flows in future periods.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

*Classification of Certain Cash Receipts and Cash Payments*

In August 2016, the FASB issued various updates to ASU No. 2016-15, *Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments* (ASU No. 2016-15), which clarifies and amends the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The provisions of ASU No. 2016-15 are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and are to be applied using a retrospective transition method. The Company adopted ASU No. 2016-15 on January 1, 2018, the impact of which was not material to its cash flows. There were no adjustments to prior periods resulting from the retrospective application of this guidance.

*Clarifying the Definition of a Business*

In January 2017, the FASB issued ASU No. 2017-01, *Business Combinations (Topic 805): Clarifying the Definition of a Business* (ASU No. 2017-01), which changes the definition of a business to assist entities in evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or a business. ASU No. 2017-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2018, the result of which did not have a significant impact on its financial position, results of operations, or cash flows.

*Retirement Benefits*

In March 2017, the FASB issued ASU No. 2017-07, *Compensation - Retirement Benefits (Topic 715)* (ASU No. 2017-07), which requires that employers offering their employees defined benefit pension plans disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The provisions of ASU No. 2017-07 are effective for fiscal years beginning after December 31, 2017, as well as interim periods within those fiscal years, and should be applied (i) retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic post-retirement benefit cost in the income statement, and (ii) prospectively for the capitalization of the service cost component of net periodic pension cost and net periodic post-retirement benefit in assets. The Company adopted this guidance on January 1, 2018, which resulted in a reclassification of non-operating pension income from the operating expense captions of the consolidated statements of operations to other income, net for the three and nine months ended September 30, 2017.

The following table sets forth a reclassification of the Company's non-operating pension and other post-retirement employee benefit income for the three months ended September 30, 2017.

|  | Three Months Ended September 30, 2017 |                                |                 |
|--|---------------------------------------|--------------------------------|-----------------|
|  | As Reported                           | ASU No. 2017-07<br>Adjustments | As Reclassified |
| Net sales  | \$ 1,584                              | \$ —                           | \$ 1,584        |
| Cost of goods sold   | 1,117                                 | 2                              | 1,119           |
| Gross profit   | 467                                   | (2)                            | 465             |
| Selling, general, and administrative expense               | 148                                   | 5                              | 153             |
| Research and development expense                           | 20                                    | —                              | 20              |
| Restructuring, asset-related, and other charges            | 8                                     | —                              | 8               |
| Total other operating expenses                             | 176                                   | 5                              | 181             |
| Equity in earnings of affiliates                           | 9                                     | —                              | 9               |
| Interest expense, net                                      | (55)                                  | —                              | (55)            |
| Loss on extinguishment of debt                             | —                                     | —                              | —               |
| Other income, net  | 5                                     | 7                              | 12              |
| <b>Income before income taxes</b>                          | <b>250</b>                            | <b>—</b>                       | <b>250</b>      |
| Provision for income taxes                                 | 43                                    | —                              | 43              |
| <b>Net income</b>  | <b>207</b>                            | <b>—</b>                       | <b>207</b>      |
| Less: Net income attributable to non-controlling interests | —                                     | —                              | —               |
| <b>Net income attributable to Chemours</b>                 | <b>\$ 207</b>                         | <b>\$ —</b>                    | <b>\$ 207</b>   |

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

The following table sets forth a reclassification of the Company's non-operating pension and other post-retirement employee benefit income for the nine months ended September 30, 2017.

|  | Nine Months Ended September 30, 2017 |                                |                 |
|--|--------------------------------------|--------------------------------|-----------------|
|  | As Reported                          | ASU No. 2017-07<br>Adjustments | As Reclassified |
| Net sales  | \$ 4,608                             | \$ —                           | \$ 4,608        |
| Cost of goods sold   | 3,341                                | 6                              | 3,347           |
| Gross profit   | 1,267                                | (6)                            | 1,261           |
| Selling, general, and administrative expense               | 444                                  | 17                             | 461             |
| Research and development expense                           | 61                                   | 1                              | 62              |
| Restructuring, asset-related, and other charges            | 31                                   | —                              | 31              |
| Total other operating expenses                             | 536                                  | 18                             | 554             |
| Equity in earnings of affiliates                           | 26                                   | —                              | 26              |
| Interest expense, net                                      | (160)                                | —                              | (160)           |
| Loss on extinguishment of debt                             | (1)                                  | —                              | (1)             |
| Other income, net  | 53                                   | 24                             | 77              |
| <b>Income before income taxes</b>                          | <b>649</b>                           | <b>—</b>                       | <b>649</b>      |
| Provision for income taxes                                 | 130                                  | —                              | 130             |
| <b>Net income</b>  | <b>519</b>                           | <b>—</b>                       | <b>519</b>      |
| Less: Net income attributable to non-controlling interests | 1                                    | —                              | 1               |
| <b>Net income attributable to Chemours</b>                 | <b>\$ 518</b>                        | <b>\$ —</b>                    | <b>\$ 518</b>   |

*Derivatives and Hedging*

In August 2017, the FASB issued ASU No. 2017-12, *Derivatives and Hedging (Topic 815)* (ASU No. 2017-12), which simplifies financial statement reporting for qualifying hedging relationships by eliminating the requirement to separately measure and report hedge ineffectiveness. For net investment hedges, the entire change in fair value of the hedging instruments is recorded in the currency translation adjustment section of other comprehensive income or loss. Pursuant to the amendments, these amounts are required to be subsequently reclassified to earnings in the same income statement line item in which the earnings effect of the hedged item is presented when the hedged item affects earnings. The provisions of ASU No. 2017-12 are effective for the Company's fiscal year beginning January 1, 2019, including interim periods within that fiscal year. Early adoption is permitted in any interim period. The amendments in this update are applied to hedging relationships existing on the date of adoption, which includes a cumulative-effect adjustment to eliminate any ineffectiveness recorded to accumulated other comprehensive income or loss with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year in which adoption occurred. Presentation and disclosure amendments are required to be applied prospectively. The Company elected to adopt this guidance during the second quarter of 2018, the result of which did not have an impact on its financial position, results of operations, or cash flows.

**Note 3. Significant Transactions and Events**

***Sale of Land in Linden, New Jersey***

In March 2016, the Company entered into an agreement to sell a 210-acre plot of land that formerly housed a DuPont manufacturing site located in Linden, New Jersey. The land was assigned to Chemours in connection with its separation from DuPont, and the Company completed the sale in March 2018 for a gain of \$42 and net cash proceeds of \$39. As part of the sales agreement, the buyer agreed to assume certain costs associated with ongoing environmental remediation activities at the site amounting to \$3, which have been reflected as a component of prepaid expenses and other on the consolidated balance sheets. Chemours remains responsible for certain other ongoing environmental remediation activities at the site, which were previously accrued as a component of other liabilities on the consolidated balance sheets.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Acquisition of ICOR International, Inc.**

In April 2018, the Company, through its wholly-owned subsidiary, The Chemours Company FC, LLC, entered into a Stock Purchase Agreement (SPA) to acquire all of the outstanding stock of ICOR International, Inc. (ICOR), a closely-held private company that produces, sells, and distributes replacement refrigerant gases for use in commercial, industrial, and automotive refrigerant applications. Pursuant to the terms of the SPA, the Company paid \$37 in total consideration at closing in the all-cash acquisition, which included customary working capital and other adjustments made within a specified time period. The acquisition of ICOR complements the Company's existing portfolio of product offerings within the Fluoroproducts segment, as well as provides the Company with access to ICOR's established customer base and assembled workforce.

The Company accounted for the acquisition of ICOR as a business combination, and as such, all assets acquired and liabilities assumed were recorded at their estimated fair values. The excess of the consideration transferred over the fair value of the identifiable net assets acquired was recorded as goodwill within the Fluoroproducts segment, which represents the expected future benefits arising from the assembled workforce and other synergies to be realized from the acquisition of ICOR. The Company intends to elect to treat the acquisition of ICOR as an asset acquisition under the Internal Revenue Code, and as such, expects that all of the related goodwill will be deductible for federal income tax purposes.

The following table sets forth the Company's preliminary fair value estimates of the assets acquired and liabilities assumed in the acquisition of ICOR. These amounts are subject to further adjustment as additional information is obtained during the applicable measurement period, which includes the finalization of a third-party appraisal. The Company expects to complete its assessment by the end of 2018.

|   | Fair Value At<br>Acquisition Date | Measurement Period<br>Adjustments | Adjusted<br>Fair Value | Weighted-average<br>Useful Life (Years) |
|---|-----------------------------------|-----------------------------------|------------------------|---|
| <b>Assets acquired:</b>                           |                                   |                                   |                        |   |
| Accounts receivable - trade                       | \$ 4                              | \$ —                              | \$ 4                   |   |
| Inventories                                       | 8                                 | —                                 | 8                      |   |
| Property, plant, and equipment                    | 1                                 | —                                 | 1                      |   |
| <b>Identifiable intangible asset:</b>             |                                   |                                   |                        |   |
| Customer relationships (1)                        | 20                                | 2                                 | 22                     | 5                                       |
| <b>Total assets acquired</b>                      | <b>33</b>                         | <b>2</b>                          | <b>35</b>              |   |
| <b>Liabilities assumed:</b>                       |                                   |                                   |                        |   |
| Accounts payable                                  | 1                                 | —                                 | 1                      |   |
| Other accrued liabilities                         | 1                                 | —                                 | 1                      |   |
| <b>Total liabilities assumed</b>                  | <b>2</b>                          | <b>—</b>                          | <b>2</b>               |   |
| <b>Total identifiable net assets<br/>acquired</b> | <b>31</b>                         | <b>2</b>                          | <b>33</b>              |   |
| <b>Goodwill (1)</b>                               | <b>6</b>                          | <b>(2)</b>                        | <b>4</b>               |   |
| <b>Net assets acquired</b>                        | <b>\$ 37</b>                      | <b>\$ —</b>                       | <b>\$ 37</b>           |   |

(1) During the three months ended September 30, 2018, the Company recorded a measurement period adjustment to its customer relationships based on an ongoing analysis associated with the preparation of a third-party appraisal.

The fair value of the customer relationships was determined using the excess earnings method, which is a discounted cash flows approach. This method takes into account significant unobservable inputs and is a Level 3 fair value measurement within the fair value hierarchy. The use of this valuation methodology requires management to make various assumptions, including, but not limited to, assumptions about future profitability, cash flows, and discount rates applicable to the acquired business and, where applicable, market participants. These assumptions are based on management's best estimates and include considerations related to management's knowledge and experience, historical trends, general economic conditions, and other situational factors.

The Company's consolidated financial statements include ICOR's results of operations from April 2, 2018, the date of acquisition, through September 30, 2018. Net sales and net income attributable to Chemours contributed by ICOR during this period were not material to the Company's or its Fluoroproducts segment's results of operations. Acquisition-related expenses amounted to less than \$1 during the three and nine months ended September 30, 2018 and are included as a component of selling, general, and administrative expense in the consolidated statements of operations.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Note 4. Net Sales**

**Revenue Recognition**

Prior to the adoption of Topic 606, Chemours recognized revenue when the earnings process was complete. Revenue for product sales was recognized when product was shipped to the customer in accordance with the terms of the agreement, when title and the risk of loss were transferred, when collectability was reasonably assured, and when pricing was fixed or determinable. Any payments received in advance were recorded as deferred revenue and recognized as shipments were made and title, ownership, and the risk of loss were transferred to the customer. The Company accrued for sales returns and other allowances based on its historical experience, with cash sales incentives reflected as a reduction in revenue and non-cash sales incentives reflected as a charge to the cost of goods sold recorded contemporaneously with the related revenue or selling expense, depending on the nature of the incentive. Amounts billed to customers for shipping and handling fees were included in net sales, and the costs incurred by the Company for the delivery of goods were classified as a component of the cost of goods sold in the consolidated statements of operations. Taxes on revenue-producing transactions were excluded from net sales.

Licensing and royalty income was recognized as a component of other income, net in the consolidated statements of operations in accordance with agreed-upon terms, when performance obligations were satisfied, when collectability was reasonably assured, and when pricing was fixed or determinable.

With the adoption of Topic 606, Chemours recognizes revenue using a five-step model resulting in revenue being recognized as performance obligations within a contract have been satisfied. The steps within that model include: (i) identifying the existence of a contract with a customer; (ii) identifying the performance obligations within the contract; (iii) determining the contract's transaction price; (iv) allocating the transaction price to the contract's performance obligations; and, (v) recognizing revenue as the contract's performance obligations are satisfied. A contract with a customer exists when: (i) the Company enters into an enforceable agreement that defines each party's rights regarding the goods or services to be transferred, and the related payment terms; (ii) the agreement has commercial substance; and, (iii) it is probable that the Company will collect the consideration to which it is entitled to in the exchange. A performance obligation is a promise in a contract to transfer a distinct good or service, or a series of distinct goods or services to a customer and serves as the unit of account for Topic 606. The transaction price is the customary amount of consideration that the Company expects to be entitled to in exchange for a transfer of the promised goods or services to a customer, excluding any amounts collected by the Company on behalf of third-parties (e.g., sales and use taxes). Judgment is required to apply the principles-based, five-step model for revenue recognition outlined in Topic 606. Management is required to make certain estimates and assumptions about the Company's contracts with its customers, including, among others, the nature and extent of its performance obligations, its transaction price amounts and any allocations thereof, the critical events which constitute satisfaction of its performance obligations, and when control of any promised goods or services is transferred to its customers.

The Company's revenue from contracts with customers is reflected in the consolidated statements of operations as net sales, the vast majority of which represents product sales that consist of a single performance obligation. Product sales to customers are made under a purchase order (PO), or in certain cases, in accordance with the terms of a master services agreement (MSA) or similar arrangement, which documents the rights and obligations of each party to the contract. When a customer submits a PO for product or requests product under an MSA, a contract for a specific quantity of distinct goods at a specified price is created, and the Company's performance obligation under the contract is satisfied when control of the product is transferred to the customer, which is indicated by shipment of the product and the transfer of title and the risk of loss to the customer. Revenue is recognized on consignment sales when control transfers to the customer, generally at the point of customer usage of the product. The transaction price for product sales is generally the amount specified in the PO or in the request under an MSA; however, as is common in Chemours' industry, the Company offers variable consideration in the form of rebates, volume discounts, early payment discounts, pricing based on formulas or indices, price matching, and guarantees to certain customers. Such amounts are included in the Company's estimated transaction price using either the expected value method or the most-likely amount, depending on the nature of the variable consideration included in the contract. The Company regularly assesses its customers' creditworthiness, and product sales are made based on established credit limits. Payment terms for the Company's invoices are typically less than 90 days.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

The Company also licenses the right to access certain of its trademarks to customers under specified terms and conditions in certain arrangements, which is recognized as a component of net sales in the consolidated statements of operations under Topic 606. Under such arrangements, the Company may receive a royalty payment for a trademark license that is entered into on a stand-alone basis or incorporated into an overall product sales arrangement. Royalty income is generally based on customer sales and recognized under the sales-based exception as the customer sale occurs. When minimum guaranteed royalty amounts are included in the transaction price, the Company recognizes royalty income ratably over the license period for the minimum amount. When there is no consideration specified for the use of the Company's trademark, the entire transaction price is recognized in connection with the transfer of control of product. Royalty income resulting from the right to use the Company's technology is considered outside the scope of Topic 606 as it is not a part of the Company's ongoing major or central activities, and consistent with past practice, is recognized as a component of other income, net in the consolidated statements of operations in accordance with agreed-upon terms at the point or points in time that performance obligations are satisfied.

Consistent with the fact that the vast majority of the Company's payment terms are less than 90 days from the point at which control of the promised goods or services is transferred, no adjustments have been made for the effects of a significant financing component under Topic 606. Additionally, the Company has elected to recognize the incremental costs associated with obtaining contracts as an expense when incurred if the amortization period of the assets that the Company would have recognized is one year or less. Amounts billed to customers for shipping and handling fees are considered a fulfillment cost and are included in net sales, and the costs incurred by the Company for the delivery of goods are classified as a component of the cost of goods sold in the consolidated statements of operations.

**Disaggregation of Net Sales**

The following table sets forth a disaggregation of the Company's net sales by geographic region, product group, and segment for the three months ended September 30, 2018.

|   | Three Months Ended September 30, 2018 |                    |                       |                 |
|---|---------------------------------------|--------------------|-----------------------|-----------------|
|   | Fluoroproducts                        | Chemical Solutions | Titanium Technologies | Total           |
| <b>Net sales by geographic region (1)</b> |                                       |                    |                       |                 |
| North America                             | \$ 273                                | \$ 87              | \$ 228                | \$ 588          |
| Asia Pacific                              | 168                                   | 21                 | 251                   | 440             |
| Europe, the Middle East, and Africa       | 188                                   | 5                  | 189                   | 382             |
| Latin America (2)                         | 53                                    | 42                 | 123                   | 218             |
| <b>Total net sales</b>                    | <u>\$ 682</u>                         | <u>\$ 155</u>      | <u>\$ 791</u>         | <u>\$ 1,628</u> |
| <b>Net sales by product group</b>         |                                       |                    |                       |                 |
| Fluorochemicals                           | \$ 345                                | \$ —               | \$ —                  | \$ 345          |
| Fluoropolymers                            | 337                                   | —                  | —                     | 337             |
| Mining solutions                          | —                                     | 74                 | —                     | 74              |
| Performance chemicals and intermediates   | —                                     | 81                 | —                     | 81              |
| Titanium dioxide and other minerals       | —                                     | —                  | 791                   | 791             |
| <b>Total net sales</b>                    | <u>\$ 682</u>                         | <u>\$ 155</u>      | <u>\$ 791</u>         | <u>\$ 1,628</u> |

(1) Net sales are attributable to countries based on customer location.

(2) Latin America includes Mexico.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

The following table sets forth a disaggregation of the Company's net sales by geographic region, product group, and segment for the nine months ended September 30, 2018.

|   | Nine Months Ended September 30, 2018 |                    |                       |                 |
|---|--------------------------------------|--------------------|-----------------------|-----------------|
|   | Fluoroproducts                       | Chemical Solutions | Titanium Technologies | Total           |
| <b>Net sales by geographic region (1)</b> |                                      |                    |                       |                 |
| North America                             | \$ 888                               | \$ 259             | \$ 700                | \$ 1,847        |
| Asia Pacific                              | 505                                  | 63                 | 754                   | 1,322           |
| Europe, the Middle East, and Africa       | 657                                  | 14                 | 682                   | 1,353           |
| Latin America (2)                         | 163                                  | 117                | 372                   | 652             |
| <b>Total net sales</b>                    | <b>\$ 2,213</b>                      | <b>\$ 453</b>      | <b>\$ 2,508</b>       | <b>\$ 5,174</b> |
| <b>Net sales by product group</b>         |                                      |                    |                       |                 |
| Fluorochemicals                           | \$ 1,183                             | \$ —               | \$ —                  | \$ 1,183        |
| Fluoropolymers                            | 1,030                                | —                  | —                     | 1,030           |
| Mining solutions                          | —                                    | 212                | —                     | 212             |
| Performance chemicals and intermediates   | —                                    | 241                | —                     | 241             |
| Titanium dioxide and other minerals       | —                                    | —                  | 2,508                 | 2,508           |
| <b>Total net sales</b>                    | <b>\$ 2,213</b>                      | <b>\$ 453</b>      | <b>\$ 2,508</b>       | <b>\$ 5,174</b> |

(1) Net sales are attributed to countries based on customer location.

(2) Latin America includes Mexico.

Substantially all of the Company's net sales are derived from goods and services transferred at a point in time.

**Contract Balances**

The Company's assets and liabilities from contracts with customers constitute accounts receivable - trade, deferred revenue, and customer rebates. An amount for accounts receivable - trade is recorded when the right to consideration under a contract becomes unconditional. An amount for deferred revenue is recorded when consideration is received prior to the conclusion that a contract exists, or when a customer transfers consideration prior to the Company satisfying its performance obligations under a contract. Customer rebates represent an expected refund liability to a customer based on a contract. In contracts with customers where a rebate is offered, it is generally applied retroactively based on the achievement of a certain sales threshold. As revenue is recognized, the Company estimates whether or not the sales threshold will be achieved to determine the amount of variable consideration to include in the transaction price.

The following table sets forth the Company's contract balances from contracts with customers at September 30, 2018 and December 31, 2017.

|                                      | September 30, 2018 | December 31, 2017 |
|--------------------------------------|--------------------|-------------------|
| Accounts receivable - trade, net (1) | \$ 925             | \$ 847            |
| Customer rebates                     | 72                 | 83                |

(1) Accounts receivable - trade, net includes trade notes receivable of \$2 and \$1 at September 30, 2018 and December 31, 2017, respectively, and is net of allowances for doubtful accounts of \$5 at September 30, 2018 and December 31, 2017. Such allowances are equal to the estimated uncollectible amounts.

The Company's deferred revenue balances at September 30, 2018 and December 31, 2017 were not significant. Additionally, changes in the Company's deferred revenue balances resulting from additions for advance payments and deductions for amounts recognized in net sales during the three and nine months ended September 30, 2018 were not significant. For the three and nine months ended September 30, 2018, the amount of revenue recognized from performance obligations satisfied in prior periods (e.g., due to changes in transaction price) was not significant.

There were no other contract asset balances or capitalized costs associated with obtaining or fulfilling customer contracts at September 30, 2018 or December 31, 2017.



**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Remaining Performance Obligations**

Certain of the Company's MSA or other arrangements contain take-or-pay clauses, whereby customers are required to purchase a fixed minimum quantity of product during a specified period, or pay the Company for such orders, even if not requested by the customer. The Company considers these take-or-pay clauses to be an enforceable contract, and as such, the legally-enforceable minimum amounts under such an arrangement are considered to be outstanding performance obligations on contracts with an original expected duration greater than one year. At September 30, 2018, Chemours had \$90 of remaining performance obligations. The Company expects to recognize approximately 10% of its remaining performance obligations as revenue in 2018, an additional 30% in 2019, and the balance thereafter. The Company applies the practical expedient in Topic 606 and does not include remaining performance obligations that have original expected durations of one year or less, or amounts for variable consideration allocated to wholly-unsatisfied performance obligations or wholly-unsatisfied distinct goods that form part of a single performance obligation, if any. Amounts for contract renewals that are not yet exercised by September 30, 2018 are also excluded.

**Note 5. Restructuring, Asset-related, and Other Charges**

The following table sets forth the components of the Company's restructuring, asset-related, and other charges by category for the three and nine months ended September 30, 2018 and 2017.

|  | Three Months Ended September 30, |             | Nine Months Ended September 30, |              |
|--|----------------------------------|-------------|---------------------------------|--------------|
|  | 2018                             | 2017        | 2018                            | 2017         |
| <b>Restructuring and other charges:</b>                      |                                  |             |                                 |              |
| Employee separation charges                                  | \$ 2                             | \$ —        | \$ 8                            | \$ 5         |
| Decommissioning and other charges                            | 10                               | 8           | 24                              | 26           |
| <b>Total restructuring, asset-related, and other charges</b> | <b>\$ 12</b>                     | <b>\$ 8</b> | <b>\$ 32</b>                    | <b>\$ 31</b> |

The following table sets forth the impacts of the Company's restructuring, asset-related, and other charges to segment earnings for the three and nine months ended September 30, 2018 and 2017.

|  | Three Months Ended September 30, |             | Nine Months Ended September 30, |              |
|--|----------------------------------|-------------|---------------------------------|--------------|
|  | 2018                             | 2017        | 2018                            | 2017         |
| <b>Plant and product line closures:</b>                      |                                  |             |                                 |              |
| Fluoroproducts   | \$ —                             | \$ —        | \$ —                            | \$ 3         |
| Chemical Solutions   | 1                                | 5           | 4                               | 16           |
| Titanium Technologies  | —                                | —           | —                               | 4            |
| Corporate and Other  | 4                                | —           | 6                               | —            |
| Total plant and product line closures                        | 5                                | 5           | 10                              | 23           |
| <b>2017 Restructuring Program:</b>                           |                                  |             |                                 |              |
| Fluoroproducts   | 2                                | —           | 7                               | —            |
| Chemical Solutions   | —                                | —           | 1                               | —            |
| Corporate and Other  | 5                                | 3           | 14                              | 8            |
| Total 2017 Restructuring Program                             | 7                                | 3           | 22                              | 8            |
| <b>Total restructuring, asset-related, and other charges</b> | <b>\$ 12</b>                     | <b>\$ 8</b> | <b>\$ 32</b>                    | <b>\$ 31</b> |

**Plant and Product Line Closures**

In August 2015, in an effort to improve the profitability of the Company's Fluoroproducts segment, management approved the closure of certain production lines in the segment's U.S. manufacturing plants. For the nine months ended September 30, 2017, the Company recorded additional decommissioning and dismantling-related charges of \$3 for certain of these production lines. At December 31, 2017, the Company had substantially completed all actions related to the restructuring activities for certain of its production lines, which amounted to \$17 in the aggregate, excluding non-cash asset-related charges.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

In the fourth quarter of 2015, the Company announced the completion of the strategic review of its Reactive Metals Solutions (RMS) business and management's decision to stop production at its Niagara Falls, New York manufacturing plant. The RMS plant had approximately 200 employees and contractors impacted by this action, and production stopped at the plant in September 2016, when the Company immediately began actions to decommission the plant. The Company recorded additional decommissioning and dismantling-related charges of \$1 and \$4 for the three and nine months ended September 30, 2018, respectively, and \$5 and \$16 for the three and nine months ended September 30, 2017, respectively. The Company expects to incur approximately \$10 in additional restructuring charges for similar activities through 2021, which will be expensed as incurred. As of September 30, 2018, the Company incurred, in the aggregate, \$35 in restructuring charges related to these activities, excluding non-cash asset-related charges.

In August 2015, the Company announced the closure of its Edge Moor, Delaware manufacturing plant. The Edge Moor plant produced TiO<sub>2</sub> pigment for use in the paper industry and certain other applications where demand had steadily declined, resulting in under-used capacity at the plant. In addition, the Company permanently closed one under-used TiO<sub>2</sub> pigment production line at its New Johnsonville, Tennessee plant. The Company stopped production at its Edge Moor plant in September 2015, and immediately began decommissioning the plant. For the nine months ended September 30, 2017, the Company recorded additional decommissioning and dismantling-related charges of \$4. The Company completed these activities in 2017, which amounted to \$60 in the aggregate, excluding non-cash asset-related charges. The Company sold the land where the plant was located for \$10 in the first quarter of 2017.

In the first quarter of 2018, the Company began a project to demolish and remove several dormant, unused buildings at its Chambers Works site in Deepwater, New Jersey, which were assigned to Chemours in connection with its separation from DuPont. For the three and nine months ended September 30, 2018, the Company incurred \$4 and \$6 in decommissioning and dismantling-related charges associated with these efforts, respectively. The Company expects to incur approximately \$25 to \$30 in additional restructuring charges related to its Chambers Works site through the end of 2020, which will be reflected in Corporate and Other, and will be expensed as incurred.

**2017 Restructuring Program**

In 2017, the Company announced certain restructuring activities designed to further the cost savings and productivity improvements outlined under management's transformation plan. These activities include, among other efforts: (i) outsourcing and further centralizing certain business process activities; (ii) consolidating existing, outsourced third-party information technology (IT) providers; and, (iii) implementing various upgrades to the Company's current IT infrastructure.

In 2017, the Company also announced a voluntary separation program (VSP) for certain eligible U.S. employees in an effort to better manage the anticipated future changes to its workforce. Employees who volunteered for and were accepted under the VSP are entitled to receive certain financial incentives above the Company's customary involuntary termination benefits to end their employment with Chemours after providing a mutually agreed-upon service period. Approximately 300 employees will separate from the Company by the end of 2018. An accrual representing the majority of these termination benefits, amounting to \$18, was recognized in the fourth quarter of 2017. The remaining incremental, one-time financial incentives under the VSP will be recognized over the period that each participating employee continues to provide service to Chemours.

The Company recorded additional charges of \$7 and \$22 for the three and nine months ended September 30, 2018, respectively, and \$3 and \$8 for the three and nine months ended September 30, 2017, respectively, for its 2017 program. The cumulative amount incurred, in the aggregate, for the Company's 2017 program amounted to \$54 at September 30, 2018.

As a result of its 2017 program, the Company expects to incur incremental charges for restructuring-related activities and termination benefits ranging from \$5 to \$10 through the end of 2018, which will be expensed as incurred.

The following table sets forth the change in the Company's employee separation-related liabilities associated with its restructuring programs for the nine months ended September 30, 2018.

|                                      | Fluoroproducts<br>Lines<br>Shutdown | Chemical<br>Solutions Site<br>Closures | Titanium<br>Technologies<br>Site Closures | 2015 Global<br>Restructuring<br>Program | 2017<br>Restructuring<br>Program | Total        |
|--------------------------------------|-------------------------------------|--|---|---|----------------------------------|--------------|
| <b>Balance at December 31, 2017</b>  | \$ —                                | \$ 2                                   | \$ 1                                      | \$ 1                                    | \$ 23                            | \$ 27        |
| Charges to income                    | —                                   | —                                      | —   | —                                       | 8                                | 8            |
| Payments                             | —                                   | (1)                                    | —   | (1)                                     | (15)                             | (17)         |
| <b>Balance at September 30, 2018</b> | <u>\$ —</u>                         | <u>\$ 1</u>                            | <u>\$ 1</u>                               | <u>\$ —</u>                             | <u>\$ 16</u>                     | <u>\$ 18</u> |

At September 30, 2018, there are no significant outstanding liabilities related to the Company's decommissioning and other restructuring-related charges.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Note 6. Other Income, Net**

The following table sets forth the components of the Company's other income, net for the three and nine months ended September 30, 2018 and 2017.

|   | Three Months Ended September 30, |              | Nine Months Ended September 30, |              |
|---|----------------------------------|--------------|---------------------------------|--------------|
|   | 2018                             | 2017         | 2018                            | 2017         |
| Leasing, contract services, and miscellaneous income (1)                | \$ 24                            | \$ 7         | \$ 47                           | \$ 24        |
| Royalty income (2)  | 2                                | 2            | 9                               | 12           |
| Gain on sales of assets and businesses (3)                              | —                                | —            | 45                              | 14           |
| Exchange (losses) gains, net (4)  | (6)                              | (4)          | (4)                             | 3            |
| Non-operating pension and other post-retirement employee benefit income | 4                                | 7            | 18                              | 24           |
| <b>Total other income, net</b>  | <b>\$ 24</b>                     | <b>\$ 12</b> | <b>\$ 115</b>                   | <b>\$ 77</b> |

- (1) Leasing, contract services, and miscellaneous income includes European Union quota authorization sales of \$18 and \$38 for the three and nine months ended September 30, 2018, respectively, and \$6 and \$14 for the three and nine months ended September 30, 2017, respectively.
- (2) Royalty income for the three and nine months ended September 30, 2018 is primarily from technology licensing. Royalty income for the three and nine months ended September 30, 2017 is primarily from technology and trademark licensing.
- (3) For the nine months ended September 30, 2018, gain on sale includes a \$3 gain and a \$42 gain associated with the sales of the Company's East Chicago, Indiana and Linden, New Jersey sites, respectively. For the nine months ended September 30, 2017, gain on sale includes a \$12 gain associated with the sale of the Company's Edge Moor, Delaware site and a \$4 gain associated with the sale of the Company's land in Repauno, New Jersey that was previously deferred and realized upon meeting certain milestones, which are offset by a \$2 adjustment associated with the sale of the Company's Sulfur business in 2016.
- (4) Exchange (losses) gains, net includes gains and losses on the Company's foreign currency forward contracts that have not been designated as a cash flow hedge.

**Note 7. Income Taxes**

For the three months ended September 30, 2018 and 2017, Chemours recorded a benefit from and a provision for income taxes amounting to \$6 and \$43, resulting in effective income tax rates of approximately negative 2% and 17%, respectively. For the nine months ended September 30, 2018 and 2017, Chemours recorded provisions for income taxes amounting to \$119 and \$130, resulting in effective income tax rates of approximately 12% and 20%, respectively.

The change in the Company's benefit from income taxes for the three months ended September 30, 2018 was primarily attributable to the following: \$17 in income tax benefits related to the reversal of the valuation allowance on carryforward foreign tax credits due to changes in normal business operations; \$14 in income tax benefits related to the filing of the Company's 2017 U.S. tax return and the associated adjustments on the revaluation of certain deferred tax assets and liabilities as a result of the reduced corporate tax rate; \$4 in income tax benefits related to windfalls on share-based payments; and, the Company's geographic mix of earnings. The aforementioned income tax benefits were somewhat offset by increased tax expenses resulting from the Company's increased profitability for the three months then-ended. The change in the Company's provision for income taxes for the nine months ended September 30, 2018 was primarily attributable to the following: \$17 in income tax benefits related to the reversal of the valuation allowance on carryforward foreign tax credits due to changes in normal business operations; \$14 in income tax benefits related to the filing of the Company's 2017 U.S. tax return and the associated adjustments on the revaluation of certain deferred tax assets and liabilities as a result of the reduced corporate tax rate; \$14 in income tax benefits related to windfalls on share-based payments; \$10 in income tax benefits related to the Company's loss on debt extinguishment; and, the Company's geographic mix of earnings. The aforementioned income tax benefits were somewhat offset by increased tax expenses resulting from the Company's increased profitability for the nine months then-ended, as well as \$10 in income tax expense related to asset sales that took place during the first quarter, and \$23 in income tax expense related to the impact of certain U.S. tax reform provisions.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

In connection with the new federal tax legislation commonly referred to as the Tax Cut and Jobs Act (Tax Act), the Company recorded provisional estimates for U.S. tax reform in its provision for income taxes for the year ended December 31, 2017, which amounted to a net benefit of \$3. Staff Accounting Bulletin No. 118 (SAB No. 118) issued by the U.S. Securities and Exchange Commission (SEC) allows registrants to record provisional estimates for the Tax Act during a measurement period not to exceed one year from the enactment date, which was December 22, 2017. The impacts of the Tax Act may differ from the Company's provisional estimates due to many factors, including, but not limited to, changes to its interpretations of the provisions in the Tax Act, U.S. Internal Revenue Service and U.S. Treasury guidance that may be issued, and actions that the Company may take. During the three and nine months ended September 30, 2018, the Company recorded a \$10 tax benefit to adjust its initial provisional estimates for U.S. tax reform in its benefit from and provision for income taxes, which impacted its effective tax rates by approximately 4% and 1%, respectively. The adjustment was specifically related to the Company's initial estimate of the revaluation of certain deferred tax assets and liabilities as a result of the reduced corporate tax rate, the transition tax (as defined in the Tax Act) on previously untaxed accumulated and current earnings and profits of certain of the Company's foreign subsidiaries, and the associated foreign tax credits. The Company, to date, has not made any other significant changes to its initial provisional estimates recorded in the fourth quarter of 2017.

The Company continues to evaluate the effects of the Tax Act's provisions on its consolidated financial statements; however, the Company expects to complete its evaluation within the applicable measurement period, pursuant to SAB No. 118. As such, the Company's provisional estimates for the Tax Act may continue to change within this period, resulting in a material impact to its financial position, results of operations, or cash flows.

Each year, Chemours and/or its subsidiaries file income tax returns in U.S. federal and state jurisdictions and non-U.S. jurisdictions. These tax returns are subject to examination and possible challenge by the cognizant taxing authorities. Positions challenged by the taxing authorities may be settled or appealed by Chemours. As a result, income tax uncertainties are recognized in Chemours' consolidated financial statements in accordance with accounting for income taxes under Topic 740, *Income Taxes*, when applicable.

**Note 8. Earnings Per Share of Common Stock**

The following table sets forth reconciliations of the numerators and denominators for the Company's basic and diluted earnings per share (EPS) calculations for the three and nine months ended September 30, 2018 and 2017.

|  | Three Months Ended September 30, |                    | Nine Months Ended September 30, |                    |
|--|----------------------------------|--------------------|---------------------------------|--------------------|
|  | 2018                             | 2017               | 2018                            | 2017               |
| <b>Numerator:</b>  |                                  |                    |                                 |                    |
| Net income attributable to Chemours                            | \$ 275                           | \$ 207             | \$ 853                          | \$ 518             |
| <b>Denominator:</b>  |                                  |                    |                                 |                    |
| Weighted-average number of common shares outstanding - basic   | 176,489,881                      | 185,431,036        | 178,765,676                     | 184,641,599        |
| Dilutive effect of the Company's employee compensation plans   | 5,387,244                        | 6,206,778          | 5,891,072                       | 5,909,015          |
| Weighted-average number of common shares outstanding - diluted | <u>181,877,125</u>               | <u>191,637,814</u> | <u>184,656,748</u>              | <u>190,550,614</u> |
| Basic earnings per share of common stock                       | \$ 1.56                          | \$ 1.12            | \$ 4.77                         | \$ 2.81            |
| Diluted earnings per share of common stock                     | 1.51                             | 1.08               | 4.62                            | 2.72               |

The following table sets forth the average number of stock options that were anti-dilutive and, therefore, were not included in the Company's diluted EPS calculations for the three and nine months ended September 30, 2018 and 2017.

|                                 | Three Months Ended September 30, |      | Nine Months Ended September 30, |        |
|---------------------------------|----------------------------------|------|---------------------------------|--------|
|                                 | 2018                             | 2017 | 2018                            | 2017   |
| Average number of stock options | 480,123                          | 954  | 160,041                         | 57,429 |

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Note 9. Accounts and Notes Receivable, Net**

The following table sets forth the components of the Company's accounts and notes receivable, net at September 30, 2018 and December 31, 2017.

|   | September 30, 2018 | December 31, 2017 |
|---|--------------------|-------------------|
| Accounts receivable - trade, net (1)            | \$ 925             | \$ 847            |
| VAT, GST, and other taxes (2)                   | 58                 | 54                |
| Other receivables (3)                           | 15                 | 18                |
| <b>Total accounts and notes receivable, net</b> | <b>\$ 998</b>      | <b>\$ 919</b>     |

- (1) Accounts receivable - trade, net includes trade notes receivable of \$2 and \$1 at September 30, 2018 and December 31, 2017, respectively, and is net of allowances for doubtful accounts of \$5 at September 30, 2018 and December 31, 2017. Such allowances are equal to the estimated uncollectible amounts.
- (2) Value added tax (VAT) and goods and services tax (GST) for various jurisdictions.
- (3) Other receivables consist of notes receivable, advances, the fair value of derivative assets, and other deposits.

Accounts and notes receivable are carried at amounts that approximate fair value. Bad debt expense was not significant for the three and nine months ended September 30, 2018 and 2017.

**Note 10. Inventories**

The following table sets forth the components of the Company's inventories at September 30, 2018 and December 31, 2017.

|   | September 30, 2018 | December 31, 2017 |
|---|--------------------|-------------------|
| Finished products                             | \$ 707             | \$ 648            |
| Semi-finished products                        | 188                | 164               |
| Raw materials, stores, and supplies           | 403                | 313               |
| Inventories before LIFO adjustment            | 1,298              | 1,125             |
| Less: Adjustment of inventories to LIFO basis | (212)              | (190)             |
| <b>Total inventories</b>                      | <b>\$ 1,086</b>    | <b>\$ 935</b>     |

Inventory values, before last-in, first-out (LIFO) adjustment, are generally determined by the average cost method, which approximates current cost. Inventories are valued under the LIFO method at substantially all of the Company's U.S. locations, which comprised \$564 and \$509 (or 44% and 45%) of its inventories balances before the LIFO adjustments at September 30, 2018 and December 31, 2017, respectively. The remainder of inventory held in international locations and certain U.S. locations is valued under the average cost method.

**Note 11. Property, Plant, and Equipment, Net**

The following table sets forth the components of the Company's property, plant, and equipment, net at September 30, 2018 and December 31, 2017.

|  | September 30, 2018 | December 31, 2017 |
|--|--------------------|-------------------|
| Equipment  | \$ 7,029           | \$ 6,961          |
| Buildings  | 898                | 875               |
| Construction-in-progress                         | 802                | 520               |
| Land   | 120                | 119               |
| Mineral rights                                   | 36                 | 36                |
| Property, plant, and equipment                   | 8,885              | 8,511             |
| Less: Accumulated depreciation                   | (5,678)            | (5,503)           |
| <b>Total property, plant, and equipment, net</b> | <b>\$ 3,207</b>    | <b>\$ 3,008</b>   |

Depreciation expense amounted to \$68 and \$207 for the three and nine months ended September 30, 2018, respectively, and \$61 and \$201 for the three and nine months ended September 30, 2017, respectively. Property, plant, and equipment, net includes gross assets under capital leases of \$7 at September 30, 2018 and December 31, 2017, and a build-to-suit lease asset of \$49 and \$8 at September 30, 2018 and December 31, 2017, respectively.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Note 12. Other Assets**

The following table sets forth the components of the Company's other assets at September 30, 2018 and December 31, 2017.

|  | September 30, 2018 | December 31, 2017 |
|--|--------------------|-------------------|
| Capitalized repair and maintenance costs | \$ 122             | \$ 117            |
| Pension assets (1)                       | 287                | 260               |
| Deferred income taxes                    | 45                 | 40                |
| Miscellaneous (2)                        | 37                 | 36                |
| <b>Total other assets</b>                | <b>\$ 491</b>      | <b>\$ 453</b>     |

- (1) Pension assets represent the funded status of certain of the Company's long-term employee benefit plans.
- (2) Miscellaneous primarily includes deferred issuance costs related to the Company's senior secured revolving credit facility of \$10 and \$9 at September 30, 2018 and December 31, 2017, respectively, and Company-owned life insurance policies on former key executives of a U.S. subsidiary. These life insurance policies have a cash surrender value of \$64 at September 30, 2018 and December 31, 2017, and are presented net of outstanding loans from the policy issuer of \$64 and \$63 at September 30, 2018 and December 31, 2017, respectively.

**Note 13. Accounts Payable**

The following table sets forth the components of the Company's accounts payable at September 30, 2018 and December 31, 2017.

|                               | September 30, 2018 | December 31, 2017 |
|-------------------------------|--------------------|-------------------|
| Trade payables                | \$ 1,095           | \$ 1,008          |
| Dividends payable (1)         | —                  | 31                |
| VAT and other payables        | 28                 | 36                |
| <b>Total accounts payable</b> | <b>\$ 1,123</b>    | <b>\$ 1,075</b>   |

- (1) Represents a \$0.17 per share dividend declared in December 2017, which was paid on March 15, 2018 to the Company's shareholders of record as of the close of business on February 15, 2018.

**Note 14. Other Accrued Liabilities**

The following table sets forth the components of the Company's other accrued liabilities at September 30, 2018 and December 31, 2017.

|   | September 30, 2018 | December 31, 2017 |
|---|--------------------|-------------------|
| Compensation and other employee-related costs | \$ 102             | \$ 174            |
| Employee separation costs (1)                 | 18                 | 27                |
| Accrued litigation (2)                        | 46                 | 13                |
| Environmental remediation (2)                 | 81                 | 66                |
| Income taxes                                  | 86                 | 58                |
| Customer rebates                              | 72                 | 83                |
| Deferred income                               | 5                  | 8                 |
| Accrued interest                              | 60                 | 24                |
| Miscellaneous (3)                             | 91                 | 105               |
| <b>Total other accrued liabilities</b>        | <b>\$ 561</b>      | <b>\$ 558</b>     |

- (1) Represents the current portion of accrued employee separation costs related to the Company's restructuring and other activities.
- (2) Represents the current portions of accrued litigation and environmental remediation, which are discussed further in "Note 17 - Commitments and Contingent Liabilities."
- (3) Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, the current portion of the Company's asset retirement obligations, and other miscellaneous expenses.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Note 15. Debt**

The following table sets forth the components of the Company's debt at September 30, 2018 and December 31, 2017.

|   | September 30, 2018 | December 31, 2017 |
|---|--------------------|-------------------|
| Senior secured term loans:  |                    |                   |
| Tranche B-1 Dollar Term Loan due May 2022                               | \$ —               | \$ 923            |
| Tranche B-1 Euro Term Loan due May 2022<br>(€395 at December 31, 2017)  | —                  | 469               |
| Tranche B-2 Dollar Term Loan due May 2025                               | 896                | —                 |
| Tranche B-2 Euro Term Loan due May 2025<br>(€348 at September 30, 2018) | 410                | —                 |
| Senior unsecured notes:   |                    |                   |
| 6.625% due May 2023   | 908                | 1,158             |
| 7.000% due May 2025   | 750                | 750               |
| 6.125% due May 2023<br>(€295 at December 31, 2017)                      | —                  | 350               |
| 4.000% due May 2026<br>(€450 at September 30, 2018)                     | 529                | —                 |
| 5.375% due May 2027   | 500                | 500               |
| Capital lease obligations   | 2                  | 3                 |
| Build-to-suit lease obligation  | 49                 | 8                 |
| <b>Total debt</b>   | <b>4,044</b>       | <b>4,161</b>      |
| Less: Unamortized issue discounts                                       | (10)               | (8)               |
| Less: Unamortized debt issuance costs                                   | (35)               | (41)              |
| Less: Current maturities of long-term debt                              | (14)               | (15)              |
| <b>Total long-term debt, net</b>  | <b>\$ 3,985</b>    | <b>\$ 4,097</b>   |

**Senior Secured Credit Facilities**

On April 3, 2017, the Company completed an amendment to its then-existing credit agreement which provided for seven-year, senior secured term loans and a five-year, \$750 senior secured revolving credit facility (Prior Revolving Credit Facility) (collectively, the Prior Senior Secured Credit Facilities). The senior secured term loan facility under the Prior Senior Secured Credit Facilities provided for a class of term loans, denominated in U.S. dollars, in an aggregate principal amount of \$940 (Prior Dollar Term Loan) and a class of term loans, denominated in euros, in an aggregate principal amount of €400 (Prior Euro Term Loan) (collectively, the Prior Term Loans). On April 3, 2018, the Company entered into an amended and restated credit agreement that provides for a seven-year, senior secured term loan facility and a five-year, \$800 senior secured revolving credit facility (New Revolving Credit Facility) (collectively, the New Senior Secured Credit Facilities). The New Senior Secured Credit Facilities replaced, in full, the Company's obligations under the Prior Senior Secured Credit Facilities, and is subject to a springing maturity in the event that the senior unsecured notes due in May 2023 are not redeemed, repaid, modified, and/or refinanced within the 91-day period prior to their maturity date.

The senior secured term loan facility under the New Senior Secured Credit Facilities provides for a class of term loans, denominated in U.S. dollars, in an aggregate principal amount of \$900 (New Dollar Term Loan) and a class of term loans, denominated in euros, in an aggregate principal amount of €350 (New Euro Term Loan) (collectively, the New Term Loans). The proceeds of the New Term Loans, together with cash on hand, were primarily used to prepay, in full, all outstanding amounts under the Prior Senior Secured Credit Facilities, which amounted to \$921 for the Prior Dollar Term Loan and €393 for the Prior Euro Term Loan. The New Dollar Term Loan bears a variable interest rate equal to, at the election of the Company, adjusted LIBOR plus 1.75% or adjusted base rate plus 0.75%, subject to an adjusted LIBOR or an adjusted base rate floor of 0.00% or 1.00%, respectively. The New Euro Term Loan bears a variable interest rate equal to adjusted EURIBOR plus 2.00%, subject to an adjusted EURIBOR floor of 0.50%. The New Term Loans will mature on April 3, 2025, and are subject to acceleration in certain circumstances.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

The proceeds of any loans made under the New Revolving Credit Facility can be used for working capital needs and other general corporate purposes, including permitted acquisitions and other transactions, as defined in the amended and restated credit agreement. The New Revolving Credit Facility bears a variable interest rate range based on the Company's total net leverage ratio, as defined in the amended and restated credit agreement, between (i) a 0.25% and a 1.00% spread for adjusted base rate loans, and (ii) a 1.25% and a 2.00% spread for LIBOR and EURIBOR loans. In addition, the Company is required to pay a commitment fee on the average daily unused amount of the New Revolving Credit Facility within an interest rate range based on its total net leverage ratio, between 0.10% and 0.25%. The New Revolving Credit Facility will mature on April 3, 2023, and is subject to acceleration in certain circumstances.

There were no borrowings under the New Revolving Credit Facility at September 30, 2018 or under the Prior Revolving Credit Facility at December 31, 2017. Issued and outstanding letters of credit under the New Revolving Credit Facility amounted to \$104 at September 30, 2018. Issued and outstanding letters of credit under the Prior Revolving Credit Facility amounted to \$101 at December 31, 2017. At September 30, 2018, the effective interest rates on the New Dollar Term Loan and the New Euro Term Loan were 4.00% and 2.50%, respectively, and commitment fees on the New Revolving Credit Facility were assessed at a rate of 0.10% per annum. In connection with the issuance of the New Senior Secured Credit Facilities, the Company incurred a loss on debt extinguishment of \$3 for the nine months ended September 30, 2018.

The amended and restated credit agreement also modified or eliminated certain provisions of the Company's prior credit agreement, including the interest coverage ratio financial covenant and certain other negative covenants to allow for further flexibility. Under the amended and restated credit agreement, solely with respect to the New Revolving Credit Facility, the Company is required to not exceed a maximum senior secured net leverage ratio of (i) 2.25 to 1.00 in each quarter through December 31, 2018, and (ii) 2.00 to 1.00 in each quarter beginning January 1, 2019, through the date of maturity. In addition, the amended and restated credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict the Company's and its subsidiaries' ability, subject to certain exceptions, to incur additional indebtedness or liens, pay dividends, and engage in certain transactions, including mergers, acquisitions, asset sales, or investments, outside of specified carve-outs. The amended and restated credit agreement also contains customary representations and warranties and events of default, which are substantially similar to those in the prior credit agreement. The Company was in compliance with its debt covenants at September 30, 2018.

The Company's obligations under the New Senior Secured Credit Facilities are guaranteed on a senior secured basis by all of its material domestic subsidiaries, which are also guarantors of the Company's outstanding notes, subject to certain exceptions. The obligations under the New Senior Secured Credit Facilities are also, subject to certain exceptions, secured by a first priority lien on substantially all of the Company's assets and substantially all of the assets of its wholly-owned, material domestic subsidiaries, including 100% of the stock of certain of its domestic subsidiaries and 65% of the stock of certain of its foreign subsidiaries.

### **Senior Unsecured Notes**

#### *Senior Unsecured Notes due May 2023*

On May 21, 2018, the Company commenced two all-cash tender offers to purchase: (i) up to \$250 of the outstanding 6.625% senior unsecured notes due May 2023, denominated in U.S. dollars (2023 Dollar Notes), for a purchase price of \$1,052.50 per \$1,000.00 of principal amount through an early tender deadline of June 4, 2018, and \$1,022.50 per \$1,000.00 of principal amount thereafter, through June 18, 2018, the tender expiration date, plus any accrued and unpaid interest thereon (Dollar Tender Offer); and, (ii) any and all of the outstanding 6.125% senior unsecured notes due May 2023, denominated in euros (2023 Euro Notes) (collectively, the 2023 Notes), for a purchase price of €1,048.75 per €1,000.00 of principal amount through an early tender deadline of June 4, 2018, and €1,018.75 per €1,000.00 of principal amount thereafter, through June 18, 2018, the tender expiration date, plus any accrued and unpaid interest thereon (Euro Tender Offer) (collectively, the Tender Offers).

The Company completed the Dollar Tender Offer on June 6, 2018 for an aggregate purchase price of \$264, inclusive of an early participation premium of \$13 and accrued interest of \$1. The Company completed the Euro Tender Offer on June 8, 2018 for an aggregate purchase price of €310, inclusive of an early participation premium of €14 and accrued interest of €1. In connection with the Euro Tender Offer, the Company received consents from the holders of a majority of the aggregate principal amount of the 2023 Euro Notes to amend certain provisions of the indenture governing the 2023 Euro Notes, thereby allowing the Company to call and redeem the remaining 2023 Euro Notes outstanding upon two business days' notice to the noteholders. On June 8, 2018, the Company completed the redemption of the remaining outstanding 2023 Euro Notes that were not purchased pursuant to the Euro Tender Offer. The Tender Offers and the redemption of the 2023 Euro Notes were funded with the proceeds from the offering of the 2026 Euro Notes (defined below) and cash on hand.



**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

*Senior Unsecured Notes due May 2026*

On June 6, 2018, the Company issued, in an underwritten public offering, 4.000% senior unsecured notes due May 2026, denominated in euros, in an aggregate principal amount of €450 (2026 Euro Notes). The 2026 Euro Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by each of the Company's existing and future direct and indirect domestic restricted subsidiaries that (i) incurs or guarantees indebtedness under the New Senior Secured Credit Facilities, or (ii) guarantees certain other indebtedness of the Company or any guarantor in an aggregate principal amount in excess of \$100. The 2026 Euro Notes require payment of principal at maturity and payments of interest semi-annually in cash and in arrears on May 15 and November 15 of each year. Pursuant to the terms of the indenture governing the 2026 Euro Notes, the Company is obligated to offer to purchase the 2026 Euro Notes at a price of 101% of the principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, upon the occurrence of certain change of control events. Prior to May 15, 2021, the Company may redeem the 2026 Euro Notes (i) in whole or in part, at an amount equal to 100% of the aggregate principal amount plus a specified "make-whole" premium, and (ii) on one or more occasions, up to 35% of the aggregate principal amount of the notes, with the net cash proceeds of one or more equity offerings at a price equal to 104% of the principal amounts of such notes, plus accrued and unpaid interest, if any, up to, but excluding, the redemption date. The guarantees of the 2026 Euro Notes will rank equally with all other senior indebtedness of the guarantors. The 2026 Euro Notes rank equally in right of payment to all of the Company's existing and future unsecured unsubordinated debt and are senior in right of payment to all of its existing and future debt that is, by its terms, expressly subordinated in right of payment to the 2026 Euro Notes. The 2026 Euro Notes are subordinated to indebtedness under the New Senior Secured Credit Facilities, as well as any future secured debt to the extent of the value of the assets securing such debt, and are structurally subordinated to the liabilities of any non-guarantor subsidiaries.

The Company received net proceeds of €445 from the offering of the 2026 Euro Notes, which, together with cash on hand, were used to purchase or redeem, as the case may be, the 2023 Notes pursuant to the Tender Offers and the redemption of the 2023 Euro Notes, as well as pay for any fees and expenses in connection therewith. In connection with the concurrent redemption of the 2023 Euro Notes and issuance of the 2026 Euro Notes, the Company incurred a loss on extinguishment of \$35 for the nine months ended September 30, 2018.

***Build-to-suit Lease Obligation***

In October 2017, Chemours executed a build-to-suit lease agreement to construct a new 312,000-square-foot research and development facility on the Science, Technology, and Advanced Research campus of the University of Delaware (UD) in Newark, Delaware (The Chemours Discovery Hub). The land on which The Chemours Discovery Hub will be located is leased to a third-party owner-lessor by UD, and Chemours will act as the construction agent and ultimate lessee of the facility based on the Company's agreement with the owner-lessor. Project costs paid by the owner-lessor are reflected in the Company's consolidated balance sheets as construction-in-progress within property, plant, and equipment, and a corresponding build-to-suit lease liability within long-term debt. Through September 30, 2018, project costs paid by the owner-lessor amounted to \$49. Construction of The Chemours Discovery Hub is expected to be completed by early 2020.

***Maturities***

The Company has required quarterly payments related to the New Senior Secured Credit Facilities equivalent to 1.00% per annum through December 2024, with the balance due at maturity. Principal maturities on the New Senior Secured Credit Facilities over the next five years are approximately \$3 for the remainder of 2018, approximately \$13 in each year from 2019 to 2022, and \$1,250 in 2023 and beyond. Also, following the end of each fiscal year commencing on the year ended December 31, 2019, on an annual basis, the Company is required to make additional principal payments depending on leverage levels, as defined in the amended and restated credit agreement, equivalent to up to 50% of excess cash flows based on certain leverage targets with step-downs to 25% and 0% as actual leverage decreases to below a 3.50 to 1.00 leverage target. Debt maturities related to the Company's senior unsecured notes in 2023 and beyond will be \$2,687.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Debt Fair Value**

The following table sets forth the estimated fair values of the Company's senior debt issues, which are based on quotes received from third-party brokers, and are classified as Level 2 financial instruments in the fair value hierarchy.

|   | September 30, 2018 |                 | December 31, 2017 |                 |
|---|--------------------|-----------------|-------------------|-----------------|
|   | Carrying Value     | Fair Value      | Carrying Value    | Fair Value      |
| <b>Senior secured term loans:</b>                                       |                    |                 |                   |                 |
| Tranche B-1 Dollar Term Loan due May 2022                               | \$ —               | \$ —            | \$ 923            | \$ 928          |
| Tranche B-1 Euro Term Loan due May 2022<br>(€395 at December 31, 2017)  | —                  | —               | 469               | 471             |
| Tranche B-2 Dollar Term Loan due May 2025                               | 896                | 897             | —                 | —               |
| Tranche B-2 Euro Term Loan due May 2025<br>(€348 at September 30, 2018) | 410                | 412             | —                 | —               |
| <b>Senior unsecured notes:</b>  |                    |                 |                   |                 |
| 6.625% due May 2023   | 908                | 950             | 1,158             | 1,228           |
| 7.000% due May 2025   | 750                | 798             | 750               | 816             |
| 6.125% due May 2023<br>(€295 at December 31, 2017)                      | —                  | —               | 350               | 373             |
| 4.000% due May 2026<br>(€450 at September 30, 2018)                     | 529                | 532             | —                 | —               |
| 5.375% due May 2027   | 500                | 483             | 500               | 521             |
| <b>Total senior debt</b>  | <u>3,993</u>       | <u>\$ 4,072</u> | <u>4,150</u>      | <u>\$ 4,337</u> |
| Less: Unamortized issue discounts                                       | (10)               |                 | (8)               |                 |
| Less: Unamortized debt issuance costs                                   | (35)               |                 | (41)              |                 |
| <b>Total senior debt, net</b>   | <u>\$ 3,948</u>    |                 | <u>\$ 4,101</u>   |                 |

**Note 16. Other Liabilities**

The following table sets forth the components of the Company's other liabilities at September 30, 2018 and December 31, 2017.

|                                | September 30, 2018 | December 31, 2017 |
|--------------------------------|--------------------|-------------------|
| Environmental remediation (1)  | \$ 158             | \$ 187            |
| Employee-related costs (2)     | 131                | 123               |
| Accrued litigation (1)         | 51                 | 48                |
| Asset retirement obligations   | 50                 | 43                |
| Deferred income                | 8                  | 6                 |
| Miscellaneous (3)              | 65                 | 68                |
| <b>Total other liabilities</b> | <u>\$ 463</u>      | <u>\$ 475</u>     |

- (1) The Company's accrued environmental remediation and accrued litigation liabilities are discussed further in "Note 17 - Commitments and Contingent Liabilities."  
(2) Employee-related costs primarily represent liabilities associated with the Company's long-term employee benefit plans.  
(3) Miscellaneous primarily includes an accrued indemnification liability of \$50 and \$52 at September 30, 2018 and December 31, 2017, respectively.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Note 17. Commitments and Contingent Liabilities**

***Litigation***

In addition to the matters discussed below, the Company and certain of its subsidiaries, from time to time, are subject to various lawsuits, claims, assessments, and proceedings with respect to product liability, intellectual property, personal injury, commercial, contractual, employment, governmental, environmental, anti-trust, and other such matters that arise in the ordinary course of business. In addition, Chemours, by virtue of its status as a subsidiary of DuPont prior to the separation, is subject to or required under the separation-related agreements executed prior to the separation to indemnify DuPont against various pending legal proceedings. It is not possible to predict the outcomes of these various lawsuits, claims, assessments, or proceedings. While management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on the Company's consolidated financial position, results of operations, or cash flows. Disputes between Chemours and DuPont may also arise with respect to indemnification matters, including disputes based on matters of law or contract interpretation. If and to the extent these disputes arise, they could materially adversely affect Chemours.

***Asbestos***

In the separation, DuPont assigned its asbestos docket to Chemours. At September 30, 2018 and December 31, 2017, there were approximately 1,500 and 1,600 lawsuits pending against DuPont alleging personal injury from exposure to asbestos, respectively. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. A small number of cases are pending outside of the U.S. Most of the actions were brought by contractors who worked at sites between the 1950s and the 1990s. A small number of cases involve similar allegations by DuPont employees or household members of contractors or DuPont employees. Finally, certain lawsuits allege personal injury as a result of exposure to DuPont products.

At September 30, 2018 and December 31, 2017, Chemours had an accrual of \$38 related to this matter.

***Benzene***

In the separation, DuPont assigned its benzene docket to Chemours. As of September 30, 2018 and December 31, 2017, there were 17 cases pending against DuPont alleging benzene-related illnesses. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at DuPont sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture DuPont products such as paints, thinners, and reducers.

Management believes that a loss is reasonably possible as to the docket as a whole; however, given the evaluation of each benzene matter is highly fact-driven and impacted by disease, exposure, and other factors, a range of such losses cannot be reasonably estimated at this time.

***PFOA***

Prior to the fourth quarter of 2014, the performance chemicals segment of DuPont made PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) at its Fayetteville, North Carolina plant and used PFOA as a processing aid in the manufacture of fluoropolymers and fluoroelastomers at certain sites including: Washington Works, Parkersburg, West Virginia; Chambers Works, Deepwater, New Jersey; Dordrecht Works, Netherlands; Changshu Works, China; and, Shimizu, Japan. These sites are now owned and/or operated by Chemours.

Chemours maintained accruals of \$20 and \$14 related to the PFOA matters discussed below at September 30, 2018 and December 31, 2017, respectively. Specific to the PFOA MDL Settlement (also discussed below), the Company recorded an accrual of \$335 at December 31, 2016, which was paid in installments of \$15 and \$320 during the second and third quarters of 2017, respectively.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

These accruals also include charges related to DuPont's obligations under agreements with the U.S. Environmental Protection Agency (EPA) and voluntary commitments to the New Jersey Department of Environmental Protection. These obligations and voluntary commitments include surveying, sampling, and testing drinking water in and around certain Company sites offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national health advisory. A provisional health advisory level was set by the EPA in 2009 at 0.4 parts per billion (ppb) that includes PFOA in drinking water. In May 2016, the EPA announced a health advisory level of 0.07 ppb that includes PFOA in drinking water. As a result, Chemours recorded an additional \$4 in the second quarter of 2016 based on management's best estimate of the impact of the new health advisory level on the Company's obligations to the EPA, which have expanded the testing and water supply commitments previously established. Based on prior testing, the Company has initiated additional testing and treatment in certain additional locations in and around the Chambers Works and Washington Works plants. The Company will continue to work with the EPA regarding the extent of work that may be required with respect to these matters.

In February 2018, the State of Ohio initiated litigation against DuPont regarding historical PFOA emissions from the Washington Works site. Chemours is an additional named defendant. Ohio alleges damage to natural resources and seeks damages including remediation and other costs and punitive damages.

In October 2018, a putative class action was filed in Ohio federal court against 3M Company (3M), DuPont, Chemours, and other defendants seeking class action status for U.S. residents having a detectable level of perfluoroalkyl and polyfluoroalkyl substances (PFAS) in their blood serum. The complaint seeks declaratory and injunctive relief, including the establishment of a PFAS Science Panel.

In October 2018, a putative class action was filed in New Jersey federal court against 3M, DuPont, and Chemours alleging causes of action, including negligence, nuisance, and trespass and seeking damages including property diminution, remediation, treatment, and abatement with compensatory and punitive damages. The purported class includes private drinking water and well owner-occupants within two to five miles of the Company's Chambers Works, New Jersey site containing any detectable level of PFOA or perfluorooctane sulfonic acid (PFOS).

#### Drinking Water Actions

In August 2001, a class action, captioned *Leach v. DuPont*, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water.

DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs' attorneys' fees and expenses of \$23 and made a payment of \$70, which class counsel designated to fund a community health project. DuPont funded a series of health studies which were completed in October 2012 by an independent science panel of experts (C8 Science Panel). The studies were conducted in communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and human disease. The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and diagnosed high cholesterol.

In May 2013, a panel of three independent medical doctors released its initial recommendations for screening and diagnostic testing of eligible class members. In September 2014, the medical panel recommended follow-up screening and diagnostic testing three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for completion of its protocol. DuPont is obligated to fund up to \$235 for a medical monitoring program for eligible class members and, in addition, administrative cost associated with the program, including class counsel fees. In January 2012, DuPont put \$1 in an escrow account to fund medical monitoring as required by the settlement agreement. The court-appointed director of medical monitoring established the program to implement the medical panel's recommendations, and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening and testing is ongoing, and associated payments to service providers are being disbursed from the escrow account. The Company may place additional funds into the escrow account from time to time, as necessary. As of September 30, 2018, approximately \$1.4 has been disbursed from the escrow account related to medical monitoring. While it is probable that the Company will incur costs related to the medical monitoring program discussed above, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing.

In addition, under the *Leach* settlement agreement, DuPont must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts and private well users. At separation, this obligation was assigned to Chemours, which is included in the accrual amounts recorded as of September 30, 2018.

Under the *Leach* settlement, class members may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determined a probable link exists. Approximately 3,500 lawsuits were filed in various federal and state courts in Ohio and West Virginia and consolidated in multi-district litigation (MDL) in Ohio federal court.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

Settlement of MDL between DuPont and MDL Plaintiffs

In March 2017, DuPont entered into an agreement with the MDL plaintiffs' counsel providing for a global settlement of all cases and claims in the MDL, including all filed and unfiled personal injury cases and claims that are part of the plaintiffs' counsel's claim inventory, as well as cases that have been tried to a jury verdict (MDL Settlement). The total settlement amount was \$670.7 in cash, with half paid by Chemours and half paid by DuPont. DuPont's payment was not subject to indemnification or reimbursement by Chemours, and Chemours accrued \$335 associated with this matter at December 31, 2016. In exchange for payment of the total settlement amount, DuPont and Chemours received a complete release of all claims by the settling plaintiffs. The MDL Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by DuPont or Chemours. By September 30, 2017, Chemours had paid the full \$335 accrued under the MDL Settlement.

Settlement between DuPont and Chemours Related to MDL

DuPont and Chemours agreed to a limited sharing of potential future PFOA costs (indemnifiable losses, as defined in the separation agreement between DuPont and Chemours) for a period of five years. During that five-year period, Chemours will annually pay future PFOA costs up to \$25 and, if such amount is exceeded, DuPont will pay any excess amount up to the next \$25 (which payment will not be subject to indemnification by Chemours), with Chemours annually bearing any further excess costs under the terms of the separation agreement. After the five-year period, this limited sharing agreement will expire, and Chemours' indemnification obligations under the separation agreement will continue unchanged. Chemours has also agreed that it will not contest its indemnification obligations to DuPont under the separation agreement for PFOA costs on the basis of ostensible defenses generally applicable to the indemnification provisions under the separation agreement, including defenses relating to punitive damages, fines or penalties, or attorneys' fees, and waives any such defenses with respect to PFOA costs. Chemours has, however, retained other defenses, including as to whether any particular PFOA claim is within the scope of the indemnification provisions of the separation agreement.

Post-MDL Settlement Injury Matters

All MDL lawsuits were dismissed or resolved through the MDL Settlement.

The MDL Settlement does not resolve PFOA personal injury claims of plaintiffs who did not have cases or claims in the MDL or personal injury claims based on diseases first diagnosed after February 11, 2017. Since the resolution of the MDL, 37 personal injury cases have been filed and are pending in West Virginia, Ohio, and New York courts. The New York matters, which are not part of the Leach class, are brought by three individual plaintiffs alleging negligence and other claims in the release of perfluorinated compounds, including PFOA, into drinking water, and seeking compensatory and punitive damages against current and former owners and suppliers of a manufacturing facility in Hoosick Falls, New York.

Water Districts

In May 2017, the Water Works and Sewer Board of the Town of Centre, Alabama filed suit against numerous carpet manufacturers located in Dalton, Georgia and suppliers and former suppliers, including DuPont, in Alabama state court. The complaint alleges negligence, nuisance, and trespass in the release of perfluorinated compounds, including PFOA, into a river leading to the town's water source, and seeks compensatory and punitive damages.

In February 2018, the New Jersey-American Water Company, Inc. (NJAW) filed suit against DuPont and Chemours in New Jersey federal court alleging that discharges of perfluorochemicals, in violation of the New Jersey Compensation and Control Act, were made into groundwater utilized in the NJAW Penns Grove water system. NJAW alleges that damages include costs associated with remediating, operating, and maintaining its system, and attorney fees.

PFOA Summary

Chemours accrued \$335 associated with the MDL Settlement at December 31, 2016, of which, all \$335 had been paid by December 31, 2017. There could be additional lawsuits filed related to DuPont's use of PFOA, its manufacture of PFOA, or its customers' use of DuPont products that may not be within the scope of the MDL Settlement. Any such litigation could result in Chemours incurring additional costs and liabilities. Management believes that a loss is reasonably possible, but not estimable as to PFOA matters and that it is reasonably possible that the Company could incur losses related to other PFOA matters in excess of amounts accrued, but any such losses are not estimable at this time due to various reasons including, among others, that such matters are in early stages and have significant factual issues to be resolved.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

*U.S. Smelter and Lead Refinery, Inc.*

Seven lawsuits, including one putative class action, are pending against DuPont by area residents concerning the U.S. Smelter and Lead Refinery multi-party Superfund site in East Chicago, Indiana. Six of the lawsuits allege that Chemours is now responsible for DuPont environmental liabilities. The lawsuits include allegations for personal injury damages, property diminution, and damages under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA, often referred to as Superfund). At separation, DuPont assigned Chemours its former plant site, which is located south of the residential portion of the Superfund area, and its responsibility for the environmental remediation at the Superfund site. DuPont has requested that Chemours defend and indemnify it, and Chemours has agreed to do so under a reservation of rights. Management believes a loss is reasonably possible, but not estimable at this time due to various reasons including, among others, that such matters are in early stages and have significant factual issues to be resolved.

*GenX and Other Perfluorinated and Polyfluorinated Compounds*

Governmental agencies and local community members have made inquiries and engaged in discussions with the Company with respect to the discharge of the polymerization processing aid HFPO Dimer Acid (sometimes referred to as GenX or C3 Dimer Acid) and other perfluorinated and polyfluorinated compounds from the Company's facility in Fayetteville, North Carolina into the Cape Fear River, groundwater, and air. The Company believes that such discharges have not impacted the safety of drinking water in North Carolina. The Company continues to capture and separately dispose of process wastewater from the Fayetteville facility and is cooperating with a variety of ongoing inquiries and investigations from federal, state, and local authorities, regulators, and other governmental entities, including responding to federal grand jury subpoenas issued in connection with an ongoing investigation being conducted by the U.S. Attorney's Office for the Eastern District of North Carolina and the Environment and Natural Resources Division of the U.S. Department of Justice.

In September 2017, the North Carolina Department of Environmental Quality (NC DEQ) issued a 60-day notice of intent to suspend the permit for the Fayetteville facility and the State of North Carolina filed an action in North Carolina state court regarding the discharges seeking a temporary restraining order and preliminary injunction, as well as other relief including abatement and site correction. A partial consent order was entered partially resolving the state's action in return for the Company's agreement to continue and supplement the voluntary wastewater-disposal measures it had previously commenced and to provide certain information. In November 2017, NC DEQ informed the Company that it was suspending the process wastewater discharge permit for the Fayetteville facility. The Company thereafter commenced the capture and separate disposal of all process wastewater from the Fayetteville facility related to the Company's own operations, and has incurred expenses of \$8 and \$28 for these efforts for the three and nine months ended September 30, 2018, respectively, and \$11 for the year ended December 31, 2017, all of which was recognized in the fourth quarter.

In February 2018, NC DEQ issued a Notice of Violation (NOV) related to groundwater on and around the site directing Chemours to respond with source control measures. In April 2018, the North Carolina Department of Air Quality (NC DAQ) issued a 60-day Notice of Intent to modify the Fayetteville site's air emissions permit to ensure that air emissions do not contribute or cause violations of groundwater rules and amended its complaint regarding air emissions and groundwater. The State of North Carolina filed a status report containing a draft injunctive order in June 2018. While the Company believes it has meritorious defenses to the claims made in these complaints, NOV's, and the draft injunctive order, it has undertaken actions in response to these issues, including the commitment to invest over \$100 designing and installing state-of-the-art environmental control technology at Fayetteville. The Company also continues to capture and separately dispose of all process wastewater at the site. In June 2018, North Carolina enacted legislation empowering the State to shut down certain facilities or to order their owners to provide alternative supplies of safe drinking water, including through the installation of household filtration systems or connection to municipal water systems for certain affected households in the facility's vicinity. The Company had previously voluntarily offered to install filtration systems to certain affected households in the vicinity of the Fayetteville facility and has accrued an estimated liability amounting to \$13 for the costs associated with that voluntary program. The Company has been seeking to resolve these issues with the State, but there can be no assurance at this stage that those discussions will result in a comprehensive resolution. In addition to the substantial costs incurred in connection with the development and installation of state-of-the-art environmental control technology at the Fayetteville site and other remedial measures, it is probable that additional costs will be incurred in connection with further actions toward a final resolution with the State, including the provision of water treatment or alternative water supply to affected households in the vicinity of the Fayetteville facility, and the Company has therefore accrued an additional estimated liability amounting to \$30 in the third quarter, for a total accrual related to these matters of \$43 at September 30, 2018. Although an additional loss is reasonably possible, it is not possible at this time to estimate the ultimate cost of any final resolution with the State, as discussions are continuing and many aspects remain open including, but not limited to, the scope and timing of additional potential remedies. It is possible that issues relating to groundwater deposition and/or air emissions could result in further litigation or regulatory demands with regard to the Fayetteville facility, including potential permit modifications. If such issues arise, if an order conforming to the draft injunctive order filed by the State were entered by the court, or if the State attempted to take action under the legislation described above, these events could adversely affect the facility's continued operations and could be material to the Company.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

Civil actions have been filed against the Company and DuPont in North Carolina federal court relating to discharges from the Fayetteville site. These actions include a consolidated action brought by public water suppliers seeking damages and injunctive relief, a consolidated purported class action seeking medical monitoring and property damage and/or other monetary and injunctive relief on behalf of the putative classes of property owners and residents in areas near or that draw drinking water from the Cape Fear River, and an action by private well owners seeking compensatory and punitive damages. In July 2018, Cape Fear River Watch (CFRW), a non-profit organization, filed a citizen suit against NC DEQ in North Carolina state court seeking review of NC DEQ's denial of requests for certain actions related to discharges from the Fayetteville facility. Chemours intervened in that action. Also in July 2018, CFRW filed a citizen suit against Chemours in North Carolina federal court alleging violations of the Clean Water Act and/or the Toxic Substances Control Act seeking declaratory and injunctive relief and penalties. The Company believes it has valid defenses to the litigation including that the discharges did not impact the safety of drinking water or cause any damages or injury. It is possible that additional litigation may be filed against the Company and/or DuPont concerning the discharges.

It is not possible at this point to predict the timing, course, or outcome of the governmental and regulatory inquiries, the notices issued by NC DEQ and NC DAQ, the action brought by North Carolina, and the other litigation, and it is possible that these matters could materially affect the Company's results and operations. In addition, local communities, organizations, and federal and state regulatory agencies have raised questions concerning HFPO Dimer Acid and other perfluorinated and polyfluorinated compounds at certain other manufacturing sites operated by the Company, and it is possible that similar developments to those described above and centering on the Fayetteville site could arise in other locations.

*Mining Solutions Facility Construction Stoppage*

In March 2018, a civil association in Mexico filed a complaint against the government authorities involved in the permitting process of the Company's new Mining Solutions facility under construction in Gomez Palacio, Durango, Mexico. The claimant sought and obtained a suspension from the district judge to stop the Company's construction work while the claim is studied and reviewed. Chemours, as the third-party affected, has filed an appeal. The Company has declared force majeure with its vendors while plant construction is idled. Chemours' project permits fully comply with the laws and regulations at the federal, state, and municipal levels, and is working with local and federal authorities, along with community leaders, to address the complaint.

**Environmental**

Chemours, due to the terms of its separation-related agreements with DuPont, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances by Chemours or other parties. Much of this liability results from CERCLA, the Resource Conservation and Recovery Act, and similar state and global laws. These laws require Chemours to undertake certain investigative, remediation, and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

At September 30, 2018 and December 31, 2017, the consolidated balance sheets included liabilities relating to these matters of \$239 and \$253, respectively, which, in management's opinion, are appropriate based on existing facts and circumstances. The time-frame for a site to go through all phases of remediation (investigation and active clean-up) may take about 15 to 20 years, followed by several years of operation, maintenance, and monitoring (OM&M) activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties. In addition, for claims that Chemours may be required to indemnify DuPont pursuant to the separation-related agreements, Chemours, through DuPont, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately \$470 above the amount accrued at September 30, 2018.

Chemours incurred environmental remediation expenses of \$8 and \$32 for the three and nine months ended September 30, 2018, respectively, and \$18 and \$36 for the three and nine months ended September 30, 2017, respectively.

Based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the Company's financial position, results of operations, or cash flows in any given year, as such obligation can be satisfied or settled over many years.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

*Sale of East Chicago, Indiana*

On June 29, 2018, the Company sold its East Chicago, Indiana site to a third-party for \$1. In connection with the sale, the buyer has agreed to assume all costs associated with environmental remediation activities at the site in excess of \$21, which will remain the responsibility of Chemours. At the time of the sale, the Company had accrued the full \$21, and will reimburse the buyer through a series of progress payments to be made at defined intervals as certain tasks are completed. The Company recognized a gain of \$3 on the sale, which includes the purchase price of \$1, plus \$2 in environmental remediation liabilities that were assumed by the buyer on the occurrence of the sale.

*Sale of Potomac River, West Virginia*

On September 27, 2018, the Company sold its Potomac River, West Virginia site to a third-party for \$4. In connection with the sale, the buyer has agreed to assume certain future environmental remediation costs, and Chemours has retained \$4 in existing environmental remediation liabilities. The Company recognized a \$3 gain on the sale, which was deferred and will be recognized as the Company completes certain environmental remediation activities at the site.

**Note 18. Equity**

On November 30, 2017, the Company's board of directors approved a share repurchase program authorizing the purchase of shares of Chemours' issued and outstanding common stock in an aggregate amount not to exceed \$500, plus any associated fees or costs in connection with the Company's share repurchase activity (2017 Share Repurchase Program). Under the 2017 Share Repurchase Program, shares of Chemours' common stock were purchased on the open market from time to time, subject to management's discretion, as well as general business and market conditions. The Company's 2017 Share Repurchase Program became effective on November 30, 2017. On May 31, 2018, the Company completed the aggregate \$500 in authorized purchases of Chemours' issued and outstanding common stock under the 2017 Share Repurchase Program, which amounted to a cumulative 10,085,647 shares purchased at an average share price of \$49.58 per share. All common shares purchased under the 2017 Share Repurchase Program are held as treasury stock and are accounted for using the cost method.

On August 1, 2018, the Company's board of directors approved a share repurchase program authorizing the purchase of shares of Chemours' issued and outstanding common stock in an aggregate amount not to exceed \$750, plus any associated fees or costs in connection with the Company's share repurchases activity (2018 Share Repurchase Program). Under the 2018 Share Repurchase Program, shares of Chemours' common stock can be purchased on the open market from time to time, subject to management's discretion, as well as general business and market conditions. The Company's 2018 Share Repurchase Program became effective on August 1, 2018 and will continue through the earlier of its expiration on December 31, 2020, or the completion of repurchases up to the approved amount. The program may be suspended or discontinued at any time. All common shares purchased under the 2018 Share Repurchase Program are expected to be held as treasury stock and accounted for using the cost method.

During the third quarter of 2018, the Company purchased 3,226,824 shares of Chemours' issued and outstanding common stock under the 2018 Share Repurchase Program, which amounted to \$136 at an average share price of \$42.23 per share. The aggregate amount of Chemours' common stock that remained available for purchase under this program at September 30, 2018 was \$614.



**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Note 19. Financial Instruments**

***Derivative Instruments***

*Objectives and Strategies for Holding Derivative Instruments*

In the ordinary course of business, Chemours enters into contractual arrangements (i.e., derivatives) to reduce its exposure to foreign currency risks. The Company has established a derivative program to be utilized for financial risk management, which currently includes three distinct risk management strategies, as follows: (i) foreign currency forward contracts are used to minimize the volatility in the Company's earnings related to foreign exchange gains and losses resulting from remeasuring its monetary assets and liabilities that are denominated in non-functional currencies; (ii) foreign currency forward contracts are also used to mitigate the risks associated with fluctuations in the euro against the U.S. dollar for forecasted U.S. dollar-denominated inventory purchases in certain of the Company's international subsidiaries that use the euro as their functional currency; and, (iii) the Company has issued euro-denominated debt to reduce the volatility in its stockholders' equity caused by changes in foreign currency exchange rates of the euro with respect to the U.S. dollar for certain of its international subsidiaries that use the euro as their functional currency. The Company's derivative program reflects varying levels of exposure coverage and time horizons based on an assessment of risk. The derivative program operates within Chemours' financial risk management policies and guidelines, and the Company does not enter into derivative financial instruments for trading or speculative purposes.

*Net Monetary Assets and Liabilities Hedge - Foreign Currency Forward Contracts*

Chemours uses foreign currency forward contracts to reduce its net exposure, by currency, related to non-functional currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. Except as described below, these derivative instruments are not part of a cash flow hedge program or a fair value hedge program, and have not been designated as a hedge. Although all of the forward contracts are subject to an enforceable master netting agreement, Chemours has elected to present any derivative assets and liabilities on a gross basis on its consolidated balance sheets. No collateral has been required for these contracts. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the consolidated statements of operations during the period in which they occurred. Gains and losses on the Company's derivative instruments are intended to be offset by any gains or losses on the underlying asset or liability.

At September 30, 2018, there were 16 foreign currency forward contracts outstanding, with an aggregate gross notional U.S. dollar equivalent of \$483 and an average maturity of one month. There were no foreign currency forward contracts outstanding at December 31, 2017. Chemours recognized in other income, net of the consolidated statements of operations net gains of \$14 and \$8 for the three and nine months ended September 30, 2018, respectively, and a net loss of \$1 and a net gain of \$6 for the three and nine months ended September 30, 2017, respectively.

*Cash Flow Hedge - Foreign Currency Forward Contracts*

Beginning in the second quarter of 2018, Chemours has elected to enter certain qualifying foreign currency forward contracts under a cash flow hedge program. The objective of the Company's cash flow hedge program is to mitigate the risks associated with fluctuations in the euro against the U.S. dollar for forecasted U.S. dollar-denominated inventory purchases in certain of its international subsidiaries that use the euro as their functional currency. All gains and losses resulting from the revaluation of any derivative assets and liabilities are recognized as a component of accumulated other comprehensive loss on the consolidated balance sheets during the period in which they occur, and are reclassified to the cost of goods sold in the consolidated statements of operations during the period in which the underlying transactions affect earnings, or when it becomes probable that the forecasted transactions will not occur.

At September 30, 2018, there were 48 foreign currency contracts outstanding under Chemours' cash flow hedge program with an aggregate notional U.S. dollar equivalent of \$135 and an average maturity of four months. The Company recognized a pre-tax loss of \$1 and a pre-tax gain of \$6 for the three and nine months ended September 30, 2018, respectively, on its cash flow hedge within accumulated other comprehensive loss. For the three and nine months ended September 30, 2018, \$1 of gain was reclassified to the costs of goods sold from accumulated other comprehensive loss.

The Company expects to reclassify an approximate \$4 of net gain from accumulated other comprehensive loss to the cost of goods sold over the next 12 months, based on current foreign currency exchange rates.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

*Net Investment Hedge - Foreign Currency Borrowings*

Chemours designated its euro-denominated debt as a hedge of its net investments in certain of its international subsidiaries that use the euro as their functional currency in order to reduce the volatility in stockholders' equity caused by changes in foreign currency exchange rates of the euro with respect to the U.S. dollar. The Company recognized the change in the carrying value of the 2026 Euro Notes and the New Euro Term Loan due to remeasurement in accumulated other comprehensive loss on the consolidated balance sheets. Chemours uses the spot method to evaluate the effectiveness of its net investment hedge on a quarterly basis.

Prior to the adoption of ASU No. 2017-12, Chemours did not record any historical ineffectiveness with regard to its net investment hedge as the relationship was perfectly effective.

The Company recognized a pre-tax loss of \$11 and a pre-tax gain of \$2 for the three and nine months ended September 30, 2018, respectively, and pre-tax losses of \$26 and \$76 for the three and nine months ended September 30, 2017, respectively, on its net investment hedges within accumulated other comprehensive loss. No amounts were reclassified from accumulated other comprehensive loss for the Company's net investment hedges during the three and nine months ended September 30, 2018 and 2017.

**Fair Value of Derivative Instruments**

The following table sets forth the fair value of the Company's derivative assets and liabilities at September 30, 2018 and December 31, 2017.

|   | Balance Sheet Location             | September 30, 2018 | December 31, 2017 |
|---|------------------------------------|--------------------|-------------------|
| <b>Asset derivatives:</b>   |                                    |                    |                   |
| Foreign currency forward contracts not designated as a hedging instrument | Accounts and notes receivable, net | \$ 1               | \$ —              |
| Foreign currency forward contracts designated as a cash flow hedge        | Accounts and notes receivable, net | 2                  | —                 |
| <b>Total asset derivatives</b>  |                                    | <u>\$ 3</u>        | <u>\$ —</u>       |
| <b>Liability derivatives:</b>   |                                    |                    |                   |
| Foreign currency forward contracts not designated as a hedging instrument | Other accrued liabilities          | \$ 1               | \$ —              |
| <b>Total liability derivatives</b>  |                                    | <u>\$ 1</u>        | <u>\$ —</u>       |

The Company's foreign currency forward contracts are classified as Level 2 financial instruments within the fair value hierarchy as the valuation inputs are based on the quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data, and subjected to tolerance/quality checks.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Summary of Derivative Instruments**

The following table sets forth the pre-tax changes in fair value of the Company's derivative assets and liabilities for the three and nine months ended September 30, 2018 and 2017.

| Three Months Ended September 30,  | Gain (Loss) Recognized In |                   | Accumulated Other<br>Comprehensive<br>Loss |
|---|---------------------------|-------------------|--|
|   | Cost of Goods Sold        | Other Income, Net |  |
| <b>2018</b>   |                           |                   |  |
| Foreign currency forward contracts not designated as a hedging instrument | \$ —                      | \$ 14             | \$ —                                       |
| Foreign currency forward contracts designated as a cash flow hedge        | 1                         | —                 | (2)  |
| Euro-denominated debt designated as a net investment hedge                | —                         | —                 | (11)                                       |

|   |      |        |      |
|---|------|--------|------|
| <b>2017</b>   |      |        |      |
| Foreign currency forward contracts not designated as a hedging instrument | \$ — | \$ (1) | \$ — |
| Euro-denominated debt designated as a net investment hedge                | —    | —      | (26) |

| Nine Months Ended September 30,   | Gain (Loss) Recognized In |                   | Accumulated Other<br>Comprehensive<br>Loss |
|---|---------------------------|-------------------|--|
|   | Cost of Goods Sold        | Other Income, Net |  |
| <b>2018</b>   |                           |                   |  |
| Foreign currency forward contracts not designated as a hedging instrument | \$ —                      | \$ 8              | \$ —                                       |
| Foreign currency forward contracts designated as a cash flow hedge        | 1                         | —                 | 5  |
| Euro-denominated debt designated as a net investment hedge                | —                         | —                 | 2  |

|   |      |      |      |
|---|------|------|------|
| <b>2017</b>   |      |      |      |
| Foreign currency forward contracts not designated as a hedging instrument | \$ — | \$ 6 | \$ — |
| Euro-denominated debt designated as a net investment hedge                | —    | —    | (76) |

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Note 20. Long-term Employee Benefits**

Chemours sponsors defined benefit pension plans for certain of its employees in various jurisdictions outside of the U.S. The Company's net periodic pension income is based on estimated values and an extensive use of assumptions about the discount rate, expected return on plan assets, and the rate of future compensation increases received by its employees.

The following table sets forth the Company's net periodic pension income and the amounts recognized in other comprehensive income, excluding any of the pre-tax effects of foreign exchange rates, for its significant defined benefit pension plans for the three and nine months ended September 30, 2018 and 2017.

|  | <u>Three Months Ended September 30,</u> |              | <u>Nine Months Ended September 30,</u> |              |
|--|---|--------------|--|--------------|
|  | 2018                                    | 2017         | 2018                                   | 2017         |
| Net periodic pension (cost) income:  |   |              |  |              |
| Service cost   | \$ (4)                                  | \$ (4)       | \$ (11)                                | \$ (11)      |
| Interest cost  | (4)                                     | (4)          | (13)                                   | (11)         |
| Expected return on plan assets   | 14                                      | 18           | 43                                     | 52           |
| Amortization of prior service gain   | —                                       | 1            | 2                                      | 1            |
| Amortization of actuarial loss   | (4)                                     | (5)          | (12)                                   | (15)         |
| Settlement loss  | (2)                                     | (1)          | (2)                                    | (1)          |
| Net periodic pension income  | —                                       | 5            | 7                                      | 15           |
| Changes in plan assets and benefit obligations recognized in other comprehensive income: |   |              |  |              |
| Amortization of prior service gain   | —                                       | (1)          | (1)                                    | (1)          |
| Amortization of actuarial loss   | 4                                       | 5            | 11                                     | 15           |
| Settlement loss  | 2                                       | 1            | 2                                      | 1            |
| Benefit recognized in other comprehensive income   | 6                                       | 5            | 12                                     | 15           |
| <b>Total net periodic pension income and benefit recognized in comprehensive income</b>  | <u>\$ 6</u>                             | <u>\$ 10</u> | <u>\$ 19</u>                           | <u>\$ 30</u> |

The Company made cash contributions of \$4 and \$12 to its pension plans during the three and nine months ended September 30, 2018, respectively, and expects to make additional cash contributions of \$3 to its pension plans during the remainder of 2018.

**Note 21. Stock-based Compensation**

Total stock-based compensation expense included in the consolidated statements of operations was \$5 and \$20 for the three and nine months ended September 30, 2018, respectively, and \$6 and \$21 for the three and nine months ended September 30, 2017, respectively.

The Chemours Company 2017 Equity and Incentive Plan and The Chemours Company Equity and Incentive Plan provide for grants to certain employees, independent contractors, or non-employee directors of the Company in different forms of awards, including stock options, restricted stock units (RSUs), and performance share units (PSUs). The Chemours Compensation Committee of the board of directors determines the long-term incentive awards mix and may authorize new grants annually.

**Stock Options**

During the nine months ended September 30, 2018, Chemours granted approximately 500,000 non-qualified stock options to certain of its employees, which will vest over a three-year period and expire 10 years from the date of grant. The fair value of the stock options is based upon the Black-Scholes valuation model.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

The following table sets forth the weighted average assumptions used to determine the fair value of the Company's stock option awards granted during the nine months ended September 30, 2018.

|                                    | <b>Nine Months Ended<br/>September 30, 2018</b> |
|------------------------------------|---|
| Risk-free interest rate            | 2.65%   |
| Expected term (years)              | 6.00  |
| Volatility                         | 47.56%  |
| Dividend yield                     | 1.42%   |
| <b>Fair value per stock option</b> | <b>\$ 20.47</b>                                 |

The Company recorded \$1 and \$7 in stock-based compensation expense specific to its stock options for the three and nine months ended September 30, 2018, respectively, and \$2 and \$5 in stock-based compensation expense specific to its stock options for the three and nine months ended September 30, 2017, respectively. At September 30, 2018, approximately 5,990,000 stock options remain outstanding.

***Restricted Stock Units***

During the nine months ended September 30, 2018, Chemours granted approximately 140,000 RSUs to certain of its employees and non-employee directors. Awards granted to employees will vest over a three-year period. Awards granted to non-employee directors will either vest immediately, on the third anniversary of the grant date, or upon departure from the board of directors, as elected. Upon vesting, RSUs convert one-for-one to Chemours' common stock. The fair value of the RSUs is based upon the market price of the underlying common stock at the grant date.

The Company recorded \$1 and \$6 in stock-based compensation expense specific to its RSUs for the three and nine months ended September 30, 2018, respectively, and \$3 and \$11 in stock-based compensation expense specific to its RSUs for the three and nine months ended September 30, 2017, respectively. At September 30, 2018, approximately 240,000 RSUs remain non-vested.

***Performance Share Units***

During the nine months ended September 30, 2018, Chemours granted approximately 140,000 PSUs to key senior management employees, which, upon vesting, convert one-for-one to Chemours' common stock if specified performance goals, including certain market-based conditions, are met over the three-year performance period specified in the grant, subject to exceptions through the respective vesting period of three years. Each grantee is granted a target award of PSUs, and may earn between 0% and 200% of the target amount, depending on the Company's performance against stated performance goals.

A portion of the fair value of PSUs was estimated at the grant date based on the probability of satisfying the market-based conditions associated with the PSUs using the Monte Carlo valuation method, which assesses probabilities of various outcomes for market conditions. The other portion of the fair value of the PSUs is based on the fair market value of the Company's stock at the grant date, regardless of whether the market-based condition is satisfied.

The Company recorded \$3 and \$7 in stock-based compensation expense specific to its PSUs for the three and nine months ended September 30, 2018, respectively, and \$1 and \$5 in stock-based compensation expense specific to its PSUs for the three and nine months ended September 30, 2017, respectively. At September 30, 2018, approximately 1,110,000 PSUs at 100% of their target amount remain non-vested.

***Employee Stock Purchase Plan***

On January 26, 2017, the Company's board of directors approved The Chemours Company Employee Stock Purchase Plan (ESPP), which was approved by Chemours' stockholders on April 26, 2017. Under the ESPP, a total of 7,000,000 shares of Chemours' common stock is reserved and authorized for issuance to participating employees, as defined by the ESPP, which excludes executive officers of the Company. The ESPP provides for consecutive 12-month offering periods, each with four purchase periods beginning and ending on the calendar quarters within those offering periods. Participating employees are eligible to purchase the Company's common stock at a discounted rate equal to 95% of its fair value on the last trading day of each purchase period.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

During the first and third quarters of 2018, the Company executed an open market transaction to purchase Chemours' common stock on behalf of ESPP participants. In each of the respective quarters, total purchases amounted to less than \$1, which was used to purchase approximately 12,000 shares of Chemours' common stock. During the second quarter of 2018, the Company issued approximately 12,000 shares out of its treasury stock to ESPP participants, which amounted to less than \$1.

**Note 22. Segment Information**

Chemours' reportable segments are: Fluoroproducts, Chemical Solutions, and Titanium Technologies. Corporate costs and certain legacy legal and environmental expenses, stock-based compensation costs, and foreign exchange gains and losses arising from the remeasurement of balances in currencies other than the functional currency of the Company's legal entities are reflected in Corporate and Other.

Segment sales include transfers to another reportable segment. Certain products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. These product transfers were limited and were not significant for each of the periods presented. Depreciation and amortization includes depreciation on research and development facilities and the amortization of other intangible assets, excluding any write-downs of assets.

Adjusted earnings before interest, taxes, depreciation, and amortization (Adjusted EBITDA) is the primary measure of segment performance used by the Company's Chief Operating Decision Maker and is defined as income (loss) before income taxes, excluding the following:

- interest expense, depreciation, and amortization;
- non-operating pension and other post-retirement employee benefit costs, which represent the components of net periodic pension (income) costs excluding the service cost component;
- exchange (gains) losses included in other income (expense), net;
- restructuring, asset-related, and other charges;
- asset impairments;
- (gains) losses on sales of assets and businesses; and,
- other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

The following table sets forth certain summary financial information for the Company's reportable segments and Corporate and Other for the three and nine months ended September 30, 2018 and 2017.

| Three Months Ended September 30, | Fluoroproducts | Chemical Solutions | Titanium Technologies | Corporate and Other | Total    |
|----------------------------------|----------------|--------------------|-----------------------|---------------------|----------|
| <b>2018</b>                      |                |                    |                       |                     |          |
| Net sales to external customers  | \$ 682         | \$ 155             | \$ 791                | \$ —                | \$ 1,628 |
| Adjusted EBITDA                  | 182            | 24                 | 268                   | (39)                | 435      |
| Depreciation and amortization    | 28             | 5                  | 30                    | 8                   | 71       |
| <b>2017</b>                      |                |                    |                       |                     |          |
| Net sales to external customers  | \$ 637         | \$ 148             | \$ 799                | \$ —                | \$ 1,584 |
| Adjusted EBITDA                  | 158            | 18                 | 249                   | (44)                | 381      |
| Depreciation and amortization    | 28             | 4                  | 24                    | 6                   | 62       |

| Nine Months Ended September 30, | Fluoroproducts | Chemical Solutions | Titanium Technologies | Corporate and Other | Total    |
|---------------------------------|----------------|--------------------|-----------------------|---------------------|----------|
| <b>2018</b>                     |                |                    |                       |                     |          |
| Net sales to external customers | \$ 2,213       | \$ 453             | \$ 2,508              | \$ —                | \$ 5,174 |
| Adjusted EBITDA                 | 619            | 50                 | 856                   | (126)               | 1,399    |
| Depreciation and amortization   | 87             | 15                 | 90                    | 21                  | 213      |
| <b>2017</b>                     |                |                    |                       |                     |          |
| Net sales to external customers | \$ 1,998       | \$ 437             | \$ 2,173              | \$ —                | \$ 4,608 |
| Adjusted EBITDA                 | 510            | 37                 | 601                   | (120)               | 1,028    |
| Depreciation and amortization   | 81             | 13                 | 89                    | 21                  | 204      |

The following table sets forth a reconciliation of Adjusted EBITDA to the Company's consolidated net income before income taxes for the three and nine months ended September 30, 2018 and 2017.

|   | Three Months Ended September 30, |               | Nine Months Ended September 30, |                 |
|---|----------------------------------|---------------|---------------------------------|-----------------|
|   | 2018                             | 2017          | 2018                            | 2017            |
| <b>Income before income taxes</b>                                       | \$ 269                           | \$ 250        | \$ 973                          | \$ 649          |
| Interest expense, net   | 47                               | 55            | 148                             | 160             |
| Depreciation and amortization   | 71                               | 62            | 213                             | 204             |
| Non-operating pension and other post-retirement employee benefit income | (4)                              | (7)           | (18)                            | (24)            |
| Exchange losses (gains), net  | 6                                | 4             | 4                               | (3)             |
| Restructuring and other charges   | 12                               | 8             | 32                              | 31              |
| Asset-related and other charges   | —                                | 1             | —                               | 3               |
| Loss on extinguishment of debt  | —                                | —             | 38                              | 1               |
| Gain on sales of assets and businesses (1)                              | —                                | —             | (45)                            | (14)            |
| Transaction costs (2)   | —                                | 1             | 9                               | 3               |
| Legal and other charges (3)   | 34                               | 7             | 45                              | 18              |
| <b>Adjusted EBITDA</b>  | <u>\$ 435</u>                    | <u>\$ 381</u> | <u>\$ 1,399</u>                 | <u>\$ 1,028</u> |

- (1) For the nine months ended September 30, 2018, gain on sale includes a \$3 gain and a \$42 gain associated with the sales of the Company's East Chicago, Indiana and Linden, New Jersey sites, respectively. For the nine months ended September 30, 2017, gain on sale includes a \$12 gain associated with the sale of the Company's Edge Moor, Delaware site and a \$4 gain associated with the sale of the Company's land in Repauno, New Jersey that was previously deferred and realized upon meeting certain milestones, which are offset by a \$2 adjustment associated with the sale of the Company's Sulfur business in 2016.
- (2) Includes costs associated with the Company's debt transactions, as well as accounting, legal, and bankers' transaction costs incurred in connection with the Company's strategic initiatives.
- (3) Includes litigation settlements, PFOA drinking water treatment accruals, and other charges, including the \$30 additional estimated liability for the Company's Fayetteville, North Carolina site for the three and nine months ended September 30, 2018, the latter of which is included as a component of selling, general, and administrative expense in the consolidated statements of operations. See "Note 17 - Commitments and Contingent Liabilities" for further detail.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Note 23. Subsequent Event**

In connection with its 2018 Share Repurchase Program, the Company purchased an additional 3,124,033 shares of Chemours' issued and outstanding common stock in October 2018, which amounted to \$114 at an average share price of \$36.30 per share.

**Note 24. Guarantor Condensed Consolidating Financial Information**

The following guarantor condensed consolidating financial information is included in accordance with Rule 3-10 of Regulation S-X (Rule 3-10) in connection with the subsidiary guarantees of the Notes (collectively, the 2023 Notes, the 7.000% senior unsecured notes due May 2025, the 2026 Euro Notes, and the 5.375% senior unsecured notes due May 2027), in each case, issued by The Chemours Company (Parent Issuer). As of the dates indicated, each series of the Notes was fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis, subject to certain exceptions, by the same group of subsidiaries of the Parent Issuer (together, the Guarantor Subsidiaries). Each of the Guarantor Subsidiaries is 100% owned by the Company. None of the other subsidiaries of the Company, either direct or indirect, guarantee the Notes (together, the Non-Guarantor Subsidiaries). Pursuant to the indentures governing the Notes, the Guarantor Subsidiaries will be automatically released from those guarantees upon the occurrence of certain customary release provisions.

The following condensed consolidating financial information is presented to comply with the Company's requirements under Rule 3-10:

- the condensed consolidating statements of comprehensive income for the three and nine months ended September 30, 2018 and 2017;
- the condensed consolidating balance sheets at September 30, 2018 and December 31, 2017; and,
- the condensed consolidating statements of cash flows for the nine months ended September 30, 2018 and 2017.

The following guarantor condensed consolidating financial information is presented using the equity method of accounting for the Company's investments in its wholly-owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for the Company's share of its subsidiaries' cumulative results of operations, capital contributions, distributions, and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information included herein may not necessarily be indicative of the financial positions, results of operations, or cash flows of the Company's subsidiaries had they operated as independent entities, and should be read in conjunction with the interim consolidated financial statements and the related notes thereto.



**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Condensed Consolidating Statements of Comprehensive Income**

|  | Three Months Ended September 30, 2018 |                        |                            |                              |               |
|--|---------------------------------------|------------------------|----------------------------|------------------------------|---------------|
|  | Parent Issuer                         | Guarantor Subsidiaries | Non-Guarantor Subsidiaries | Eliminations and Adjustments | Consolidated  |
| Net sales  | \$ —                                  | \$ 987                 | \$ 1,103                   | \$ (462)                     | \$ 1,628      |
| Cost of goods sold   | —                                     | 769                    | 834                        | (452)                        | 1,151         |
| Gross profit   | —                                     | 218                    | 269                        | (10)                         | 477           |
| Selling, general, and administrative expense               | 5                                     | 122                    | 40                         | (4)                          | 163           |
| Research and development expense                           | —                                     | 18                     | 2                          | —                            | 20            |
| Restructuring, asset-related, and other charges            | —                                     | 12                     | —                          | —                            | 12            |
| Total other operating expenses                             | 5                                     | 152                    | 42                         | (4)                          | 195           |
| Equity in earnings of affiliates                           | —                                     | —                      | 10                         | —                            | 10            |
| Equity in earnings of subsidiaries                         | 308                                   | (1)                    | —                          | (307)                        | —             |
| Interest (expense) income, net                             | (51)                                  | 1                      | 3                          | —                            | (47)          |
| Intercompany interest income (expense), net                | 13                                    | 3                      | (16)                       | —                            | —             |
| Loss on extinguishment of debt                             | —                                     | —                      | —                          | —                            | —             |
| Other income (expense), net                                | 2                                     | 52                     | (26)                       | (4)                          | 24            |
| <b>Income before income taxes</b>                          | <b>267</b>                            | <b>121</b>             | <b>198</b>                 | <b>(317)</b>                 | <b>269</b>    |
| (Benefit from) provision for income taxes                  | (8)                                   | (31)                   | 33                         | —                            | (6)           |
| <b>Net income</b>  | <b>275</b>                            | <b>152</b>             | <b>165</b>                 | <b>(317)</b>                 | <b>275</b>    |
| Less: Net income attributable to non-controlling interests | —                                     | —                      | —                          | —                            | —             |
| <b>Net income attributable to Chemours</b>                 | <b>\$ 275</b>                         | <b>\$ 152</b>          | <b>\$ 165</b>              | <b>\$ (317)</b>              | <b>\$ 275</b> |
| <b>Comprehensive income attributable to Chemours</b>       | <b>\$ 304</b>                         | <b>\$ 152</b>          | <b>\$ 202</b>              | <b>\$ (354)</b>              | <b>\$ 304</b> |

|  | Nine Months Ended September 30, 2018 |                        |                            |                              |               |
|--|--------------------------------------|------------------------|----------------------------|------------------------------|---------------|
|  | Parent Issuer                        | Guarantor Subsidiaries | Non-Guarantor Subsidiaries | Eliminations and Adjustments | Consolidated  |
| Net sales  | \$ —                                 | \$ 3,071               | \$ 3,493                   | \$ (1,390)                   | \$ 5,174      |
| Cost of goods sold   | —                                    | 2,403                  | 2,590                      | (1,390)                      | 3,603         |
| Gross profit   | —                                    | 668                    | 903                        | —                            | 1,571         |
| Selling, general, and administrative expense               | 28                                   | 339                    | 119                        | (20)                         | 466           |
| Research and development expense                           | —                                    | 56                     | 5                          | —                            | 61            |
| Restructuring, asset-related, and other charges            | —                                    | 31                     | 1                          | —                            | 32            |
| Total other operating expenses                             | 28                                   | 426                    | 125                        | (20)                         | 559           |
| Equity in earnings of affiliates                           | —                                    | —                      | 32                         | —                            | 32            |
| Equity in earnings of subsidiaries                         | 983                                  | 2                      | —                          | (985)                        | —             |
| Interest (expense) income, net                             | (159)                                | 2                      | 9                          | —                            | (148)         |
| Intercompany interest income (expense), net                | 35                                   | 6                      | (41)                       | —                            | —             |
| Loss on extinguishment of debt                             | (38)                                 | —                      | —                          | —                            | (38)          |
| Other income (expense), net                                | 22                                   | 146                    | (33)                       | (20)                         | 115           |
| <b>Income before income taxes</b>                          | <b>815</b>                           | <b>398</b>             | <b>745</b>                 | <b>(985)</b>                 | <b>973</b>    |
| (Benefit from) provision for income taxes                  | (39)                                 | 31                     | 127                        | —                            | 119           |
| <b>Net income</b>  | <b>854</b>                           | <b>367</b>             | <b>618</b>                 | <b>(985)</b>                 | <b>854</b>    |
| Less: Net income attributable to non-controlling interests | —                                    | —                      | 1                          | —                            | 1             |
| <b>Net income attributable to Chemours</b>                 | <b>\$ 854</b>                        | <b>\$ 367</b>          | <b>\$ 617</b>              | <b>\$ (985)</b>              | <b>\$ 853</b> |
| <b>Comprehensive income attributable to Chemours</b>       | <b>\$ 855</b>                        | <b>\$ 367</b>          | <b>\$ 618</b>              | <b>\$ (985)</b>              | <b>\$ 855</b> |

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Condensed Consolidating Statements of Comprehensive Income**

|  | Three Months Ended September 30, 2017 |                        |                            |                              |               |
|--|---------------------------------------|------------------------|----------------------------|------------------------------|---------------|
|  | Parent Issuer                         | Guarantor Subsidiaries | Non-Guarantor Subsidiaries | Eliminations and Adjustments | Consolidated  |
| Net sales  | \$ —                                  | \$ 960                 | \$ 1,053                   | \$ (429)                     | \$ 1,584      |
| Cost of goods sold   | —                                     | 773                    | 755                        | (409)                        | 1,119         |
| Gross profit   | —                                     | 187                    | 298                        | (20)                         | 465           |
| Selling, general, and administrative expense               | 7                                     | 105                    | 48                         | (7)                          | 153           |
| Research and development expense                           | —                                     | 19                     | 1                          | —                            | 20            |
| Restructuring, asset-related, and other charges            | —                                     | 8                      | —                          | —                            | 8             |
| Total other operating expenses                             | 7                                     | 132                    | 49                         | (7)                          | 181           |
| Equity in earnings of affiliates                           | —                                     | —                      | 9                          | —                            | 9             |
| Equity in earnings of subsidiaries                         | 233                                   | —                      | —                          | (233)                        | —             |
| Interest (expense) income, net                             | (57)                                  | 2                      | —                          | —                            | (55)          |
| Intercompany interest income (expense), net                | 16                                    | —                      | (16)                       | —                            | —             |
| Loss on extinguishment of debt                             | —                                     | —                      | —                          | —                            | —             |
| Other income (expense), net                                | 6                                     | 22                     | (10)                       | (6)                          | 12            |
| <b>Income before income taxes</b>                          | <b>191</b>                            | <b>79</b>              | <b>232</b>                 | <b>(252)</b>                 | <b>250</b>    |
| (Benefit from) provision for income taxes                  | (16)                                  | 18                     | 42                         | (1)                          | 43            |
| <b>Net income</b>  | <b>207</b>                            | <b>61</b>              | <b>190</b>                 | <b>(251)</b>                 | <b>207</b>    |
| Less: Net income attributable to non-controlling interests | —                                     | —                      | —                          | —                            | —             |
| <b>Net income attributable to Chemours</b>                 | <b>\$ 207</b>                         | <b>\$ 61</b>           | <b>\$ 190</b>              | <b>\$ (251)</b>              | <b>\$ 207</b> |
| <b>Comprehensive income attributable to Chemours</b>       | <b>\$ 228</b>                         | <b>\$ 63</b>           | <b>\$ 225</b>              | <b>\$ (288)</b>              | <b>\$ 228</b> |

|  | Nine Months Ended September 30, 2017 |                        |                            |                              |               |
|--|--------------------------------------|------------------------|----------------------------|------------------------------|---------------|
|  | Parent Issuer                        | Guarantor Subsidiaries | Non-Guarantor Subsidiaries | Eliminations and Adjustments | Consolidated  |
| Net sales  | \$ —                                 | \$ 2,904               | \$ 2,941                   | \$ (1,237)                   | \$ 4,608      |
| Cost of goods sold   | —                                    | 2,358                  | 2,216                      | (1,227)                      | 3,347         |
| Gross profit   | —                                    | 546                    | 725                        | (10)                         | 1,261         |
| Selling, general, and administrative expense               | 26                                   | 339                    | 118                        | (22)                         | 461           |
| Research and development expense                           | —                                    | 57                     | 5                          | —                            | 62            |
| Restructuring, asset-related, and other charges            | —                                    | 28                     | 3                          | —                            | 31            |
| Total other operating expenses                             | 26                                   | 424                    | 126                        | (22)                         | 554           |
| Equity in earnings of affiliates                           | —                                    | —                      | 26                         | —                            | 26            |
| Equity in earnings of subsidiaries                         | 594                                  | —                      | —                          | (594)                        | —             |
| Interest (expense) income, net                             | (163)                                | 1                      | 2                          | —                            | (160)         |
| Intercompany interest income (expense), net                | 48                                   | —                      | (48)                       | —                            | —             |
| Loss on extinguishment of debt                             | (1)                                  | —                      | —                          | —                            | (1)           |
| Other income (expense), net                                | 19                                   | 93                     | (13)                       | (22)                         | 77            |
| <b>Income before income taxes</b>                          | <b>471</b>                           | <b>216</b>             | <b>566</b>                 | <b>(604)</b>                 | <b>649</b>    |
| (Benefit from) provision for income taxes                  | (47)                                 | 40                     | 136                        | 1                            | 130           |
| <b>Net income</b>  | <b>518</b>                           | <b>176</b>             | <b>430</b>                 | <b>(605)</b>                 | <b>519</b>    |
| Less: Net income attributable to non-controlling interests | —                                    | —                      | 1                          | —                            | 1             |
| <b>Net income attributable to Chemours</b>                 | <b>\$ 518</b>                        | <b>\$ 176</b>          | <b>\$ 429</b>              | <b>\$ (605)</b>              | <b>\$ 518</b> |
| <b>Comprehensive income attributable to Chemours</b>       | <b>\$ 675</b>                        | <b>\$ 178</b>          | <b>\$ 640</b>              | <b>\$ (818)</b>              | <b>\$ 675</b> |

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Condensed Consolidating Balance Sheets**

|   | September 30, 2018 |                        |                            |                              |                 |
|---|--------------------|------------------------|----------------------------|------------------------------|-----------------|
|   | Parent Issuer      | Guarantor Subsidiaries | Non-Guarantor Subsidiaries | Eliminations and Adjustments | Consolidated    |
| <b>Assets</b>                             |                    |                        |                            |                              |                 |
| Current assets:                           |                    |                        |                            |                              |                 |
| Cash and cash equivalents                 | \$ —               | \$ 457                 | \$ 818                     | \$ —                         | \$ 1,275        |
| Accounts and notes receivable, net        | —                  | 324                    | 674                        | —                            | 998             |
| Intercompany receivable                   | 18                 | 848                    | 87                         | (953)                        | —               |
| Inventories                               | —                  | 440                    | 734                        | (88)                         | 1,086           |
| Prepaid expenses and other                | —                  | 64                     | 25                         | —                            | 89              |
| Total current assets                      | 18                 | 2,133                  | 2,338                      | (1,041)                      | 3,448           |
| Property, plant, and equipment            | —                  | 6,730                  | 2,155                      | —                            | 8,885           |
| Less: Accumulated depreciation            | —                  | (4,557)                | (1,121)                    | —                            | (5,678)         |
| Property, plant and equipment, net        | —                  | 2,173                  | 1,034                      | —                            | 3,207           |
| Goodwill and other intangible assets, net | —                  | 150                    | 37                         | —                            | 187             |
| Investments in affiliates                 | —                  | —                      | 179                        | —                            | 179             |
| Investment in subsidiaries                | 4,446              | 42                     | —                          | (4,488)                      | —               |
| Intercompany notes receivable             | 1,150              | —                      | —                          | (1,150)                      | —               |
| Other assets                              | 23                 | 122                    | 359                        | (13)                         | 491             |
| <b>Total assets</b>                       | <b>\$ 5,637</b>    | <b>\$ 4,620</b>        | <b>\$ 3,947</b>            | <b>\$ (6,692)</b>            | <b>\$ 7,512</b> |
| <b>Liabilities</b>                        |                    |                        |                            |                              |                 |
| Current liabilities:                      |                    |                        |                            |                              |                 |
| Accounts payable                          | \$ —               | \$ 634                 | \$ 489                     | \$ —                         | \$ 1,123        |
| Current maturities of long-term debt      | 14                 | —                      | —                          | —                            | 14              |
| Intercompany payable                      | 466                | 87                     | 400                        | (953)                        | —               |
| Other accrued liabilities                 | 70                 | 298                    | 193                        | —                            | 561             |
| Total current liabilities                 | 550                | 1,019                  | 1,082                      | (953)                        | 1,698           |
| Long-term debt, net                       | 3,934              | 51                     | —                          | —                            | 3,985           |
| Intercompany notes payable                | —                  | —                      | 1,150                      | (1,150)                      | —               |
| Deferred income taxes                     | 13                 | 120                    | 114                        | (27)                         | 220             |
| Other liabilities                         | —                  | 378                    | 85                         | —                            | 463             |
| Total liabilities                         | 4,497              | 1,568                  | 2,431                      | (2,130)                      | 6,366           |
| Commitments and contingent liabilities    |                    |                        |                            |                              |                 |
| <b>Equity</b>                             |                    |                        |                            |                              |                 |
| Total Chemours stockholders' equity       | 1,140              | 3,052                  | 1,510                      | (4,562)                      | 1,140           |
| Non-controlling interests                 | —                  | —                      | 6                          | —                            | 6               |
| Total equity                              | 1,140              | 3,052                  | 1,516                      | (4,562)                      | 1,146           |
| <b>Total liabilities and equity</b>       | <b>\$ 5,637</b>    | <b>\$ 4,620</b>        | <b>\$ 3,947</b>            | <b>\$ (6,692)</b>            | <b>\$ 7,512</b> |

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Condensed Consolidating Balance Sheets**

|   | December 31, 2017 |                        |                            |                              |                 |
|---|-------------------|------------------------|----------------------------|------------------------------|-----------------|
|   | Parent Issuer     | Guarantor Subsidiaries | Non-Guarantor Subsidiaries | Eliminations and Adjustments | Consolidated    |
| <b>Assets</b>                             |                   |                        |                            |                              |                 |
| Current assets:                           |                   |                        |                            |                              |                 |
| Cash and cash equivalents                 | \$ —              | \$ 761                 | \$ 795                     | \$ —                         | \$ 1,556        |
| Accounts and notes receivable, net        | —                 | 308                    | 611                        | —                            | 919             |
| Intercompany receivable                   | 3                 | 904                    | 581                        | (1,488)                      | —               |
| Inventories                               | —                 | 394                    | 631                        | (90)                         | 935             |
| Prepaid expenses and other                | —                 | 57                     | 15                         | 11                           | 83              |
| Total current assets                      | 3                 | 2,424                  | 2,633                      | (1,567)                      | 3,493           |
| Property, plant, and equipment            | —                 | 6,449                  | 2,062                      | —                            | 8,511           |
| Less: Accumulated depreciation            | —                 | (4,438)                | (1,065)                    | —                            | (5,503)         |
| Property, plant and equipment, net        | —                 | 2,011                  | 997                        | —                            | 3,008           |
| Goodwill and other intangible assets, net | —                 | 152                    | 14                         | —                            | 166             |
| Investments in affiliates                 | —                 | —                      | 173                        | —                            | 173             |
| Investment in subsidiaries                | 4,393             | —                      | —                          | (4,393)                      | —               |
| Intercompany notes receivable             | 1,150             | —                      | —                          | (1,150)                      | —               |
| Other assets                              | 23                | 115                    | 328                        | (13)                         | 453             |
| <b>Total assets</b>                       | <b>\$ 5,569</b>   | <b>\$ 4,702</b>        | <b>\$ 4,145</b>            | <b>\$ (7,123)</b>            | <b>\$ 7,293</b> |
| <b>Liabilities</b>                        |                   |                        |                            |                              |                 |
| Current liabilities:                      |                   |                        |                            |                              |                 |
| Accounts payable                          | \$ 31             | \$ 606                 | \$ 438                     | \$ —                         | \$ 1,075        |
| Current maturities of long-term debt      | 15                | —                      | —                          | —                            | 15              |
| Intercompany payable                      | 542               | 581                    | 365                        | (1,488)                      | —               |
| Other accrued liabilities                 | 34                | 343                    | 181                        | —                            | 558             |
| Total current liabilities                 | 622               | 1,530                  | 984                        | (1,488)                      | 1,648           |
| Long-term debt, net                       | 4,087             | 10                     | —                          | —                            | 4,097           |
| Intercompany notes payable                | —                 | —                      | 1,150                      | (1,150)                      | —               |
| Deferred income taxes                     | —                 | 127                    | 105                        | (24)                         | 208             |
| Other liabilities                         | —                 | 388                    | 87                         | —                            | 475             |
| Total liabilities                         | 4,709             | 2,055                  | 2,326                      | (2,662)                      | 6,428           |
| Commitments and contingent liabilities    |                   |                        |                            |                              |                 |
| <b>Equity</b>                             |                   |                        |                            |                              |                 |
| Total Chemours stockholders' equity       | 860               | 2,647                  | 1,814                      | (4,461)                      | 860             |
| Non-controlling interests                 | —                 | —                      | 5                          | —                            | 5               |
| Total equity                              | 860               | 2,647                  | 1,819                      | (4,461)                      | 865             |
| <b>Total liabilities and equity</b>       | <b>\$ 5,569</b>   | <b>\$ 4,702</b>        | <b>\$ 4,145</b>            | <b>\$ (7,123)</b>            | <b>\$ 7,293</b> |

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Condensed Consolidating Statements of Cash Flows**

|   | Nine Months Ended September 30, 2018 |                        |                            |                              |                 |
|---|--------------------------------------|------------------------|----------------------------|------------------------------|-----------------|
|   | Parent Issuer                        | Guarantor Subsidiaries | Non-Guarantor Subsidiaries | Eliminations and Adjustments | Consolidated    |
| <b>Cash flows from operating activities</b>                           |                                      |                        |                            |                              |                 |
| Cash provided by (used for) operating activities                      | \$ 2                                 | \$ (138)               | \$ 1,017                   | \$ —                         | \$ 881          |
| <b>Cash flows from investing activities</b>                           |                                      |                        |                            |                              |                 |
| Purchases of property, plant, and equipment                           | —                                    | (259)                  | (85)                       | —                            | (344)           |
| Acquisition of business, net  | —                                    | (37)                   | —                          | —                            | (37)            |
| Proceeds from sales of assets and businesses, net                     | —                                    | 46                     | —                          | —                            | 46              |
| Intercompany investing activities                                     | —                                    | 76                     | (897)                      | 821                          | —               |
| Foreign exchange contract settlements, net                            | —                                    | 8                      | —                          | —                            | 8               |
| Cash used for investing activities                                    | —                                    | (166)                  | (982)                      | 821                          | (327)           |
| <b>Cash flows from financing activities</b>                           |                                      |                        |                            |                              |                 |
| Proceeds from issuance of debt, net                                   | 520                                  | —                      | —                          | —                            | 520             |
| Debt repayments   | (675)                                | —                      | —                          | —                            | (675)           |
| Payments related to extinguishment of debt                            | (29)                                 | —                      | —                          | —                            | (29)            |
| Payments of debt issuance costs                                       | (12)                                 | —                      | —                          | —                            | (12)            |
| Purchases of treasury stock, at cost                                  | (520)                                | —                      | —                          | —                            | (520)           |
| Intercompany financing activities                                     | 821                                  | —                      | —                          | (821)                        | —               |
| Proceeds from exercised stock options, net                            | 15                                   | —                      | —                          | —                            | 15              |
| Payments related to tax withholdings on vested restricted stock units | (16)                                 | —                      | —                          | —                            | (16)            |
| Payments of dividends   | (106)                                | —                      | —                          | —                            | (106)           |
| Cash used for financing activities                                    | (2)                                  | —                      | —                          | (821)                        | (823)           |
| Effect of exchange rate changes on cash and cash equivalents          | —                                    | —                      | (12)                       | —                            | (12)            |
| <b>(Decrease) increase in cash and cash equivalents</b>               | <b>—</b>                             | <b>(304)</b>           | <b>23</b>                  | <b>—</b>                     | <b>(281)</b>    |
| <b>Cash and cash equivalents at beginning of the period</b>           | <b>—</b>                             | <b>761</b>             | <b>795</b>                 | <b>—</b>                     | <b>1,556</b>    |
| <b>Cash and cash equivalents at end of the period</b>                 | <b>\$ —</b>                          | <b>\$ 457</b>          | <b>\$ 818</b>              | <b>\$ —</b>                  | <b>\$ 1,275</b> |

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts and par values)*

**Condensed Consolidating Statements of Cash Flows**

|   | Nine Months Ended September 30, 2017 |                        |                            |                              |                 |
|---|--------------------------------------|------------------------|----------------------------|------------------------------|-----------------|
|   | Parent Issuer                        | Guarantor Subsidiaries | Non-Guarantor Subsidiaries | Eliminations and Adjustments | Consolidated    |
| <b>Cash flows from operating activities</b>                           |                                      |                        |                            |                              |                 |
| Cash (used for) provided by operating activities                      | \$ (59)                              | \$ 32                  | \$ 364                     | \$ —                         | \$ 337          |
| <b>Cash flows from investing activities</b>                           |                                      |                        |                            |                              |                 |
| Purchases of property, plant, and equipment                           | —                                    | (204)                  | (42)                       | —                            | (246)           |
| Proceeds from sales of assets and businesses, net                     | —                                    | 39                     | —                          | —                            | 39              |
| Intercompany investing activities                                     | —                                    | 408                    | —                          | (408)                        | —               |
| Foreign exchange contract settlements, net                            | —                                    | 5                      | —                          | —                            | 5               |
| Cash provided by (used for) investing activities                      | —                                    | 248                    | (42)                       | (408)                        | (202)           |
| <b>Cash flows from financing activities</b>                           |                                      |                        |                            |                              |                 |
| Intercompany short-term borrowing repayments, net                     | (408)                                | —                      | —                          | 408                          | —               |
| Proceeds from issuance of debt, net                                   | 494                                  | —                      | —                          | —                            | 494             |
| Debt repayments   | (24)                                 | —                      | —                          | —                            | (24)            |
| Payments related to extinguishment of debt                            | (1)                                  | —                      | —                          | —                            | (1)             |
| Payments of debt issuance costs                                       | (6)                                  | —                      | —                          | —                            | (6)             |
| Proceeds from exercised stock options, net                            | 30                                   | —                      | —                          | —                            | 30              |
| Payments related to tax withholdings on vested restricted stock units | (10)                                 | —                      | —                          | —                            | (10)            |
| Payments of dividends   | (16)                                 | —                      | —                          | —                            | (16)            |
| Cash provided by financing activities                                 | 59                                   | —                      | —                          | 408                          | 467             |
| Effect of exchange rate changes on cash and cash equivalents          | —                                    | —                      | 31                         | —                            | 31              |
| <b>Increase in cash and cash equivalents</b>                          | <b>—</b>                             | <b>280</b>             | <b>353</b>                 | <b>—</b>                     | <b>633</b>      |
| <b>Cash and cash equivalents at beginning of the period</b>           | <b>—</b>                             | <b>224</b>             | <b>678</b>                 | <b>—</b>                     | <b>902</b>      |
| <b>Cash and cash equivalents at end of the period</b>                 | <b>\$ —</b>                          | <b>\$ 504</b>          | <b>\$ 1,031</b>            | <b>\$ —</b>                  | <b>\$ 1,535</b> |

## Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

*This Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) supplements the unaudited Interim Consolidated Financial Statements and the related notes thereto included elsewhere herein to help provide an understanding of our financial condition, changes in our financial condition, and the results of our operations for the periods presented. Unless the context otherwise requires, references herein to "The Chemours Company," "Chemours," "the Company," "our Company," "we," "us," and "our" refer to The Chemours Company and its consolidated subsidiaries. References herein to "DuPont" refer to E. I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries (other than Chemours and its consolidated subsidiaries), unless the context otherwise requires.*

*This MD&A should be read in conjunction with the unaudited Interim Consolidated Financial Statements and the related notes thereto included in Item 1 of this Quarterly Report on Form 10-Q, as well as our audited Consolidated Financial Statements and the related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017.*

*This section and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements, within the meaning of the federal securities laws, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words "believe," "expect," "anticipate," "plan," "estimate," "target," "project," and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those set forth in the forward-looking statements.*

*Our forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements, as well as our historical performance, are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond our control. Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. Factors that could cause or contribute to these differences include, but are not limited to, the risks, uncertainties, and other factors discussed in the Forward-looking Statements and the Risk Factors sections in our Annual Report on Form 10-K for the year ended December 31, 2017. We assume no obligation to revise or update any forward-looking statement for any reason, except as required by law.*

### Overview

We are a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemical products for markets, including plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining. Our principal products include refrigerants, industrial fluoropolymer resins, sodium cyanide, performance chemicals and intermediates, and titanium dioxide (TiO<sub>2</sub>) pigment. Our business consists of three reportable segments: Fluoroproducts, Chemical Solutions, and Titanium Technologies. The Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrials, and consumer applications. The Titanium Technologies segment is a leading, global provider of TiO<sub>2</sub> pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications.

Our positions within each of these businesses reflect the strong value proposition we provide to our customers based on our long history and reputation in the chemicals industry for safety, quality, and reliability.

### Recent Developments

#### **Capital Allocation**

In the third quarter of 2018, we returned \$170 million in cash to our shareholders by purchasing \$126 million in our issued and outstanding common stock under the share repurchase program approved by our board of directors in August 2018, and through the payment of \$44 million in cash dividends, which amounted to \$0.25 per share.

Subsequent to September 30, 2018, we purchased an additional \$114 million of our issued and outstanding common stock under the share repurchase program.

## The Chemours Company

### Fayetteville, North Carolina

Governmental agencies and local community members have made inquiries and engaged in discussions with us with respect to the discharge of the polymerization processing aid HFPO Dimer Acid (sometimes referred to as GenX or C3 Dimer Acid) and other perfluorinated and polyfluorinated compounds from our facility in Fayetteville, North Carolina into the Cape Fear River, groundwater, and air. We believe that such discharges have not impacted the safety of drinking water in North Carolina. We continue to capture and separately dispose of process wastewater from the Fayetteville facility and are cooperating with a variety of ongoing inquiries and investigations from federal, state, and local authorities, regulators, and other governmental entities. For the three and nine months ended September 30, 2018, we have accrued an additional estimated liability amounting to \$30 million for these matters. Our total accrual for these matters amounted to \$43 million at September 30, 2018. See "Note 17 - Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements* for further information.

### Third Quarter 2018 Results and Business Highlights

#### Results of Operations

The following table sets forth our results of operations for the three and nine months ended September 30, 2018 and 2017.

| <i>(Dollars in millions, except per share amounts)</i>     | Three Months Ended September 30, |               | Nine Months Ended September 30, |               |
|--|----------------------------------|---------------|---------------------------------|---------------|
|  | 2018                             | 2017          | 2018                            | 2017          |
| Net sales  | \$ 1,628                         | \$ 1,584      | \$ 5,174                        | \$ 4,608      |
| Cost of goods sold   | 1,151                            | 1,119         | 3,603                           | 3,347         |
| Gross profit   | 477                              | 465           | 1,571                           | 1,261         |
| Selling, general, and administrative expense               | 163                              | 153           | 466                             | 461           |
| Research and development expense                           | 20                               | 20            | 61                              | 62            |
| Restructuring, asset-related, and other charges            | 12                               | 8             | 32                              | 31            |
| Total other operating expenses                             | 195                              | 181           | 559                             | 554           |
| Equity in earnings of affiliates                           | 10                               | 9             | 32                              | 26            |
| Interest expense, net                                      | (47)                             | (55)          | (148)                           | (160)         |
| Loss on extinguishment of debt                             | —                                | —             | (38)                            | (1)           |
| Other income, net  | 24                               | 12            | 115                             | 77            |
| <b>Income before income taxes</b>                          | <b>269</b>                       | <b>250</b>    | <b>973</b>                      | <b>649</b>    |
| (Benefit from) provision for income taxes                  | (6)                              | 43            | 119                             | 130           |
| <b>Net income</b>  | <b>275</b>                       | <b>207</b>    | <b>854</b>                      | <b>519</b>    |
| Less: Net income attributable to non-controlling interests | —                                | —             | 1                               | 1             |
| <b>Net income attributable to Chemours</b>                 | <b>\$ 275</b>                    | <b>\$ 207</b> | <b>\$ 853</b>                   | <b>\$ 518</b> |
| <b>Per share data</b>                                      |                                  |               |                                 |               |
| Basic earnings per share of common stock                   | \$ 1.56                          | \$ 1.12       | \$ 4.77                         | \$ 2.81       |
| Diluted earnings per share of common stock                 | 1.51                             | 1.08          | 4.62                            | 2.72          |

Our net sales for the three and nine months ended September 30, 2018 amounted to \$1.63 billion and \$5.17 billion, which represented increases of 3% and 12%, respectively, when compared with the same periods in 2017. Our net income attributable to Chemours for the three and nine months ended September 30, 2018 amounted to \$275 million and \$853 million, which represented increases of 33% and 65%, respectively, when compared with the same periods in 2017. Our basic and diluted earnings per share (EPS) for the three and nine months ended September 30, 2018 amounted to \$1.56 per share and \$4.77 per share, and \$1.51 per share and \$4.62 per share, which represented increases of approximately 40% and 70%, respectively, when compared with the same periods in 2017. Our adjusted earnings before interest, taxes, depreciation, and amortization (Adjusted EBITDA) amounted to \$435 million and \$1.40 billion, which represented increases of 14% and 36%, respectively, when compared with the same periods in 2017.



## The Chemours Company

Our results of operations for the three and nine months ended September 30, 2018 were driven primarily by higher global average selling prices in our Titanium Technologies segment, and strong demand in our Fluoroproducts segment. Additionally, we incurred lower interest expense, net, primarily attributable to higher interest income, higher capitalized interest, and net savings on interest costs associated with our debt transactions, and higher amounts of other income, net, primarily attributable to European Union (EU) quota authorization sales in our Fluoroproducts segment for the three and nine months then-ended, and a gain on the sale of our Linden, New Jersey site during the first quarter of 2018. Our net income also improved due to certain discrete income tax benefits attributable to the three and nine months ended September 30, 2018. Our results of operations for the three months ended September 30, 2018 were somewhat offset by lower volume in our Titanium Technologies segment due to faster-than-anticipated customer inventory reductions attributable to destocking throughout the value chain, higher costs for certain raw materials, and the accrual of an additional estimated liability for ongoing legal and environmental matters at our Fayetteville, North Carolina site. Our results of operations for the nine months ended September 30, 2018 were somewhat offset by higher costs for certain raw materials, higher distribution, freight, and logistics expenses, process water treatment costs, and the accrual of an additional estimated liability for ongoing legal and environmental matters at our Fayetteville site.

### Net sales

The following table sets forth the impact of price, volume, and currency changes on our net sales for the three and nine months ended September 30, 2018.

| Change in net sales from prior period | Three Months Ended<br>September 30, 2018 | Nine Months Ended<br>September 30, 2018 |
|---------------------------------------|--|---|
| Price                                 | 6%                                       | 8%                                      |
| Volume                                | (3)%                                     | 3%                                      |
| Currency                              | —%                                       | 1%                                      |
| <b>Total change in net sales</b>      | <b>3%</b>                                | <b>12%</b>                              |

Our net sales increased by \$44 million and \$566 million (or 3% and 12%) for the three and nine months ended September 30, 2018, respectively, compared with net sales for the same periods in 2017. The increase in our net sales for the three months ended September 30, 2018 was primarily attributable to a 6% increase in price, driven by higher global average selling prices for Ti-Pure™ TiO<sub>2</sub> pigment in our Titanium Technologies segment, increases in the average selling prices for all of our Chemical Solutions segment's product lines, and increases in the average selling prices for fluoropolymers products in our Fluoroproducts segment. These increases were somewhat offset by a 3% decrease in volume, which is the net result of volume decreases in our Titanium Technologies and Chemical Solutions segments, and a volume increase in our Fluoroproducts segment driven by the continued adoption of Opteon™ refrigerants and increased demand for our base refrigerants and fluoropolymers products for the three months then-ended. The increase in our net sales for the nine months ended September 30, 2018 was primarily attributable to the following: an 8% increase in price, driven by higher global average selling prices for Ti-Pure™ TiO<sub>2</sub> pigment in our Titanium Technologies segment, increases in the average selling prices for all of our Chemical Solutions segment's product lines, and increases in the average selling prices for base refrigerants and fluoropolymers products in our Fluoroproducts segment; a 3% increase in volume, driven by the continued adoption of Opteon™ refrigerants and increased demand for base refrigerants and fluoropolymers products in our Fluoroproducts segment; and, a 1% increase from favorable foreign currency movements.

### Cost of goods sold

Our cost of goods sold increased by \$32 million and \$256 million (or 3% and 8%) for the three and nine months ended September 30, 2018, respectively, compared with cost of goods sold for the same periods in 2017. The increase in our cost of goods sold for the three months ended September 30, 2018 was primarily attributable to higher costs for certain raw materials. The increase in our cost of goods sold for the nine months ended September 30, 2018 was primarily attributable to higher costs for certain raw materials, higher distribution, freight, and logistics expenses, and process water treatment costs.

### Selling, general, and administrative expense

Our selling, general, and administrative expense increased by \$10 million and \$5 million (or 7% and 1%) for the three and nine months ended September 30, 2018, respectively, compared with selling, general, and administrative expense for the same periods in 2017. The increase in our selling, general, and administrative expense for the three months ended September 30, 2018 was primarily attributable to the accrual of an additional estimated liability for ongoing legal and environmental matters at our Fayetteville, North Carolina site, which was somewhat offset by lower performance-related compensation expenses, as well as lower costs associated with our transformation activities. The increase in our selling, general, and administrative expense for the nine months ended September 30, 2018 was primarily attributable to the accrual of an additional estimated liability for ongoing legal and environmental matters at our Fayetteville site, as well as higher costs for our debt transactions and certain other legal matters. These increases were somewhat offset by lower costs associated with our transformation activities and lower performance-related compensation expenses for the nine months then-ended.

## The Chemours Company

### ***Research and development expense***

Our research and development expense was largely unchanged at \$20 million and \$61 million for the three and nine months ended September 30, 2018, respectively, compared with research and development expense of \$20 million and \$62 million for the three and nine months ended September 30, 2017, respectively.

### ***Restructuring, asset-related, and other charges***

Our restructuring, asset-related, and other charges amounted to \$12 million and \$32 million for the three and nine months ended September 30, 2018, respectively, compared with restructuring, asset-related, and other charges of \$8 million and \$31 million for the three and nine months ended September 30, 2017, respectively. The increases in our restructuring, asset-related, and other charges for the three and nine months ended September 30, 2018 were primarily attributable to employee separation and other charges incurred in connection with our 2017 restructuring program, as well as ongoing decommissioning and dismantling-related charges for the demolition and removal of certain unused buildings at our Chambers Works site in Deepwater, New Jersey, which began in 2018. These increases were somewhat offset by higher decommissioning and dismantling-related charges incurred during 2017 for the production shutdown at our Reactive Metals Solutions manufacturing site in Niagara Falls, New York.

### ***Interest expense, net***

We incurred interest expense, net of \$47 million and \$148 million for the three and nine months ended September 30, 2018, respectively, compared with interest expense, net of \$55 million and \$160 million for the three and nine months ended September 30, 2017, respectively. The decreases in our interest expense, net for the three and nine months ended September 30, 2018 were primarily attributable to increases in both interest income and capitalized interest over the same periods in the prior year, as well as decreased interest expense as a result of our 2017 and 2018 debt refinancing activities. These decreases were somewhat offset by increases in interest expense resulting from the first full year of outstanding principal on our 5.375% senior unsecured notes due May 2027 (2027 Notes), which were issued in May 2017.

### ***Loss on extinguishment of debt***

We incurred a loss on extinguishment of debt of \$38 million for the nine months ended September 30, 2018, compared with a loss on extinguishment of debt of \$1 million for the nine months ended September 30, 2017. Our loss on extinguishment of debt for the nine months ended September 30, 2018 was attributable to our debt transactions, including the amendment and restatement of our credit agreement and issuance of senior secured debt, and our tender offers to purchase any and all of our outstanding euro-denominated 6.125% senior unsecured notes due May 2023 and a portion of our outstanding dollar-denominated 6.625% senior unsecured notes due May 2023, all of which occurred during the second quarter. Our loss on extinguishment of debt for the nine months ended September 30, 2017 was attributable to the April 2017 amendment to our then-existing credit agreement, which has since been superseded by certain of our 2018 debt refinancing activities.

### ***Other income, net***

Our other income, net amounted to \$24 million and \$115 million for the three and nine months ended September 30, 2018, respectively, compared with other income, net of \$12 million and \$77 million for the three and nine months ended September 30, 2017, respectively. The increase in our other income, net for the three months ended September 30, 2018 was primarily attributable to an increase in miscellaneous income resulting from EU quota authorization sales in our Fluoroproducts segment. The increase in our other income, net for the nine months ended September 30, 2018 was primarily attributable to an increase in miscellaneous income resulting from EU quota authorization sales in our Fluoroproducts segment, and a \$42 million gain on the sale of our Linden, New Jersey site in March 2018.

## The Chemours Company

### Provision for income taxes

Our benefit from and provision for income taxes amounted to \$6 million and \$119 million, which represented effective income tax rates of approximately negative 2% and 12% for the three and nine months ended September 30, 2018, respectively, compared with provisions for income taxes of \$43 million and \$130 million, which represented effective income tax rates of approximately 17% and 20% for the three and nine months ended September 30, 2017, respectively. The change in our benefit from income taxes for the three months ended September 30, 2018 was primarily attributable to income tax benefits from the release of a valuation allowance on carryforward foreign tax credits due to changes in normal business operations, the filing of our 2017 U.S. tax return and the associated adjustments on the revaluation of certain deferred tax assets and liabilities as a result of the reduced U.S. corporate tax rate, windfalls on our share-based payments, and the geographic mix of our earnings. The aforementioned income tax benefits were somewhat offset by increased tax expenses resulting from our increased profitability for the three months then-ended. The change in our provision for income taxes for the nine months ended September 30, 2018 was primarily attributable to income tax benefits from the release of a valuation allowance on carryforward foreign tax credits due to changes in normal business operations, the filing of our 2017 U.S. tax return and the associated adjustments on the revaluation of certain deferred tax assets and liabilities as a result of the reduced U.S. corporate tax rate, windfalls on our share-based payments, our loss on debt extinguishment, and the geographic mix of our earnings. The aforementioned income tax benefits were somewhat offset by increased tax expenses resulting from our increased profitability for the nine months then-ended, as well as income tax expenses related to asset sales that took place during the first quarter, and the impact of certain U.S. tax reform provisions.

### Segment Reviews

We prepare our interim consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (GAAP). To supplement our financial information presented in accordance with GAAP, we provide the following non-GAAP financial measures - Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, Free Cash Flows (FCF), and Return on Invested Capital (ROIC) - in order to clarify and provide investors with a better understanding of our performance when analyzing changes in our underlying business between reporting periods and provide for greater transparency with respect to supplemental information used by management in its financial and operational decision-making.

Adjusted EBITDA is the primary measure of segment performance used by our Chief Operating Decision Maker (CODM) and is defined as income (loss) before income taxes, excluding the following:

- interest expense, depreciation, and amortization;
- non-operating pension and other post-retirement employee benefit costs, which represent the components of net periodic pension (income) costs excluding the service cost component;
- exchange (gains) losses included in other income (expense), net;
- restructuring, asset-related, and other charges;
- asset impairments;
- (gains) losses on sales of assets and businesses; and,
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

Reconciliations of Adjusted EBITDA and our other non-GAAP financial measures to their closest GAAP financial measures for the three and nine months ended September 30, 2018 and 2017 are included in "Non-GAAP Financial Measures" within this MD&A.

The following table sets forth our total Adjusted EBITDA by segment for the three and nine months ended September 30, 2018 and 2017.


| (Dollars in millions)        | Three Months Ended September 30, |               | Nine Months Ended September 30, |                 |
|------------------------------|----------------------------------|---------------|---------------------------------|-----------------|
|                              | 2018                             | 2017          | 2018                            | 2017            |
| Fluoroproducts               | \$ 182                           | \$ 158        | \$ 619                          | \$ 510          |
| Chemical Solutions           | 24                               | 18            | 50                              | 37              |
| Titanium Technologies        | 268                              | 249           | 856                             | 601             |
| Corporate and Other          | (39)                             | (44)          | (126)                           | (120)           |
| <b>Total Adjusted EBITDA</b> | <b>\$ 435</b>                    | <b>\$ 381</b> | <b>\$ 1,399</b>                 | <b>\$ 1,028</b> |

## The Chemours Company


### Fluoroproducts

The following chart sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Fluoroproducts segment for the three and nine months ended September 30, 2018 and 2017.

**Fluoroproducts Segment Results of Operations**  
**Three Months Ended September 30,**



**Fluoroproducts Segment Results of Operations**  
**Nine Months Ended September 30,**



| <i>(Dollars in millions)</i> | Three Months Ended September 30, |        | Nine Months Ended September 30, |          |
|------------------------------|----------------------------------|--------|---------------------------------|----------|
|                              | 2018                             | 2017   | 2018                            | 2017     |
| Segment net sales            | \$ 682                           | \$ 637 | \$ 2,213                        | \$ 1,998 |
| Adjusted EBITDA              | 182                              | 158    | 619                             | 510      |
| Adjusted EBITDA margin       | 27%                              | 25%    | 28%                             | 26%      |

The following table sets forth the impacts of price, volume, and currency changes on our Fluoroproducts segment's net sales for the three and nine months ended September 30, 2018.

| Change in segment net sales from prior period | Three Months Ended<br>September 30, 2018 | Nine Months Ended<br>September 30, 2018 |
|---|--|---|
| Price   | 1%                                       | 2%                                      |
| Volume  | 7%                                       | 9%                                      |
| Currency                                      | (1)%                                     | —%                                      |
| <b>Total change in segment net sales</b>      | <b>7%</b>                                | <b>11%</b>                              |

## The Chemours Company

### *Segment Net Sales*

Segment net sales increased by \$45 million and \$215 million (or 7% and 11%) for the three and nine months ended September 30, 2018, respectively, when compared with the same periods in 2017. The increase to segment net sales for the three months ended September 30, 2018 was primarily attributable to a 7% increase in volume, driven by the continued adoption of Opteon™ refrigerants, as well as higher demand for our base refrigerants and fluoropolymers products, and a 1% increase in price, driven by increases in the average selling prices for our fluoropolymers products. These increases were somewhat offset by unfavorable foreign currency movements, which negatively impacted segment net sales by 1% for the three months then-ended. The increase to segment net sales for the nine months ended September 30, 2018 was primarily attributable to a 9% increase in volume, driven by the continued adoption of Opteon™ refrigerants as well as higher demand for our base refrigerants and fluoropolymers products, and a 2% increase in price, driven by increases in the average selling prices for our base refrigerants and fluoropolymers products.

### *Adjusted EBITDA and Adjusted EBITDA Margin*

Segment Adjusted EBITDA increased by \$24 million and \$109 million (or 15% and 21%), and segment Adjusted EBITDA margin increased by approximately 200 basis points for the three and nine months ended September 30, 2018 when compared with the same periods in 2017. The increases to segment Adjusted EBITDA and Adjusted EBITDA margin for the three and nine months ended September 30, 2018 were primarily attributable to the aforementioned increases in volume and price, as well as increases in other income, net resulting from EU quota authorization sales amounting to \$18 million and \$38 million during the periods then-ended, respectively. During the three and nine months ended September 30, 2017, EU quota authorization sales amounted to \$6 million and \$14 million, respectively. The increases to segment Adjusted EBITDA and Adjusted EBITDA margin for the three months ended September 30, 2018 were somewhat offset by higher costs for certain raw materials. The increases to segment Adjusted EBITDA and Adjusted EBITDA margin for the nine months ended September 30, 2018 were somewhat offset by higher costs for certain raw materials, distribution expenses, and process water treatment costs.


The segment's operating results for the three and nine months ended September 30, 2018 included \$8 million and \$28 million of additional costs for process water treatment at our Fayetteville, North Carolina site, respectively. These costs are expected to total approximately \$35 million for the year ended December 31, 2018. The segment's operating results for the year ended December 31, 2017 included \$11 million for these costs, which were recognized entirely in the fourth quarter.

## The Chemours Company


### Chemical Solutions

The following chart sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Chemical Solutions segment for the three and nine months ended September 30, 2018 and 2017.

**Chemical Solutions Segment Results of Operations**  
**Three Months Ended September 30,**



**Chemical Solutions Segment Results of Operations**  
**Nine Months Ended September 30,**



| <i>(Dollars in millions)</i> | Three Months Ended September 30, |        | Nine Months Ended September 30, |        |
|------------------------------|----------------------------------|--------|---------------------------------|--------|
|                              | 2018                             | 2017   | 2018                            | 2017   |
| Segment net sales            | \$ 155                           | \$ 148 | \$ 453                          | \$ 437 |
| Adjusted EBITDA              | 24                               | 18     | 50                              | 37     |
| Adjusted EBITDA margin       | 16%                              | 12%    | 11%                             | 9%     |

The following table sets forth the impacts of price, volume, and currency changes on our Chemical Solutions segment's net sales for the three and nine months ended September 30, 2018.

| Change in segment net sales from prior period | Three Months Ended<br>September 30, 2018 | Nine Months Ended<br>September 30, 2018 |
|---|--|---|
| Price   | 12%                                      | 4%                                      |
| Volume  | (7)%                                     | (1)%                                    |
| Currency                                      | —%                                       | 1%                                      |
| <b>Total change in segment net sales</b>      | <u>5%</u>                                | <u>4%</u>                               |

## The Chemours Company

### *Segment Net Sales*

Segment net sales increased by \$7 million and \$16 million (or 5% and 4%) for the three and nine months ended September 30, 2018, respectively, when compared with the same periods in 2017. The increase to segment net sales for the three months ended September 30, 2018 was primarily attributable to a 12% increase in price, driven by increases in the average selling prices for all of the segment's product lines. This increase was somewhat offset by a 7% decrease in volume, primarily within our Performance Chemicals and Intermediates businesses. The increase to segment net sales for the nine months ended September 30, 2018 was primarily attributable to a 4% increase in price, driven by increases in the average selling prices for all of the segment's product lines, and a 1% increase from favorable foreign currency movements. These increases were somewhat offset by a 1% decrease in volume, which was primarily attributable to our Performance Chemicals and Intermediates businesses.

### *Adjusted EBITDA and Adjusted EBITDA Margin*


Segment Adjusted EBITDA increased by \$6 million and \$13 million (or 33% and 35%), and segment Adjusted EBITDA margin increased by approximately 400 basis points and 200 basis points for the three and nine months ended September 30, 2018, respectively, when compared with the same periods in 2017. The increases to segment Adjusted EBITDA and Adjusted EBITDA margin for the three and nine months ended September 30, 2018 were primarily attributable to the aforementioned price increases, which were somewhat offset by higher costs for certain raw materials.

## The Chemours Company


### Titanium Technologies

The following chart sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Titanium Technologies segment for the three and nine months ended September 30, 2018 and 2017.

**Titanium Technologies Segment Results of Operations**  
Three Months Ended September 30,



**Titanium Technologies Segment Results of Operations**  
Nine Months Ended September 30,



| <i>(Dollars in millions)</i> | Three Months Ended September 30, |        | Nine Months Ended September 30, |          |
|------------------------------|----------------------------------|--------|---------------------------------|----------|
|                              | 2018                             | 2017   | 2018                            | 2017     |
| Segment net sales            | \$ 791                           | \$ 799 | \$ 2,508                        | \$ 2,173 |
| Adjusted EBITDA              | 268                              | 249    | 856                             | 601      |
| Adjusted EBITDA margin       | 34%                              | 31%    | 34%                             | 28%      |

The following table sets forth the impacts of price, volume, and currency changes on our Titanium Technologies segment's net sales for the three and nine months ended September 30, 2018.

| Change in segment net sales from prior period | Three Months Ended<br>September 30, 2018 | Nine Months Ended<br>September 30, 2018 |
|---|--|---|
| Price   | 9%                                       | 15%                                     |
| Volume  | (10)%                                    | (2)%                                    |
| Currency                                      | —%                                       | 2%                                      |
| <b>Total change in segment net sales</b>      | <b>(1)%</b>                              | <b>15%</b>                              |



## The Chemours Company

### *Segment Net Sales*

Segment net sales decreased by \$8 million (or 1%) and increased by \$335 million (or 15%) for the three and nine months ended September 30, 2018, respectively, when compared with the same periods in 2017. The decrease to segment net sales for the three months ended September 30, 2018 was primarily attributable to a 10% decrease in volume due to faster-than-anticipated customer inventory reductions attributable to destocking throughout the value chain, which was mostly offset by a 9% increase in global average selling prices for our Ti-Pure™ TiO<sub>2</sub> pigment. The increase to segment net sales for the nine months ended September 30, 2018 was primarily attributable to a 15% increase in global average selling prices for our Ti-Pure™ TiO<sub>2</sub> pigment, and a 2% increase from favorable foreign currency movements. These increases were somewhat offset by a 2% decrease in volume due to faster-than-anticipated customer inventory reductions attributable to destocking throughout the value chain for the nine months then-ended.

### *Adjusted EBITDA and Adjusted EBITDA Margin*

Segment Adjusted EBITDA increased by \$19 million and \$255 million (or 8% and 42%), and segment Adjusted EBITDA margin increased by approximately 300 basis points and 600 basis points for the three and nine months ended September 30, 2018, respectively, when compared with the same periods in 2017. The increases to segment Adjusted EBITDA and Adjusted EBITDA margin for the three and nine months ended September 30, 2018 were primarily attributable to the aforementioned price increases, which were somewhat offset by lower volume and higher costs for certain raw materials and higher freight and logistics expenses.

### *Corporate and Other*

Corporate costs and certain legacy legal and environmental expenses, stock-based compensation costs, and foreign exchange gains and losses arising from the remeasurement of balances in currencies other than the functional currency of our legal entities are reflected in Corporate and Other. Corporate and Other costs were \$39 million and \$126 million for the three and nine months ended September 30, 2018, respectively, compared with Corporate and Other costs of \$44 million and \$120 million for the three and nine months ended September 30, 2017, respectively. The decrease in Corporate and Other costs for the three months ended September 30, 2018 was primarily attributable to lower expenses for legacy environmental issues. The increase in Corporate and Other costs for the nine months ended September 30, 2018 was primarily attributable to higher costs associated with certain legacy legal matters.

### Growth Expectations and Outlook

We expect each of our businesses to contribute to our overall growth. For our Fluoroproducts segment, we are optimizing our fluorochemicals product mix with the expansion of Opteon™ refrigerants capacity and renewing our fluoropolymers portfolio through application development. For our Chemical Solutions segment, we plan to expand our capacity to meet demand for our Mining Solutions products. For our Titanium Technologies segment, we are implementing a value stabilization strategy in order to seek to reduce volatility for our Ti-Pure™ TiO<sub>2</sub> pigment earnings. To the extent we are successful in implementing such plans, as to which no assurance can be given, we identified key financial targets through 2020, including goals for our future net sales growth, Adjusted EBITDA margin improvement, Adjusted EPS, FCF, and ROIC. For further discussion regarding the risks associated with meeting our key financial targets for 2020 and the factors that may affect our ability to achieve these targets, see *Item 1A - Risk Factors* of our Annual Report on Form 10-K for the year ended December 31, 2017. For further discussion regarding our use of non-GAAP financial measures and reconciliations to their closest comparable GAAP financial measures, see "Non-GAAP Financial Measures" within this MD&A.

Our 2018 results will be driven by the expectation that: (i) average prices for our TiO<sub>2</sub> pigment will be above 2017 average prices, and that volume in our Titanium Technologies segment may be directly impacted by destocking throughout the value chain; (ii) there will be continued transition to Opteon™ refrigerants; (iii) there will be increased demand for our fluoropolymer products; and, (iv) there will be strong demand for our Mining Solutions products. We expect our capital expenditures for 2018 to be approximately \$500 million, which will be driven largely by capital expenditures associated with our new Opteon™ plant under construction in Corpus Christi, Texas and our planned Mining Solutions plant under construction in Laguna, Mexico. Our outlook for 2018 reflects our current visibility and expectations based on market factors, such as currency movements, TiO<sub>2</sub> pigment pricing, and end-market demand, and our ability to meet these targets is subject to numerous risks, such as those described in *Item 1A - Risk Factors* of our Annual Report on Form 10-K for the year ended December 31, 2017. We expect our earnings growth to meet or exceed our three-year targets.

## The Chemours Company

### Liquidity and Capital Resources

Our primary sources of liquidity are cash generated from operations, available cash, and borrowings under our debt financing arrangements, which are described in further detail below. We believe these sources are sufficient to fund our planned operations and to meet our interest, dividend, and contractual obligations. Our financial policy seeks to: (i) selectively invest in organic and inorganic growth to enhance our portfolio, including certain strategic capital investments; (ii) return cash to shareholders through dividends and share repurchases; and, (iii) maintain appropriate leverage by using free cash flows to repay outstanding borrowings. Subject to approval by our board of directors, we may raise additional capital or borrowings from time to time, or seek to refinance our existing debt. There can be no assurance that future capital or borrowings will be available to us, and the cost and availability of new capital or borrowings could be materially impacted by market conditions. Further, the decision to refinance our existing debt is based on a number of factors, including general market conditions and our ability to refinance on attractive terms at any given point in time. Any attempts to raise additional capital or borrowings, or refinance our existing debt, could cause us to incur significant charges. Such charges could have a material impact on our financial position, results of operations, or cash flows.

Our operating cash flow generation is driven by, among other things, the general global economic conditions at any point in time and their resulting impact on demand for our products, raw materials and energy prices, and industry-specific issues, such as production capacity and utilization. We have generated strong operating cash flows through various industry and economic cycles, evidencing the operating strength of our businesses.

On August 1, 2018, our board of directors increased our cash dividend to \$0.25 per share for the third quarter of 2018, which was paid on September 14, 2018 to our shareholders of record as of the close of business on August 17, 2018. Additionally, on August 1, 2018, our board of directors approved a share repurchase program, which authorizes us to purchase shares of our issued and outstanding common stock in an aggregate amount not to exceed \$750 million, plus any fees or costs in connection with our share repurchase activity (2018 Share Repurchase Program). The 2018 Share Repurchase Program became effective on August 1, 2018 and will continue through the earlier of its expiration on December 31, 2020, or the completion of repurchases up to the approved amount.

We anticipate making significant payments for interest, capital expenditures, dividends, and other actions over the next 12 months, which we expect to fund through cash generated from operations, available cash, and borrowings. We further anticipate that our operations and existing debt financing arrangements will provide us with sufficient liquidity over the next 12 months. The availability under our New Revolving Credit Facility, which is discussed further under the heading "Credit Facilities and Notes," is subject to the last 12 months of consolidated EBITDA, as defined in the amended and restated credit agreement.

At September 30, 2018, we had total cash and cash equivalents of \$1.28 billion, of which, \$811 million was held by our foreign subsidiaries. All of the cash and cash equivalents held by our foreign subsidiaries is readily convertible into currencies used in our operations, including the U.S. dollar. The cash and earnings of our foreign subsidiaries are generally used to finance their operations and capital expenditures. At September 30, 2018, management believed that sufficient liquidity was available in the U.S., and it is our intention to indefinitely reinvest the undistributed earnings of our foreign subsidiaries outside of the U.S.; however, we continue to evaluate this assertion as a result of U.S. tax reform.

No deferred tax liabilities have been recognized with regard to the \$811 million of cash and cash equivalents held by our foreign subsidiaries at September 30, 2018, or on our undistributed earnings. The potential tax implications of the repatriation of unremitted earnings are driven by facts at the time of distribution; however, due to the U.S. deemed repatriation transition tax as a result of U.S. tax reform, the incremental cost to repatriate earnings would be reduced if a distribution was made in the future.

### **Cash Flows**

The following table sets forth a summary of our net cash provided by (used for) operating, investing, and financing activities for the nine months ended September 30, 2018 and 2017.

| <i>(Dollars in millions)</i>                     | Nine Months Ended September 30, |        |
|--|---------------------------------|--------|
|  | 2018                            | 2017   |
| Cash provided by operating activities            | \$ 881                          | \$ 337 |
| Cash used for investing activities               | (327)                           | (202)  |
| Cash (used for) provided by financing activities | (823)                           | 467    |

## The Chemours Company

### Operating Activities

We received \$881 million and \$337 million in cash flows from our operating activities for the nine months ended September 30, 2018 and 2017, respectively. The increase in our operating cash inflows for the nine months ended September 30, 2018 was primarily attributable to an improvement in our net income. Additionally, during the nine months ended September 30, 2017, we paid \$335 million to satisfy the PFOA MDL Settlement (as discussed in “Note 17 - Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*), which negatively impacted our operating cash flows resulting from changes in working capital.

### Investing Activities

We used \$327 million and \$202 million in cash flows for our investing activities during the nine months ended September 30, 2018 and 2017, respectively. For the nine months ended September 30, 2018, our investing cash outflows were primarily attributable to purchases of property, plant, and equipment for \$344 million, as well as \$37 million in total cash consideration payments for the acquisition of ICOR International, Inc. in April 2018. These cash outflows were somewhat offset by \$46 million in net proceeds received from the sales of assets and businesses, primarily attributable to the sale of our Linden, New Jersey site in March 2018 for \$39 million, and \$8 million in net foreign exchange contract settlements. For the nine months ended September 30, 2017, our investing cash outflows were primarily attributable to purchases of property, plant, and equipment for \$246 million. These cash outflows were somewhat offset by \$39 million in net proceeds received from the sales of assets and businesses, primarily attributable to the sales of our headquarters building in Wilmington, Delaware in April 2017 for \$29 million and our Edge Moor, Delaware site in March 2017 for \$9 million, and \$5 million in net foreign exchange contract settlements.

### Financing Activities

We used \$823 million in cash flows for, and received \$467 million in cash flows from our financing activities during the nine months ended September 30, 2018 and 2017, respectively. For the nine months ended September 30, 2018, our financing cash outflows were primarily attributable to debt repayments of \$675 million and debt extinguishment payments of \$29 million for “make-whole” and early prepayment premiums in connection with our debt transactions during the second quarter (discussed further under the heading “Credit Facilities and Notes” within this *MD&A*). Additionally, we made cash payments totaling \$520 million for the repurchase of approximately 10.9 million shares of our issued and outstanding common stock under our share repurchase programs, and paid dividends amounting to \$106 million during the nine months then-ended. These cash outflows were somewhat offset by \$520 million in net proceeds received from the issuance of our euro-denominated 4.000% senior unsecured notes due May 2026 (2026 Euro Notes) in June 2018. For the nine months ended September 30, 2017, our financing cash inflows were primarily attributable to \$494 million in net proceeds received from the issuance of our 2027 Notes in May 2017.

### Current Assets

The following table sets forth the components of our current assets at September 30, 2018 and December 31, 2017.

| <i>(Dollars in millions)</i>       | September 30, 2018 | December 31, 2017 |
|------------------------------------|--------------------|-------------------|
| Cash and cash equivalents          | \$ 1,275           | \$ 1,556          |
| Accounts and notes receivable, net | 998                | 919               |
| Inventories                        | 1,086              | 935               |
| Prepaid expenses and other         | 89                 | 83                |
| <b>Total current assets</b>        | <b>\$ 3,448</b>    | <b>\$ 3,493</b>   |

Our accounts and notes receivable, net increased by \$79 million (or 9%) to \$998 million at September 30, 2018 from \$919 million at December 31, 2017. The increase in our accounts and notes receivable, net was primarily attributable to increased sales volume, and the timing of customer receipts.

Our inventories increased by \$151 million (or 16%) to \$1.09 billion at September 30, 2018 from \$935 million at December 31, 2017. The increase in our inventories was primarily attributable to faster-than-anticipated customer inventory reductions attributable to destocking throughout the value chain, inventory build-up for plant turnarounds, and higher costs for certain raw materials.

Our prepaid expenses and other increased by \$6 million (or 7%) to \$89 million at September 30, 2018 from \$83 million at December 31, 2017. The increase in our prepaid expenses and other was primarily attributable to normal fluctuations in prepaid expense balances.

## The Chemours Company

### Current Liabilities

The following table sets forth the components of our current liabilities at September 30, 2018 and December 31, 2017.

| <i>(Dollars in millions)</i>         | September 30, 2018 | December 31, 2017 |
|--------------------------------------|--------------------|-------------------|
| Accounts payable                     | \$ 1,123           | \$ 1,075          |
| Current maturities of long-term debt | 14                 | 15                |
| Other accrued liabilities            | 561                | 558               |
| <b>Total current liabilities</b>     | <b>\$ 1,698</b>    | <b>\$ 1,648</b>   |

Our accounts payable increased by \$48 million (or 4%) to \$1.12 billion at September 30, 2018 from \$1.08 billion at December 31, 2017. The increase in our accounts payable was primarily attributable to the timing of vendor payments, which impacted the balance of trade payables. This increase was somewhat offset by a reduction in dividends payable due to the payment of dividends in the first quarter of 2018, which were declared and accrued during the fourth quarter of 2017.

Our current maturities of long-term debt remained largely unchanged at \$14 million and \$15 million at September 30, 2018 and December 31, 2017, respectively.

Our other accrued liabilities increased by \$3 million (or 1%) to \$561 million at September 30, 2018 from \$558 million at December 31, 2017. The increase in our other accrued liabilities was primarily attributable to increases in accrued interest, due to the timing of semi-annual interest payments on our debt, accrued litigation, due to the accrual of an additional estimated liability for ongoing legal and environmental matters at our Fayetteville, North Carolina site, income taxes payable, due to the timing of payments, and the current portion of accrued environmental remediation liabilities. These increases were mostly offset by a reduction in accrued compensation and other employee-related costs, which is consistent with the payment of accrued performance-related compensation in the first quarter of 2018.

### Credit Facilities and Notes

#### Senior Secured Credit Facilities

On April 3, 2018, we entered into an amended and restated credit agreement that provides for a seven-year, senior secured term loan facility and a five-year, \$800 million senior secured revolving credit facility (New Revolving Credit Facility) (collectively, the New Senior Secured Credit Facilities). The New Senior Secured Credit Facilities replaced, in full, our obligations under our then-existing credit agreement. The senior secured term loan facility under the New Senior Secured Credit Facilities provides for a class of term loans, denominated in U.S. dollars, in an aggregate principal amount of \$900 million (New Dollar Term Loan) and a class of term loans, denominated in euros, in an aggregate principal amount of €350 million (New Euro Term Loan) (collectively, the New Term Loans). The proceeds of the New Term Loans, together with cash on hand, were primarily used to prepay, in full, all outstanding amounts under our prior credit agreement, which amounted to \$921 million and €393 million, respectively. The New Dollar Term Loan bears a variable interest rate equal to, at our election, adjusted LIBOR plus 1.75% or adjusted base rate plus 0.75%, subject to an adjusted LIBOR or an adjusted base rate floor of 0.00% or 1.00%, respectively. The New Euro Term Loan bears a variable interest rate equal to adjusted EURIBOR plus 2.00%, subject to an adjusted EURIBOR floor of 0.50%. The New Term Loans will mature on April 3, 2025, and are subject to acceleration in certain circumstances, including a springing maturity in the event our senior unsecured notes due in May 2023 are not redeemed, repaid, and/or refinanced within the 91-day period prior to their maturity date.

The proceeds of any loans made under the New Revolving Credit Facility can be used for working capital needs and other general corporate purposes, including permitted acquisitions and other transactions, as defined in the amended and restated credit agreement. The New Revolving Credit Facility bears a variable interest rate range based on our total net leverage ratio, as defined in the amended and restated credit agreement, between (i) a 0.25% and a 1.00% spread for adjusted base rate loans, and (ii) a 1.25% and a 2.00% spread for LIBOR and EURIBOR loans. In addition, we are required to pay a commitment fee on the average daily unused amount of the New Revolving Credit Facility within an interest rate range based on our total net leverage ratio, between 0.10% and 0.25%. The New Revolving Credit Facility will mature on April 3, 2023, and is subject to acceleration in certain circumstances. At September 30, 2018, the New Revolving Credit Facility had a full borrowing capacity of \$800 million, from which we had \$104 million in letters of credit issued and outstanding.

## The Chemours Company

The amended and restated credit agreement also modified or eliminated certain provisions of our prior credit agreement, including the interest coverage ratio financial covenant and certain other negative covenants to allow for further flexibility. Under the amended and restated credit agreement, solely with respect to the New Revolving Credit Facility, we are required to not exceed a maximum senior secured net leverage ratio of (i) 2.25 to 1.00 in each quarter through December 31, 2018, and (ii) 2.00 to 1.00 in each quarter beginning January 1, 2019, through the date of maturity. In addition, the amended and restated credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict our and our subsidiaries' ability, subject to certain exceptions, to incur additional indebtedness or liens, pay dividends, and engage in certain transactions, including mergers, acquisitions, asset sales, or investments, outside of specified carve-outs. The amended and restated credit agreement also contains customary representations and warranties and events of default, which are substantially similar to those in the prior credit agreement. We were in compliance with our debt covenants at September 30, 2018.

Our obligations under the New Senior Secured Credit Facilities are guaranteed on a senior secured basis by all of our material domestic subsidiaries, which are also guarantors of our outstanding notes, subject to certain exceptions. The obligations under the New Senior Secured Credit Facilities are also, subject to certain exceptions, secured by a first priority lien on substantially all of our assets and substantially all of the assets of our wholly-owned, material domestic subsidiaries, including 100% of the stock of certain of our domestic subsidiaries and 65% of the stock of certain of our foreign subsidiaries.

The transaction resulted in a net prepayment of our total outstanding senior secured debt balances by approximately \$75 million, based on the euro exchange rate on April 3, 2018. In connection with the issuance of the New Senior Secured Credit Facilities, we incurred a loss on debt extinguishment of \$3 million for the nine months ended September 30, 2018.

### *Senior Unsecured Notes due May 2023*

On May 21, 2018, we commenced two all-cash tender offers to purchase: (i) up to \$250 million of the outstanding 6.625% senior unsecured notes due May 2023, denominated in U.S. dollars (2023 Dollar Notes), for a purchase price of \$1,052.50 per \$1,000.00 of principal amount through an early tender deadline of June 4, 2018, and \$1,022.50 per \$1,000.00 of principal amount thereafter, through June 18, 2018, the tender expiration date, plus any accrued and unpaid interest thereon (Dollar Tender Offer); and, (ii) any and all of the outstanding 6.125% senior unsecured notes due May 2023, denominated in euros (2023 Euro Notes) (collectively, the 2023 Notes), for a purchase price of €1,048.75 per €1,000.00 of principal amount through an early tender deadline of June 4, 2018, and €1,018.75 per €1,000.00 of principal amount thereafter, through June 18, 2018, the tender expiration date, plus any accrued and unpaid interest thereon (Euro Tender Offer) (collectively, the Tender Offers).

We completed the Dollar Tender Offer on June 6, 2018 for an aggregate purchase price of \$264 million, inclusive of an early participation premium of \$13 million and accrued interest of \$1 million. We completed the Euro Tender Offer on June 8, 2018 for an aggregate purchase price of €310 million, inclusive of an early participation premium of €14 million and accrued interest of €1 million. In connection with the Euro Tender Offer, we received consents from the holders of a majority of the aggregate principal amount of the 2023 Euro Notes to amend certain provisions of the indenture governing the 2023 Euro Notes, thereby allowing us to call and redeem the remaining 2023 Euro Notes outstanding upon two business days' notice to the noteholders. On June 8, 2018, we completed the redemption of the remaining outstanding 2023 Euro Notes that were not purchased pursuant to the Euro Tender Offer. The Tender Offers and the redemption of the 2023 Euro Notes were funded with the proceeds of the offering of the 2026 Euro Notes and cash on hand.

### *Senior Unsecured Notes due May 2026*

On June 6, 2018, we issued, in an underwritten public offering, the 2026 Euro Notes in an aggregate principal amount of €450 million. The 2026 Euro Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by each of our existing and future direct and indirect domestic restricted subsidiaries that (i) incurs or guarantees indebtedness under the New Senior Secured Credit Facilities, or (ii) guarantees certain of our other indebtedness or any guarantor in an aggregate principal amount in excess of \$100 million. The 2026 Euro Notes require payment of principal at maturity and payments of interest semi-annually in cash and in arrears on May 15 and November 15 of each year. Pursuant to the terms of the indenture governing the 2026 Euro Notes, we are obligated to offer to purchase the 2026 Euro Notes at a price of 101% of the principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, upon the occurrence of certain change of control events. Prior to May 15, 2021, we may redeem the 2026 Euro Notes (i) in whole or in part, at an amount equal to 100% of the aggregate principal amount plus a specified "make-whole" premium, and (ii) on one or more occasions, up to 35% of the aggregate principal amount of the notes, with the net cash proceeds of one or more equity offerings at a price equal to 104% of the principal amounts of such notes, plus accrued and unpaid interest, if any, up to, but excluding, the redemption date. The guarantees of the 2026 Euro Notes will rank equally with all other senior indebtedness of the guarantors. The 2026 Euro Notes rank equally in right of payment to all of our existing and future unsecured unsubordinated debt and are senior in right of payment to all of our existing and future debt that is, by its terms, expressly subordinated in right of payment to the 2026 Euro Notes. The 2026 Euro Notes are subordinated to indebtedness under the New Senior Secured Credit Facilities, as well as any future secured debt to the extent of the value of the assets securing such debt, and are structurally subordinated to the liabilities of any non-guarantor subsidiaries.

## The Chemours Company

We received net proceeds of €445 million from the offering of the 2026 Euro Notes, which, together with cash on hand, were used to purchase or redeem, as the case may be, the 2023 Notes pursuant to the Tender Offers and the redemption of the 2023 Euro Notes, as well as pay for any fees and expenses in connection therewith. In connection with the concurrent redemption of the 2023 Euro Notes and issuance of the 2026 Euro Notes, we incurred a loss on extinguishment of \$35 million for the nine months ended September 30, 2018.

### *Maturities*

We have required quarterly payments related to the New Senior Secured Credit Facilities equivalent to 1.00% per annum through December 2024, with the balance due at maturity. Principal maturities on the New Senior Secured Credit Facilities over the next five years are \$3 million for the remainder of 2018, approximately \$13 million in each year from 2019 to 2022, and \$1.25 billion in 2023 and beyond. Also, following the end of each fiscal year commencing on the year ended December 31, 2019, on an annual basis, we are required to make additional principal payments depending on leverage levels, as defined in the amended and restated credit agreement, equivalent to up to 50% of excess cash flows based on certain leverage targets with step-downs to 25% and 0% as actual leverage decreases to below a 3.50 to 1.00 leverage target. Debt maturities related to our senior unsecured notes in 2023 and beyond will be \$2.69 billion.

### **Supplier Financing**

We maintain global paying services agreements with several financial institutions. Under these agreements, the financial institutions act as our paying agents with respect to accounts payable due to our suppliers who elect to participate in the program. The agreements allow our suppliers to sell their receivables to one of the participating financial institutions at the discretion of both parties on terms that are negotiated between the supplier and the respective financial institution. Our obligations to our suppliers, including the amounts due and scheduled payment dates, are not impacted by our suppliers' decisions to sell their receivables under this program. At September 30, 2018 and December 31, 2017, total payment instructions from us amounted to \$195 million and \$172 million, respectively. Pursuant to their agreement with one of the financial institutions, certain suppliers may elect to be paid early at their discretion. The available capacity under these programs can vary based on the number of investors and/or financial institutions participating in these programs at any point in time.

### **Contractual Obligations**

Our contractual obligations at September 30, 2018, except as previously discussed for our debt arrangements, did not materially change from the contractual obligations previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017.

### **Off Balance Sheet Arrangements**

Information with respect to our guarantees is included in "Note 20 - Commitments and Contingent Liabilities" to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2017. Historically, we have not made significant payments to satisfy guarantee obligations; however, we believe we have the financial resources to satisfy these guarantees in the event required. Any remaining guarantees outstanding at September 30, 2018 were insignificant.

### **Critical Accounting Policies and Estimates**

Our significant accounting policies are described in "Critical Accounting Policies and Estimates" within our *MD&A* and in "Note 3 - Summary of Significant Accounting Policies" to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2017. Aside from the critical accounting policies and estimates set forth below, there have been no material changes to the critical accounting policies and estimates previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017.

### **Revenue from Contracts with Customers**

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, *Revenue from Contracts with Customers (Topic 606)* (ASU No. 2014-09). The objective of this standard is to remove inconsistent practices with regard to revenue recognition between GAAP and International Financial Reporting Standards. The standard intends to improve the comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. Subsequent to the issuance of ASU No. 2014-09, the FASB issued multiple clarifying updates in connection with the standard (collectively, Topic 606).

## The Chemours Company

Effective January 1, 2018, we adopted the new revenue recognition guidance contained in Topic 606 using the modified retrospective transition method. With the adoption of Topic 606, we recognize revenue using a five-step model resulting in revenue being recognized as performance obligations within a contract have been satisfied. The steps within that model include: (i) identifying the existence of a contract with a customer; (ii) identifying the performance obligations within the contract; (iii) determining the contract's transaction price; (iv) allocating the transaction price to the contract's performance obligations; and, (v) recognizing revenue as the contract's performance obligations are satisfied. A contract with a customer exists when: (i) we enter into an enforceable agreement that defines each party's rights regarding the goods or services to be transferred, and the related payment terms; (ii) the agreement has commercial substance; and, (iii) it is probable that we will collect the consideration to which we are entitled to in the exchange. A performance obligation is a promise in a contract to transfer a distinct good or service, or a series of distinct goods or services to a customer and serves as the unit of account for Topic 606. The transaction price is the customary amount of consideration that we expect to be entitled to in exchange for a transfer of the promised goods or services to a customer, excluding any amounts collected by us on behalf of third-parties (e.g., sales and use taxes). Judgment is required to apply the principles-based, five-step model for revenue recognition outlined in Topic 606. Management is required to make certain estimates and assumptions about our contracts with customers, including, among others, the nature and extent of our performance obligations, our transaction price amounts and any allocations thereof, the critical events which constitute satisfaction of our performance obligations, and when control of any promised goods or services is transferred to our customers.

Our revenue from contracts with customers is reflected in the consolidated statements of operations as net sales, the vast majority of which represents product sales that consist of a single performance obligation. Product sales to customers are made under a purchase order (PO), or in certain cases, in accordance with the terms of a master services agreement (MSA) or similar arrangement, which documents the rights and obligations of each party to the contract. When a customer submits a PO for product or requests product under an MSA, a contract for a specific quantity of distinct goods at a specified price is created, and our performance obligation under the contract is satisfied when control of the product is transferred to the customer, which is indicated by shipment of the product and the transfer of title and the risk of loss to the customer. Revenue is recognized on consignment sales when control transfers to the customer, generally at the point of customer usage of the product. The transaction price for product sales is generally the amount specified in the PO or in the request under an MSA; however, as is common in our industry, we offer variable consideration in the form of rebates, volume discounts, early payment discounts, pricing based on formulas or indices, price matching, and guarantees to certain customers. Such amounts are included in our estimated transaction price using either the expected value method or the most-likely amount, depending on the nature of the variable consideration included in the contract. We regularly assess our customers' creditworthiness, and product sales are made based on established credit limits. Payment terms for our invoices are typically less than 90 days.

We also license the right to access certain of our trademarks to customers under specified terms and conditions in certain arrangements, which is recognized as a component of net sales in the consolidated statements of operations under Topic 606. Under such arrangements, we may receive a royalty payment for a trademark license that is entered into on a stand-alone basis or incorporated into an overall product sales arrangement. Royalty income is generally based on customer sales and recognized under the sales-based exception as the customer sale occurs. When minimum guaranteed royalty amounts are included in the transaction price, we recognize royalty income ratably over the license period for the minimum amount. When there is no consideration specified for the use of our trademark, the entire transaction price is recognized in connection with the transfer of control of product. Royalty income resulting from the right to use our technology is considered outside the scope of Topic 606 as it is not a part of our ongoing major or central activities, and consistent with past practice, is recognized as a component of other income, net in the consolidated statements of operations in accordance with agreed-upon terms at the point or points in time that performance obligations are satisfied.

Consistent with the fact that the vast majority of our payment terms are less than 90 days from the point at which control of the promised goods or services is transferred, no adjustments have been made for the effects of a significant financing component under Topic 606. Additionally, we have elected to recognize the incremental costs associated with obtaining contracts as an expense when incurred if the amortization period of the assets that we would have recognized is one year or less. Amounts billed to customers for shipping and handling fees are considered a fulfillment cost and are included in net sales, and the costs incurred by us for the delivery of goods are classified as a component of the cost of goods sold in the consolidated statements of operations.

The adoption of Topic 606 did not have a material impact on our financial position, results of operations, or cash flows in future periods.

## The Chemours Company

### **U.S. Tax Reform**

In December 2017, the U.S. enacted new federal tax legislation commonly referred to as the Tax Cuts and Jobs Act (Tax Act), which, except for certain provisions, is effective for tax years beginning on or after January 1, 2018. The Tax Act significantly changes existing U.S. tax law and includes numerous provisions that will affect businesses, such as: (i) reducing the U.S. federal corporate income tax rate from 35% to 21%; (ii) requiring companies to pay a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries; (iii) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (iv) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (v) eliminating the corporate alternative minimum tax (AMT) and changing how existing AMT credits can be realized; (vi) creating the base erosion anti-abuse tax, a new minimum tax; (vii) creating a new limitation on deductible interest expense; (viii) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; and, (ix) creating the global intangibles low-tax income inclusions. We have performed preliminary analyses of the impacts of the Tax Act in accordance with the U.S. Securities and Exchange Commission's (SEC) Staff Accounting Bulletin No. 118 (SAB No. 118). SAB No. 118 allows us to record provisional amounts during a measurement period not to exceed one year from the enactment date, which was December 22, 2017. Under these preliminary analyses, we recorded additional GAAP tax benefits in the fourth quarter of 2017, which amounted to \$3 million. The impacts of the Tax Act may differ from our provisional estimates due to many factors, including, but not limited to, changes to our interpretation of the provisions in the Tax Act, U.S. Internal Revenue Service and U.S. Treasury guidance that may be issued, and actions that we may take.

During the three and nine months ended September 30, 2018, we recorded a \$10 million income tax benefit to adjust our initial provisional estimates for U.S. tax reform, which is included as a component of our benefit from and provision for income taxes, which impacted our effective tax rates by approximately 4% and 1%, respectively. The adjustment was specifically related to our initial estimates of the revaluation of certain deferred tax assets and liabilities as a result of the filing of our 2017 U.S. tax return and the associated adjustments on these deferred tax assets and liabilities as a result of the reduced corporate tax rate, the transition tax on previously untaxed accumulated and current earnings and profits of certain of our foreign subsidiaries, and the associated foreign tax credits. We have not, to date, made any other significant changes to our initial provisional estimates recorded in the fourth quarter of 2017.

Management is still evaluating the effects of the Tax Act's provisions on our consolidated financial statements; however, we expect to complete our analyses within the applicable measurement period, pursuant to SAB No. 118. As such, our provisional estimates for the Tax Act could change significantly within this period, resulting in a material impact to our financial position, results of operations, or cash flows.

### **Recent Accounting Pronouncements**

See "Note 2 - Recent Accounting Pronouncements" to the *Interim Consolidated Financial Statements* for a discussion about recent accounting pronouncements.

### **Environmental Matters**

Consistent with our values and our *Environment, Health, Safety, and Sustainability* policy, we are committed to preventing releases to the environment at our manufacturing sites to keep our people and communities safe, and to be good stewards of the environment. We are also subject to environmental laws and regulations relating to the protection of the environment. We believe that, as a general matter, our policies, standards, and procedures are properly designed to prevent an unreasonable risk of harm to people and the environment, and that our handling, manufacture, use, and disposal of hazardous substances are in accordance with applicable environmental laws and regulations.

### **Environmental Remediation**

As a result of past operations, operations of predecessor companies, or past disposal practices, we, like many other similar companies, have clean-up responsibilities and associated remediation costs, and are subject to claims by other parties, including claims for matters that are liabilities of DuPont and its subsidiaries that we may be required to indemnify pursuant to the separation-related agreements executed prior to our separation from DuPont.

Our environmental reserve includes estimated costs related to a number of sites for which it is probable that environmental remediation will be required, whether or not subject to enforcement activities, as well as those obligations that result from environmental laws such as the Comprehensive Environmental Response Compensation and Liability Act (CERCLA, often referred to as Superfund), the Resource Conservation and Recovery Act (RCRA), and similar federal, state, local, and foreign laws. These laws require certain investigative, remediation, and restoration activities at sites where we conduct or once conducted operations or at sites where our generated waste was disposed. At September 30, 2018 and December 31, 2017, we recorded environmental remediation accruals of \$239 million and \$253 million, respectively, relating to these matters which, in management's opinion, are appropriate based on existing facts and circumstances.



## The Chemours Company

Our remediation portfolio is relatively mature, with many of our sites under active clean-up moving towards final completion. As remediation efforts progress, sites move from the investigation phase (Investigation) to the active clean-up phase (Active Remediation), and as construction is completed at Active Remediation sites, those sites move to the operation, maintenance, and monitoring (OM&M) or closure phase. As final clean-up activities for some significant sites are completed over the next several years, we expect our annual payments related to these active sites to decline over time. The time frame for a site to go through all phases of remediation (Investigation and Active Remediation) may take about 15 to 20 years, followed by several years of OM&M activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, and diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties (PRPs). In addition, for claims that we may be required to indemnify DuPont pursuant to the separation-related agreements, we, through DuPont, have limited available information for certain sites or are in the early stages of discussions with regulators. For these sites in particular, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs, and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately \$470 million above the amount accrued at September 30, 2018. In general, uncertainty is greatest and the range of potential liability is widest in the Investigation phase, narrowing over time as regulatory agencies approve site remedial plans. As a result, uncertainty is reduced, and sites ultimately move into OM&M, as needed. As more sites advance from Investigation to Active Remediation to OM&M or closure, the upper end of the range of potential liability is expected to decrease over time.

Some remediation sites will achieve site closure and will require no further action to protect people and the environment and comply with laws and regulations. At certain sites, we expect that there will continue to be some level of remediation activity due to ongoing OM&M of remedial systems. In addition, portfolio changes, such as an acquisition or divestiture, or notification as a PRP for a multi-party Superfund site, could result in additional remediation activity and potentially additional accrual.

Management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on our financial position, results of operations, or cash flows in any given year, as such obligation can be satisfied or settled over many years. For additional information, refer to the "Environmental Matters" section of MD&A included in our Annual Report on Form 10-K for the year ended December 31, 2017.

While there are many remediation sites that contribute to our total environmental remediation accrual, the following table sets forth the sites that are the most significant.

| <i>(Dollars in millions)</i>                   | September 30, 2018 | December 31, 2017 |
|--|--------------------|-------------------|
| Beaumont, Texas                                | \$ 11              | \$ 12             |
| Chambers Works, New Jersey                     | 18                 | 19                |
| East Chicago, Indiana                          | 21                 | 20                |
| Pompton Lakes, New Jersey                      | 46                 | 55                |
| USS Lead, East Chicago, Indiana                | 16                 | 26                |
| All other sites                                | 127                | 121               |
| <b>Total accrued environmental remediation</b> | <b>\$ 239</b>      | <b>\$ 253</b>     |

The five sites listed above represent approximately 47% and 50% of our environmental reserve at September 30, 2018 and December 31, 2017, respectively. We expect to spend, in the aggregate, approximately \$60 million over the next three years for these five sites. For all other sites, in the aggregate, we expect to spend approximately \$85 million over the next three years.

### *Beaumont Works, Beaumont, Texas*

Beaumont Works began operations in 1954 in Beaumont, Jefferson County, Texas. Over the years, Beaumont Works has produced a number of basic chemicals and elastomer products including acrylonitrile, ammonia, methanol, methyl methacrylate, caprolactam, Hypalon® synthetic rubber, Nordel® hydrocarbon rubber, and blended tetraethyl lead with halo-carbon solvent/stabilizers. With the sale of our aniline production unit to The Dow Chemical Company (Dow) in 2016, we have no ongoing manufacturing operations on the site. Dow and Lucite International, Inc. (Lucite) remain as long-term manufacturing tenants.

## The Chemours Company

As site owner, we remain responsible for the remediation of historical chemical releases from past operations and are conducting this work under an RCRA hazardous waste post-closure permit and Compliance Plan (CP) issued by the State of Texas. The hazardous waste permit includes provisions to manage wastes and to investigate and mitigate releases. The CP is a component of the permit and includes mitigation and monitoring requirements, including a groundwater remediation system that was installed in 1991 to control chemical migration and protect adjacent water bodies. In addition, several solid waste management unit closures have been conducted and areas of past release addressed through interim measures to protect people and the environment. Over the years, extensive site studies have been completed and a final investigation report (Affected Property Assessment Report, or APAR, under the Texas Risk Reduction Program) for the entire site was approved by the state in 2014. The Remedial Action Plan (RAP) submitted in 2016 has been approved by the State of Texas, and is consistent with our remedy proposal, which addresses all remaining historical solid waste management units and areas of concern identified in these studies.

The remediation accrual for Beaumont addresses remaining work identified in the RAP under review by the state, as well as post-closure care and monitoring and ongoing operation of the groundwater remediation system. A portion of the accrual also addresses an outstanding Natural Resource Damage claim by state and federal trustees directed to impacts on marshlands within the plant property.

### *Chambers Works, Deepwater, New Jersey*

The Chambers Works complex is located on the eastern shore of the Delaware River in Deepwater, Salem County, New Jersey. The site comprises the former Carneys Point Works in the northern area and the Chambers Works manufacturing area in the southern area. Site operations began in 1892 when the former Carneys Point smokeless gunpowder plant was constructed at the northern end of Carneys Point. Site operations began in the manufacturing area around 1914 and included the manufacture of dyes, aromatics, elastomers, chlorofluorocarbons, and tetraethyl lead. We continue to manufacture a variety of fluorochemicals and finished products at Chambers Works. In addition, three tenants operate processes at Chambers Works including steam/electricity generation, industrial gas production, and the manufacture of intermediate chemicals. As a result of over 100 years of continuous industrial activity, site soils and groundwater have been impacted by chemical releases.

In response to identified groundwater contamination, a groundwater interceptor well system (IWS) was installed in 1970, which was designed to contain contaminated groundwater and restrict off-site migration. Additional remediation is being completed under a federal RCRA Corrective Action (CA) permit. The site has been studied extensively over the years, and more than 25 remedial actions have been completed to date and engineering and institutional controls put in place to ensure protection of people and the environment. In the fourth quarter of 2017, a site perimeter sheet pile barrier intended to more efficiently contain groundwater was completed.

Remaining work beyond continued operation of the IWS and groundwater monitoring includes completion of various targeted studies onsite and in adjacent water bodies to close investigation data gaps, as well as selection and implementation of final remedies under RCRA CA for various solid waste management units and areas of concern not yet addressed through interim measures.

### *East Chicago, Indiana*

East Chicago is a former manufacturing facility owned by us in East Chicago, Lake County, Indiana. The approximate 440-acre site is bounded to the south by the east branch of the Grand Calumet River, to the east and north by residential and commercial areas, and to the west by industrial areas, including a former lead processing facility. The inorganic chemicals unit on site produced various chloride, ammonia, and zinc products and inorganic agricultural chemicals beginning in 1892 and ending in 1986. Organic chemical manufacturing began in 1944, consisting primarily of chlorofluorocarbons production. Current operations, including support activities, now cover 28 acres of the site. The remaining business was sold to W. R. Grace Company (Grace) in early 2000, and Grace operates the unit as a tenant. Approximately 172 acres of the site were never developed and are managed by The Nature Conservancy for habitat preservation.

A comprehensive evaluation of soil and groundwater conditions at the site was performed as part of the RCRA CA process. Studies of historical site impacts began in 1983 in response to preliminary CERCLA actions undertaken by the U.S. Environmental Protection Agency (EPA). The EPA eventually issued an Administrative Order on Consent for the site in 1997. The order specified that remediation work be performed under RCRA CA authority. Work has proceeded under the RCRA CA process since that time.

Subsequent investigations included the preparation of initial environmental site assessments and multiple phases of investigation. In 2002, as an interim remedial measure, two 2,000-foot long permeable reactive barrier treatment walls were installed along the northern property boundary to address migration of chemicals in groundwater. Since that time, the investigation process has been completed and approved by the EPA, and the final remedy for the site has been selected by the EPA.

## The Chemours Company

On June 29, 2018, we sold the East Chicago site to a third-party for \$1 million. In connection with the sale, the buyer has agreed to assume all costs associated with environmental remediation activities at the site in excess of \$21 million, which will remain our responsibility. At the time of the sale, we had accrued the full \$21 million, and will reimburse the buyer through a series of progress payments to be made at defined intervals as certain tasks are completed. We recognized a gain of \$3 million on the sale, which includes the purchase price of \$1 million, plus \$2 million in environmental remediation liabilities that were assumed by the buyer on the occurrence of the sale.

### *Pompton Lakes, New Jersey*

During the 20th century, blasting caps, fuses, and related materials were manufactured at Pompton Lakes, Passaic County, New Jersey. Operating activities at the site were ceased in the mid-1990s. The primary contaminants in the soil and sediments are lead and mercury. Groundwater contaminants include volatile organic compounds. Under the authority of the EPA and the New Jersey Department of Environmental Protection, remedial actions at the site are focused on investigating and cleaning up the area. Groundwater monitoring at the site is ongoing, and we have installed and continue to install vapor mitigation systems at residences within the groundwater plume. In addition, we are further assessing groundwater conditions. In June 2015, the EPA issued a modification to the site's RCRA permit that requires us to dredge mercury contamination from a 36-acre area of the lake and remove sediment from two other areas of the lake near the shoreline. The remediation activities commenced when permits and implementation plans were approved in May 2016, and work on the lake dredging project was completed.

### *U.S. Smelter and Lead Refinery, Inc., East Chicago, Indiana*

The U.S. Smelter and Lead Refinery, Inc. (USS Lead) Superfund site is located in the Calumet neighborhood of East Chicago, Lake County, Indiana. The site includes the former USS Lead facility along with nearby commercial, municipal, and residential areas. The primary compounds of interest are lead and arsenic which may be found in soils within the impacted area. The EPA is directing and organizing remediation on this site, and we are one of a number of parties working cooperatively with the EPA on the safe and timely completion of this work. DuPont's former East Chicago manufacturing facility was located adjacent to the site, and DuPont assigned responsibility for the site to us in our separation-related agreement.

The USS Lead Superfund site was listed on the National Priorities List in 2009. To facilitate negotiations with PRPs, the EPA divided the residential part of the USS Lead Superfund site into three zones, referred to as Zone 1, Zone 2, and Zone 3. The division into three zones resulted in Atlantic Richfield Co. (Atlantic Richfield) and DuPont entering into an agreement in 2014 with the EPA and the State of Indiana to reimburse the EPA's costs to implement clean-up in Zone 1 and Zone 3. More recently, in March 2017, we and three other parties (Atlantic Richfield, DuPont, and the U.S. Metals Refining Co.) entered into an administrative order on consent to reimburse the EPA's costs to clean-up a portion of Zone 2. The EPA is continuing its efforts to identify additional PRPs for the USS Lead Superfund site clean-up, including the remainder of Zone 2. The EPA has scheduled negotiations with some of these parties. The EPA has stated its intention to issue a unilateral order to PRPs to complete the Zone 2 work. There is uncertainty as to whether the parties who receive the unilateral order will be able to reach an allocation and agree to comply with it.

The environmental accrual for USS Lead is based on the Record of Decision (ROD) and Statement of Work currently in place for Zone 1 and Zone 3, as well as the current estimate of our share of the EPA's Zone 2 clean-up cost. The EPA has announced its intent to reconsider the ROD for Zone 1, and the result of that review could increase or decrease our future obligations.

## **PFOA**

See our discussion under the heading "PFOA" in "Note 17 - Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements*.

## **Non-GAAP Financial Measures**

We prepare our interim consolidated financial statements in accordance with GAAP. To supplement our financial information presented in accordance with GAAP, we provide the following non-GAAP financial measures - Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, FCF, and ROIC - in order to clarify and provide investors with a better understanding of our performance when analyzing changes in our underlying business between reporting periods and provide for greater transparency with respect to supplemental information used by management in its financial and operational decision-making.

We utilize Adjusted EBITDA as the primary measure of segment profitability used by our CODM.

## The Chemours Company

Adjusted EBITDA is defined as income (loss) before income taxes, excluding the following:

- interest expense, depreciation, and amortization;
- non-operating pension and other post-retirement employee benefit costs, which represent the components of net periodic pension (income) costs excluding the service cost component;
- exchange (gains) losses included in other income (expense), net;
- restructuring, asset-related, and other charges;
- asset impairments;
- (gains) losses on sales of assets and businesses; and,
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

Adjusted Net Income is defined as our net income or loss, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, certain amortization, and certain provision for (benefit from) income tax amounts. Adjusted EPS is presented on a diluted basis and is calculated by dividing Adjusted Net Income by the weighted-average number of our common shares outstanding, accounting for the dilutive impact of our stock-based compensation awards. FCF is defined as our cash flows provided by operating activities, less purchases of property, plant, and equipment as shown in our consolidated statements of cash flows. ROIC is defined as Adjusted EBIT, divided by the average of our invested capital, which amounts to net debt plus equity.

We believe the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing our operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. In the future, we may incur expenses similar to those eliminated in this presentation. Our presentation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, FCF, and ROIC should not be construed as an inference that our future results will be unaffected by unusual or infrequently occurring items. The non-GAAP financial measures that we use may be defined differently from measures with the same or similar names used by other companies. This analysis, as well as the other information provided in this Quarterly Report on Form 10-Q, should be read in conjunction with the *Interim Consolidated Financial Statements* and the related notes thereto included in this report, as well as the *Consolidated Financial Statements* and the related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017.

## The Chemours Company

The following table sets forth a reconciliation of Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS to our net income attributable to Chemours for the three and nine months ended September 30, 2018 and 2017.

| <i>(Dollars in millions, except per share amounts)</i>                  | Three Months Ended September 30, |               | Nine Months Ended September 30, |                 |
|---|----------------------------------|---------------|---------------------------------|-----------------|
|   | 2018                             | 2017          | 2018                            | 2017            |
| <b>Net income attributable to Chemours</b>                              | \$ 275                           | \$ 207        | \$ 853                          | \$ 518          |
| Non-operating pension and other post-retirement employee benefit income | (4)                              | (7)           | (18)                            | (24)            |
| Exchange losses (gains), net  | 6                                | 4             | 4                               | (3)             |
| Restructuring and other charges   | 12                               | 8             | 32                              | 31              |
| Asset-related and other charges   | —                                | 1             | —                               | 3               |
| Loss on extinguishment of debt  | —                                | —             | 38                              | 1               |
| Gain on sales of assets and businesses (1)                              | —                                | —             | (45)                            | (14)            |
| Transaction costs (2)   | —                                | 1             | 9                               | 3               |
| Legal and other charges (3)   | 34                               | 7             | 45                              | 18              |
| Adjustments made to income taxes (4,6)                                  | (41)                             | (11)          | (54)                            | (24)            |
| Benefit from income taxes relating to reconciling items (5,6)           | (11)                             | (7)           | (15)                            | (10)            |
| <b>Adjusted Net Income</b>  | <b>271</b>                       | <b>203</b>    | <b>849</b>                      | <b>499</b>      |
| Net income attributable to non-controlling interests                    | —                                | —             | 1                               | 1               |
| Interest expense, net   | 47                               | 55            | 148                             | 160             |
| Depreciation and amortization   | 71                               | 62            | 213                             | 204             |
| All remaining provision for income taxes (6)                            | 46                               | 61            | 188                             | 164             |
| <b>Adjusted EBITDA</b>  | <b>\$ 435</b>                    | <b>\$ 381</b> | <b>\$ 1,399</b>                 | <b>\$ 1,028</b> |

|  |                    |                    |                    |                    |
|--|--------------------|--------------------|--------------------|--------------------|
| Weighted-average number of common shares outstanding - basic   | 176,489,881        | 185,431,036        | 178,765,676        | 184,641,599        |
| Dilutive effect of our employee compensation plans             | 5,387,244          | 6,206,778          | 5,891,072          | 5,909,015          |
| Weighted-average number of common shares outstanding - diluted | <u>181,877,125</u> | <u>191,637,814</u> | <u>184,656,748</u> | <u>190,550,614</u> |

### Per share data

|   |         |         |         |         |
|---|---------|---------|---------|---------|
| Basic earnings per share of common stock            | \$ 1.56 | \$ 1.12 | \$ 4.77 | \$ 2.81 |
| Diluted earnings per share of common stock          | 1.51    | 1.08    | 4.62    | 2.72    |
| Adjusted basic earnings per share of common stock   | 1.54    | 1.09    | 4.75    | 2.70    |
| Adjusted diluted earnings per share of common stock | 1.49    | 1.06    | 4.60    | 2.62    |

- (1) For the nine months ended September 30, 2018, gain on sale includes a \$3 million gain and a \$42 million gain associated with the sales of our East Chicago, Indiana and Linden, New Jersey sites, respectively. For the nine months ended September 30, 2017, gain on sale includes a \$12 million gain associated with the sale of our Edge Moor, Delaware site and a \$4 million gain associated with the sale of our land in Repauno, New Jersey that was previously deferred and realized upon meeting certain milestones, which are offset by a \$2 million adjustment associated with the sale of our Sulfur business in 2016.
- (2) Includes costs associated with our debt transactions, as well as accounting, legal, and bankers' transaction costs incurred in connection with our strategic initiatives.
- (3) Includes litigation settlements, PFOA drinking water treatment accruals, and other charges, including the \$30 million additional estimated liability for our Fayetteville, North Carolina site for the three and nine months ended September 30, 2018, the latter of which is included as a component of selling, general, and administrative expense in our consolidated statements of operations. See "Note 17 - Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements* for further detail.
- (4) Includes the removal of certain discrete income tax amounts within our (benefit from) provision for income taxes. For the three months ended September 30, 2018, our adjustments to income taxes include the following: \$19 million in tax benefits primarily related to the filing of our 2017 U.S. tax return and the associated adjustments including the revaluation of deferred tax assets and liabilities as a result of the reduced corporate tax rate and other associated adjustments, \$17 million in tax benefits for the reversal of our valuation allowance on foreign tax credit carryforwards due to changes in normal business operations, \$4 million in windfall tax benefits on our share-based payments, and \$1 million in tax benefits resulting from unrealized losses on foreign exchange rates related to toll charges pursuant to U.S. tax reform. For the nine months ended September 30, 2018, our adjustments to income taxes include the following: \$19 million in tax benefits primarily related to the filing of our 2017 U.S. tax return and the associated adjustments including the revaluation of deferred tax assets and liabilities as a result of the reduced corporate tax rate, \$17 million in tax benefits for the reversal of our valuation allowance on foreign tax credit carryforwards due to changes in normal business operations, \$14 million in windfall tax benefits on our share-based payments, and \$4 million in tax benefits resulting from unrealized losses on foreign exchange rates related to toll charges pursuant to U.S. tax reform. For the three and nine months ended September 30, 2017, adjustments made to income taxes include \$5 million and \$18 million in windfall tax benefits on our share-based payments, respectively, and the reversal of a reserve for uncertain tax positions of \$6 million.
- (5) The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred and include both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.
- (6) The total (benefit from) provision for income taxes reconciles to the amount reported in the consolidated statements of operations for the three and nine months ended September 30, 2018 and 2017.

## The Chemours Company

The following table sets forth a reconciliation of FCF to our cash provided by operating activities for the nine months ended September 30, 2018 and 2017.

| <i>(Dollars in millions)</i>                      | Nine Months Ended September 30, |              |
|---|---------------------------------|--------------|
|   | 2018                            | 2017         |
| Cash provided by operating activities             | \$ 881                          | \$ 337       |
| Less: Purchases of property, plant, and equipment | (344)                           | (246)        |
| <b>Free Cash Flows</b>                            | <b>\$ 537</b>                   | <b>\$ 91</b> |

The following table sets forth a reconciliation of invested capital, net, a component of ROIC, to our total debt, equity, and cash and cash equivalents at September 30, 2018 and 2017.

| <i>(Dollars in millions)</i>            | Twelve Months Ended September 30, |                 |
|---|-----------------------------------|-----------------|
|   | 2018                              | 2017            |
| Adjusted EBITDA (1)                     | \$ 1,794                          | \$ 1,266        |
| Less: Depreciation and amortization (1) | (281)                             | (276)           |
| <b>Adjusted EBIT</b>                    | <b>1,513</b>                      | <b>990</b>      |
| <br>                                    |                                   |                 |
| Total debt                              | 3,999                             | 4,095           |
| Total equity                            | 1,146                             | 805             |
| Less: Cash and cash equivalents         | (1,275)                           | (1,535)         |
| <b>Invested capital, net</b>            | <b>\$ 3,870</b>                   | <b>\$ 3,365</b> |
| <br>                                    |                                   |                 |
| Average invested capital (2)            | \$ 3,637                          | \$ 3,102        |
| <br>                                    |                                   |                 |
| <b>Return on Invested Capital</b>       | <b>41.6%</b>                      | <b>31.9%</b>    |

(1) Based on amounts for the trailing 12 months ended September 30, 2018 and 2017. Reconciliations of Adjusted EBITDA to net income (loss) attributable to Chemours are provided on a quarterly basis. See the preceding tables for the reconciliation of Adjusted EBITDA to net income attributable to Chemours for the three and nine months ended September 30, 2018 and 2017.

(2) Average invested capital is based on a five-quarter trailing average of invested capital, net.

### Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to changes in foreign currency exchange rates because of our global operations. As a result, we have assets, liabilities, and cash flows denominated in a variety of foreign currencies. We are also exposed to changes in the prices of certain commodities that we use in production. Changes in these rates and commodity prices may have an impact on our future cash flows and earnings. We manage these risks through normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. We do not enter into derivative financial instruments for trading or speculative purposes.

We enter into foreign currency forward contracts to minimize the volatility in our earnings related to foreign exchange gains and losses resulting from remeasuring our monetary assets and liabilities that are denominated in non-functional currencies. These derivatives are stand-alone and, except as described below, have not been designated as a hedge. At September 30, 2018, we had 16 foreign currency forward contracts outstanding, with an aggregate gross notional U.S. dollar equivalent of \$483 million, the fair value of which amounted to less than \$1 million. We had no foreign currency forward contracts outstanding at December 31, 2017. We recognized net gains of \$14 million and \$8 million for the three and nine months ended September 30, 2018, respectively, and a net loss of \$1 million and a net gain of \$6 million for the three and nine months ended September 30, 2017, respectively, within other income, net in the consolidated statements of operations related to our foreign currency forward contracts.

We enter certain qualifying foreign currency forward contracts under a cash flow hedge program to mitigate the risks associated with fluctuations in the euro against the U.S. dollar for forecasted U.S. dollar-denominated inventory purchases in certain of our international subsidiaries that use the euro as their functional currency. At September 30, 2018, we had 48 foreign currency forward contracts outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of \$135 million, the fair value of which amounted to \$2 million of net unrealized gain. We recognized a pre-tax loss of \$1 million and a pre-tax gain of \$6 million for the three and nine months ended September 30, 2018, respectively, on our cash flow hedge within accumulated other comprehensive loss. For the three and nine months ended September 30, 2018, \$1 million of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss.

We have also designated our euro-denominated debt as a hedge of our net investment in certain of our international subsidiaries that use the euro as their functional currency in order to reduce the volatility in stockholders' equity caused by changes in foreign currency exchange rates of the euro with respect to the U.S. dollar. We recognized a pre-tax loss of \$11 million and a pre-tax gain of \$2 million for the three and nine months ended September 30, 2018, respectively, and pre-tax losses of \$26 million and \$76 million for the three and nine months ended September 30, 2017, respectively, on our net investment hedges within accumulated other comprehensive loss.

Our risk management programs and the underlying exposures are closely correlated, such that the potential loss in value for the risk management portfolio described above would be largely offset by the changes in the value of the underlying exposures. See "Note 19 - Financial Instruments" to the *Interim Consolidated Financial Statements* for further information.

#### Additional Information

See Part II, Item 7A, *Quantitative and Qualitative Disclosures About Market Risk*, in our Annual Report on Form 10-K for the year ended December 31, 2017 for additional information related to our utilization of financial instruments and an analysis of the sensitivity of these instruments. There have been no material changes in the market risks previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017, other than as set forth above.

### Item 4. CONTROLS AND PROCEDURES

#### Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to provide reasonable assurance that the information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also provide reasonable assurance that the information required to be disclosed in such reports is accumulated and communicated to management, including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), to allow for timely decisions regarding required disclosures.

As of September 30, 2018, our CEO and CFO, together with management, conducted an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act. Based on that evaluation, the CEO and CFO have concluded that these disclosure controls and procedures are effective at the reasonable assurance level.

## The Chemours Company

### Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the three and nine months ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



## The Chemours Company

### PART II. OTHER INFORMATION

#### Item 1. LEGAL PROCEEDINGS

##### Legal Proceedings

We are subject to various legal proceedings, including, but not limited to, product liability, intellectual property, personal injury, commercial, contractual, employment, governmental, environmental, anti-trust, and other such matters that arise in the ordinary course of business. Information regarding certain of these matters is set forth below and in “Note 17 - Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*.

##### Litigation

###### **PFOA: Environmental and Litigation Proceedings**

For the purposes of this report, the term PFOA means collectively perfluorooctanoic acid and its salts, including the ammonium salt, and does not distinguish between the two forms. Information related to this and other litigation matters is included in “Note 17 - Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*.

###### **Fayetteville, North Carolina**

The following actions related to Fayetteville, North Carolina, as discussed in “Note 17 - Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*, are filed in the U.S. District Court for the Eastern District of North Carolina, Southern Division:

- *Carey et al. vs. E. I. DuPont de Nemours and Company* (7:17-cv-00189-D; 7:17-cv-00197-D; and, 7:17-cv-00201-D);
- *Cape Fear Public Utility Authority vs. The Chemours Company FC, LLC et al. and Brunswick County v. DowDuPont et al.* (7:17-cv-00195-D and 7:17-cv-00209-D);
- *Dew et al. vs. E. I. DuPont de Nemours and Company et al.* (17:18-cv-00030-D); and,
- *Cape Fear River Watch vs. Chemours Company FC, LLC* (7:18-cv-00159-D).

The following action is filed in the State of North Carolina County of New Hanover General Court of Justice, Superior Court Division:

- *Cape Fear River Watch vs. North Carolina Department of Environmental Quality* (18 CVS 2462).

##### Environmental Proceedings

###### **LaPorte Plant, LaPorte, Texas**

The EPA conducted a multimedia inspection at the DuPont LaPorte, Texas facility in January 2008. DuPont, the EPA, and the U.S. Department of Justice began discussions in the fall of 2011 relating to the management of certain materials in the facility’s waste water treatment system, hazardous waste management, flare, and air emissions. These negotiations continue. We operate a fluoroproducts production facility at this site.

###### **Dordrecht, Netherlands**

We have received requests from the local environmental agency (DCMR, formerly under the jurisdiction of OZHZ), the Labor Inspectorate (iSZW), the Inspectorate for Environment and Transportation (ILT), and the Water Authority (RWS) in the Netherlands for information and documents regarding the Dordrecht site’s operations. We have complied with the requests, and the agencies have published several reports between 2016 and 2018, all of them publicly available. The National Institute for Public Health and the Environment (RIVM) has also published several reports with respect to PFOA and GenX. In September 2018, DCMR initially proposed a €1 million fine after undertaking wastewater tests, which detected low levels of PFOA. DCMR has not made a final determination and we believe we have valid defenses to avoid the imposition of a fine. We continue to cooperate with all authorities in responding to information requests, including those related to a preliminary investigation initiated by a public prosecutor.

## The Chemours Company

### Fayetteville, North Carolina

Upon notifying the North Carolina Department of Environmental Quality (NC DEQ) of findings from groundwater studies conducted on the site, we received, on September 6, 2017, a Notice of Violation (NOV) and Notice of Intent to Enforce from NC DEQ pursuant to North Carolina groundwater quality standards. Since then, we have been conducting further studies on-site and off-site in cooperation with NC DEQ to better understand the nature and extent of environmental contamination involving certain perfluorinated compounds related to our Fayetteville, North Carolina operations. These studies are ongoing and will be used to determine what groundwater-focused remedial actions, if any, may be necessary to protect people and the environment and comply with the state's standards. On February 12, 2018, NC DEQ issued an NOV related to groundwater on and around the site which directs us to respond with source control measures. We continue to take action in response to the NOV and will continue to cooperate with NC DEQ.

### Item 1A. RISK FACTORS

There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017.

### Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

#### Issuer Purchases of Equity Securities

On August 1, 2018, our board of directors approved the 2018 Share Repurchase Program authorizing the purchase of shares of our issued and outstanding common stock in an aggregate amount not to exceed \$750 million, plus any associated fees or costs in connection with our share repurchase activity. Under the 2018 Share Repurchase Program, shares of our common stock can be purchased on the open market from time to time, subject to management's discretion, as well as general business and market conditions. Our 2018 Share Repurchase Program became effective on August 1, 2018 and will continue through the earlier of its expiration on December 31, 2020, or the completion of repurchases up to the approved amount. The program may be suspended or discontinued at any time. All common shares purchased under the 2018 Share Repurchase Program are expected to be held as treasury stock and accounted for using the cost method. Our 2018 Share Repurchase Program was announced to the public on August 2, 2018.

The following table sets forth the purchases of our issued and outstanding common stock under the 2018 Share Repurchase Program for the three months ended September 30, 2018.

*(Dollars in millions, except per share amounts)*

| Period                         | Total Number of<br>Shares<br>Purchased<br>(1) | Average Price<br>Paid per Share<br>(2) | Total Number of<br>Shares<br>Purchased as<br>Part of Publicly<br>Announced<br>Plans or<br>Programs | Approximate<br>Dollar Value of<br>Shares That May<br>Yet be<br>Purchased<br>Under the Plans<br>or Programs<br>(2) |
|--------------------------------|---|--|--|---|
| Month ended July 31, 2018      | —   | \$ —                                   | —  | \$ 750  |
| Month ended August 31, 2018    | 1,161,655                                     | 44.75                                  | 1,161,655  | 698   |
| Month ended September 30, 2018 | 2,065,169                                     | 40.81                                  | 2,065,169  | 614   |
| <b>Total</b>                   | <u>3,226,824</u>                              | <u>\$ 42.23</u>                        | <u>3,226,824</u>   | <u>\$ 614</u>   |

(1) The total number of shares purchased under the 2018 Share Repurchase Program is determined using trade dates for the related transactions.

(2) The average price paid per share and approximate dollar value of shares that may yet be purchased under the 2018 Share Repurchase Program exclude fees, commissions, and other charges for the related transactions.

Subsequent to September 30, 2018, we purchased an additional 3,124,033 shares of our issued and outstanding common stock, which amounted to \$114 million at an average share price of \$36.30 per share.

## The Chemours Company

### Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

### Item 4. MINE SAFETY DISCLOSURES

Information regarding mine safety and other regulatory actions at our surface mine in Starke, Florida is included in *Exhibit 95* to this Quarterly Report on Form 10-Q.

### Item 5. OTHER INFORMATION

None.

### Item 6. EXHIBITS

| Exhibit Number | Description  |
|----------------|--|
| 3.1            | Company's Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 1, 2015).   |
| 3.2            | Company's Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 1, 2015).   |
| 31.1           | Rule 13a-14(a)/15d-14(a) Certification of the Company's Principal Executive Officer.   |
| 31.2           | Rule 13a-14(a)/15d-14(a) Certification of the Company's Principal Financial Officer.   |
| 32.1           | Section 1350 Certification of the Company's Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended. |
| 32.2           | Section 1350 Certification of the Company's Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended. |
| 95             | Mine Safety Disclosures.   |
| 101.INS        | XBRL Instance Document.  |
| 101.SCH        | XBRL Taxonomy Extension Schema Document.   |
| 101.CAL        | XBRL Taxonomy Extension Calculation Linkbase Document.   |
| 101.DEF        | XBRL Taxonomy Extension Definition Linkbase Document.  |
| 101.LAB        | XBRL Taxonomy Extension Label Linkbase Document.   |
| 101.PRE        | XBRL Taxonomy Extension Presentation Linkbase Document.  |

**The Chemours Company**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THE CHEMOURS COMPANY  
(Registrant)

Date: November 2, 2018

By: /s/ Mark E. Newman

Mark E. Newman  
Senior Vice President and Chief Financial Officer  
(As Duly Authorized Officer and Principal Financial Officer)

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

I, Mark P. Vergnano, certify that:

1. I have reviewed this quarterly report on Form 10-Q of The Chemours Company;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2018

By: /s/ Mark P. Vergnano

Mark P. Vergnano  
President and Chief Executive Officer

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

I, Mark E. Newman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of The Chemours Company;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2018

By: /s/ Mark E. Newman

Mark E. Newman  
Senior Vice President and  
Chief Financial Officer

**Certification of CEO Pursuant to  
18 U.S.C. Section 1350,  
As Adopted Pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of The Chemours Company (the "Company") on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mark P. Vergnano, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Mark P. Vergnano

---

Mark P. Vergnano  
President and Chief Executive Officer  
November 2, 2018

**Certification of CFO Pursuant to  
18 U.S.C. Section 1350,  
As Adopted Pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of The Chemours Company (the "Company") on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mark E. Newman, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Mark E. Newman

---

Mark E. Newman  
Senior Vice President and Chief Financial Officer  
November 2, 2018



**MINE SAFETY DISCLOSURES**

The company owns and operates a surface mine near Starke, Florida. The following table provides information about citations, orders and notices issued from the Mine Safety and Health Administration (MSHA) under the Federal Mine Safety and Health Act of 1977 (Mine Act) for the quarter ended September 30, 2018.

| Mine (MSHA Identification Number) | Section 104 S&S <sup>1</sup> Citations (#) | Section 104(b) Orders (#) | Section 104(d) Citations and Orders (#) | Section 110(b)(2) Violations (#) | Section 107(a) Orders (#) | Total Dollar Value of MSHA Assessments Proposed (\$) | Total Number of Mining Related Fatalities (#) | Received Notice of Pattern of Violations Under Section 104(e) (yes/no) | Received Notice of Potential to Have Pattern Under Section 104(e) (yes/no) | Legal Actions Pending as of Last Day of Period (#) | Legal Actions Initiated During Period (#) | Legal Actions Resolved During Period (#) |
|-----------------------------------|--|---------------------------|---|----------------------------------|---------------------------|--|---|--|--|--|---|--|
| Starke, FL (0800225)              | 7  | —                         | —                                       | —                                | —                         | \$ 2,292   | —   | No   | No   | —  | —   | —  |

<sup>1</sup> S&S refers to significant and substantial violations of mandatory health or safety standards under section 104 of the Mine Act.